


**CUMULATIVE  
SUPPLEMENT 4**  
April 2026



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46th EDITION**

**Department of Health and Human Services**

Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46<sup>th</sup> EDITION**

**Cumulative Supplement 4  
April 2026**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT .....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT .....	vi
1.3	LEVOTHYROXINE SODIUM .....	vii
1.4	AVAILABILITY OF THE EDITION.....	viii
1.5	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	ix
1.6	CUMULATIVE SUPPLEMENT LEGEND.....	x
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 4  
April 2026**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

#### 1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2025</u>	<u>MAR</u> <u>2026</u>	<u>JUN</u> <u>2026</u>	<u>SEP</u> <u>2026</u>	<u>DEC</u> <u>2026</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	24120 2765 (11.5%)	24441 2813 (11.5%)			
MULTISOURCE	21355 (88.5%)	21628 (88.5%)			
THERAPEUTICALLY EQUIVALENT	21260 (87.1%)	21534 (88.1%)			
NOT THERAPEUTICALLY EQUIVALENT	95 (0.4%)	94 (0.4%)			

EXCEPTIONS <sup>4</sup>	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	19	41
NUMBER OF APPLICANTS	1198	1198

## 1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CPOT Change. Potency amount/unit.  
CRLD Change. Reference Listed Drug  
CHRS Change. Reference Standard  
CTEC Change. Therapeutic Equivalence Code.  
CTNA Change. Trade Name.  
DISC Discontinued. The Rx or OTC listed product is not  
being marketed and will appear in the discontinued  
section in the next edition.

ABAMETAPIR

		LOTION; TOPICAL		XEGLYZE	
>D>	@ +	HATCHTECH	0.74%	N206966 001	Jul 24, 2020 Apr CAHN
>A>	@ +	LNHC	0.74%	N206966 001	Jul 24, 2020 Apr CAHN

ABARELIX

		POWDER; INTRAMUSCULAR		PLENAXIS	
	@	SPECIALITY EUROPEAN	100MG/VIAL	N021320 001	Nov 25, 2003 Jan CDFR

ACAMPROSATE CALCIUM

		TABLET, DELAYED RELEASE; ORAL		ACAMPROSATE CALCIUM	
AB		APPCO	333MG	A218984 001	Mar 16, 2026 Mar NEWA

ACARBOSE

		TABLET; ORAL		ACARBOSE	
	@	NATCO PHARMA USA	25MG	A091053 001	Jan 06, 2011 Mar CAHN
	@		50MG	A091053 002	Jan 06, 2011 Mar CAHN
	@		100MG	A091053 003	Jan 06, 2011 Mar CAHN

ACETAMINOPHEN; BUTALBITAL

		TABLET; ORAL		BUTAPAP	
AA	!	MIKART	325MG; 50MG	A089987 001	Oct 26, 1992 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

		CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	
AA		INGENUS PHARMS LLC	300MG; 50MG; 40MG	A215047 001	Nov 17, 2021 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

		CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE	
>A>	@	QUAGEN	325MG; 50MG; 40MG; 30MG	A204649 001	Jul 08, 2020 Apr CAHN
>D>	@	STRIDES PHARMA	325MG; 50MG; 40MG; 30MG	A204649 001	Jul 08, 2020 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

		TABLET; ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN	
AA		LANNETT CO INC	300MG; 5MG	A207171 001	Jun 20, 2017 Mar CMFD
AA			300MG; 7.5MG	A207171 002	Jun 20, 2017 Mar CMFD
AA			300MG; 10MG	A207171 003	Jun 20, 2017 Mar CMFD
AA			325MG; 5MG	A207172 001	Jun 22, 2017 Mar CMFD
AA			325MG; 7.5MG	A207172 002	Jun 22, 2017 Mar CMFD
AA			325MG; 10MG	A207172 003	Jun 22, 2017 Mar CMFD
	@	STRIDES PHARMA INTL	325MG; 5MG	A040655 001	Jan 19, 2006 Jan DISC
	@		325MG; 7.5MG	A040656 001	Jan 19, 2006 Jan DISC
	@		325MG; 10MG	A040355 001	May 31, 2000 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

		TABLET; ORAL		OXYCODONE AND ACETAMINOPHEN	
AA		LANNETT CO INC	325MG; 5MG	A207333 001	Sep 25, 2017 Feb CMFD
AA			325MG; 10MG	A207333 002	Sep 25, 2017 Feb CMFD
		PERCOCET			
>D>	AA	!	ENDO OPERATIONS	A040330 001	Jun 25, 1999 Apr CAHN
>D>	AA	!		A040330 002	Jun 25, 1999 Apr CAHN
>D>	@ +			A085106 002	Apr CAHN
>D>	AA	!		A040330 003	Nov 23, 2001 Apr CAHN
>D>	AA	!		A040330 004	Nov 23, 2001 Apr CAHN
>A>	AA	!	OZANTRI	A040330 001	Jun 25, 1999 Apr CAHN
>A>	AA	!		A040330 002	Jun 25, 1999 Apr CAHN
>A>	@ +			A085106 002	Apr CAHN
>A>	AA	!		A040330 003	Nov 23, 2001 Apr CAHN
>A>	AA	!		A040330 004	Nov 23, 2001 Apr CAHN

ACOLIDINIUM BROMIDEPOWDER, METERED; INHALATION  
TUDORZA PRESSAIR

+! AZURITY 0.4MG/INH N202450 001 Jul 23, 2012 Mar CAHN

ACOLIDINIUM BROMIDE; FORMOTEROL FUMARATEPOWDER, METERED; INHALATION  
DUAKLIR PRESSAIR

+! AZURITY 0.4MG/INH; 0.012MG/INH N210595 001 Mar 29, 2019 Mar CAHN

ACYCLOVIRTABLET; ORAL  
ACYCLOVIR@ STRIDES PHARMA INTL 400MG A074946 001 Nov 19, 1997 Jan DISC  
@ 800MG A074946 002 Nov 19, 1997 Jan DISCADAPALENESOLUTION; TOPICAL  
ADAPALENEAB WAYLIS THERAP 0.1% A203981 001 Sep 23, 2016 Jan CAHN  
AB 0.1% A204593 001 Jan 05, 2016 Jan CAHNALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

>A> ALBUTEROL SULFATE  
>A> AB3 CIPLA EQ 0.09MG BASE/INH A219409 001 Apr 22, 2026 Apr NFTG  
VENTOLIN HFA  
>D> BX +! GLAXOSMITHKLINE EQ 0.09MG BASE/INH N020983 001 Apr 19, 2001 Apr CFTG  
>A> AB3 +! EQ 0.09MG BASE/INH N020983 001 Apr 19, 2001 Apr CFTG

TABLET; ORAL

ALBUTEROL SULFATE

AB NATCO PHARMA USA EQ 2MG BASE A072894 002 Jan 17, 1991 Mar CAHN  
AB ! EQ 4MG BASE A072894 001 Jan 17, 1991 Mar CAHNALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

AB + LXO IRELAND EQ 150MG BASE N021985 001 Mar 05, 2007 Jan CAHN  
AB +! EQ 300MG BASE N021985 002 Mar 05, 2007 Jan CAHNALPELISIB>A> GRANULE; ORAL  
>A> VIJOICE  
>A> +! NOVARTIS 50MG/PACKET N218466 001 Apr 24, 2024 Apr CDFR  
>D> GRANULES; ORAL  
>D> VIJOICE  
>D> +! NOVARTIS 50MG/PACKET N218466 001 Apr 24, 2024 Apr CDFRALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

>D> +! SANDOZ CANADA INC 2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML N021163 001 May 18, 2000 Apr CFTG  
>A> AP +! 2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML N021163 001 May 18, 2000 Apr CFTG  
>D> +! 2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML N021163 002 Jun 16, 2003 Apr CFTG  
>A> AP +! 2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML N021163 002 Jun 16, 2003 Apr CFTG

SOLUTION;INTRAVENOUS

>A> MULTIPLE VITAMINS INJECTION ADULT

>A> AP APOTEX 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML A210273 001 Apr 09, 2026 Apr NFTG

>A> AP 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML A210672 001 Apr 09, 2026 Apr NFTG

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

@ STRIDES PHARMA INTL 0.25MG A090248 001 Sep 17, 2010 Jan DISC  
 @ 0.5MG A090248 002 Sep 17, 2010 Jan DISC  
 @ 1MG A090248 003 Sep 17, 2010 Jan DISC  
 @ 2MG A090248 004 Sep 17, 2010 Jan DISC

AMANTADINE HYDROCHLORIDE

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

>A> AA POM PHARMA 50MG/5ML A214178 001 Aug 20, 2021 Apr CAHN  
 >D> AA SHREE HARI INTL 50MG/5ML A214178 001 Aug 20, 2021 Apr CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

>D> AB ATHEM 100MG A210215 001 Mar 10, 2020 Apr CAHN  
 >A> AB POM PHARMA 100MG A210215 001 Mar 10, 2020 Apr CAHN

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

@ LEGACY PHARMA 375MG/VIAL N020221 002 Sep 10, 1999 Mar CAHN  
 +! 500MG/VIAL N020221 001 Dec 08, 1995 Mar CMFD  
 @ + 500MG/VIAL N020221 001 Dec 08, 1995 Mar CAHN

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP ZENARA 250MG/ML A215374 001 Aug 28, 2025 Mar CAHN

SOLUTION;ORAL

AMINOCAPROIC ACID

AA CARNEGIE 0.25GM/ML A214140 001 Jan 26, 2021 Feb CAHN

TABLET;ORAL

AMINOCAPROIC ACID

AB CARNEGIE 500MG A213928 001 Feb 12, 2021 Feb CAHN  
 AB 1GM A213928 002 Feb 12, 2021 Feb CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB AUROBINDO PHARMA USA 10MG A086009 002 Mar CMFD  
 AB 25MG A086009 003 Mar CMFD  
 AB 50MG A086009 001 Mar CMFD  
 AB 75MG A086009 004 Mar CMFD  
 AB 100MG A086009 005 Mar CMFD  
 AB 150MG A086009 006 Mar CMFD

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL

SDAMLO

+! BRILLIAN PHARMA EQ 2.5MG BASE/BOT N219531 001 Jul 24, 2025 Jan CMFD  
 +! EQ 5MG BASE/BOT N219531 002 Jul 24, 2025 Jan CMFD  
 +! EQ 10MG BASE/BOT N219531 003 Jul 24, 2025 Jan CMFD

TABLET;ORAL

AMLODIPINE BESYLATE

AB GRAVITI PHARMS EQ 2.5MG BASE A201380 003 Feb 17, 2026 Feb NEWA  
 AB TEVA PHARMS INC EQ 2.5MG BASE A219686 001 Jan 22, 2026 Jan NEWA  
 AB EQ 5MG BASE A219686 002 Jan 22, 2026 Jan NEWA  
 AB EQ 10MG BASE A219686 003 Jan 22, 2026 Jan NEWA

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET; ORAL

WIDAPLIK

+	AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Mar	CMFD
+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Mar	CMFD
+	!	EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Mar	CMFD

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

@	LUPIN	EQ 5MG BASE;40MG	A201586	001	Jan 08, 2014	Jan	DISC
@		EQ 5MG BASE;80MG	A201586	003	Jan 08, 2014	Jan	DISC
@		EQ 10MG BASE;40MG	A201586	002	Jan 08, 2014	Jan	DISC
@		EQ 10MG BASE;80MG	A201586	004	Jan 08, 2014	Jan	DISC
	MYLAN	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Feb	CMFD
@		EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Jan	DISC
		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Feb	CMFD
@		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Jan	DISC
		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Feb	CMFD
@		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Jan	DISC
	!	EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Feb	CMFD
@		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Jan	DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>D>	AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Apr	DISC
>A>		@	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Apr	DISC
>D>	AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Apr	DISC
>A>		@	EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Apr	DISC
>D>	AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Apr	DISC
>A>		@	EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Apr	DISC
>D>	AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Apr	DISC
>A>		@	EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Apr	DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>D>	AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr	DISC
>A>		@	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr	DISC
		!	WA UNIV SCH MED	A204506	002	Feb 13, 2026	Feb	NFTG
			37.5mCi-800mCi/10ML (3.75-80mCi/ML)					

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB		PADAGIS ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	Jan	CHRS	
AB		!	SUN PHARMA CANADA	EQ 12% BASE	A075883	001	Apr 10, 2003	Jan	CHRS
AB			ZYDUS LIFESCIENCES	EQ 12% BASE	A217815	001	Feb 12, 2026	Feb	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Jan	CTEC
			AUGMENTIN XR						
AB		+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Jan	CMFD

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

@	INGENUS PHARMS LLC	5MG	A213763	001	Aug 24, 2020	Feb	CAHN
@		10MG	A213763	002	Aug 24, 2020	Feb	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

@	EUROFARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Feb	CAHN
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Feb	CAHN

APREPITANT

		EMULSION; INTRAVENOUS							
		APONVIE							
	AB	+	HERON THERAPS INC	32MG/4.4ML	(7.2MG/ML)	N216457	001	Sep 16, 2022	Mar CTEC
	AB	+		32MG/4.4ML	(7.2MG/ML)	N216457	001	Sep 16, 2022	Feb CFTG
		APREPITANT							
	AB	@	MYLAN	32MG/4.4ML	(7.2MG/ML)	A218851	001	Mar 05, 2026	Mar DISC
	AB			32MG/4.4ML	(7.2MG/ML)	A218851	001	Mar 05, 2026	Feb NFTG

ARIPIPIRAZOLE

		TABLET; ORAL							
		ARIPIPIRAZOLE							
>D>	AB		APOTEX	2MG		A078583	001	Jul 24, 2015	Apr DISC
>A>		@		2MG		A078583	001	Jul 24, 2015	Apr DISC
>D>	AB			5MG		A078583	002	Jul 24, 2015	Apr DISC
>A>		@		5MG		A078583	002	Jul 24, 2015	Apr DISC
>D>	AB			10MG		A078583	003	Jul 24, 2015	Apr DISC
>A>		@		10MG		A078583	003	Jul 24, 2015	Apr DISC
>D>	AB			15MG		A078583	004	Jul 24, 2015	Apr DISC
>A>		@		15MG		A078583	004	Jul 24, 2015	Apr DISC
>D>	AB			20MG		A078583	005	Jul 24, 2015	Apr DISC
>A>		@		20MG		A078583	005	Jul 24, 2015	Apr DISC
>D>	AB			30MG		A078583	006	Jul 24, 2015	Apr DISC
>A>		@		30MG		A078583	006	Jul 24, 2015	Apr DISC
		TABLET, ORALLY DISINTEGRATING; ORAL							
		ARIPIPIRAZOLE							
	AB		AUROBINDO PHARMA	10MG		A216208	001	Feb 18, 2026	Feb NEWA
	AB			15MG		A216208	002	Feb 18, 2026	Feb NEWA

ARMODAFINIL

		TABLET; ORAL							
		ARMODAFINIL							
	AB		COREPHARMA	50MG		A201514	001	Mar 25, 2019	Jan CMFD
	AB			150MG		A201514	002	Mar 25, 2019	Jan CMFD
	AB			250MG		A201514	003	Mar 25, 2019	Jan CMFD

ARSENIC TRIOXIDE

		INJECTABLE; INJECTION							
		ARSENIC TRIOXIDE							
	AP		INGENUS PHARMS LLC	1MG/ML		A209315	001	Nov 15, 2018	Feb CAHN
		@		2MG/ML		A209315	002	Jan 14, 2021	Feb CAHN

ARTICAINE HYDROCHLORIDE

		SOLUTION/DROPS; OPHTHALMIC							
		CYKLX							
>D>		@ +	AM GENOMICS	EQ 8% BASE		N218643	001	Aug 15, 2025	Apr CAHN
>A>		@ +		EQ 8% BASE		N218643	001	Aug 15, 2025	Feb DISC
>A>		@ +	THEA PHARMA	EQ 8% BASE		N218643	001	Aug 15, 2025	Apr CAHN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

		INJECTABLE; INTRAVENOUS							
		INFUVITE PEDIATRIC							
>D>		+	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL		N021265	001	Feb 21, 2001	Apr CFTG
>A>	AP	+		80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL		N021265	001	Feb 21, 2001	Apr CFTG
>D>		+	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL		N021265	002	Jan 29, 2004	Apr CFTG
>A>	AP	+		80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL;		N021265	002	Jan 29, 2004	Apr CFTG

## INJECTABLE; INTRAVENOUS

## INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL  
; 1.4MG/VIAL; 1.2MG/VIAL; 7  
IU/VIAL; 2, 300  
IU/VIAL; 0.2MG/VIAL

>A>	MULTIPLE VITAMINS INJECTION PEDIATRIC							
>A> AP	APOTEX	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL ; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2, 300 IU/VIAL; 0.2MG/VIAL	A210671	001	Apr 21, 2026	Apr	NFTG	
>A>	MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE)							
>A> AP	APOTEX	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL ; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2, 300 IU/VIAL; 0.2MG/VIAL	A210456	001	Apr 21, 2026	Apr	NFTG	

ASENAPINE MALEATE

## TABLET; SUBLINGUAL

## SAPHRIS

AB	+	ABBVIE	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Mar	CAHN
AB	+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Mar	CAHN
AB	+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Mar	CAHN

>D> ASPIRIN; OXYCODONE HYDROCHLORIDE

## &gt;D&gt; TABLET; ORAL

## &gt;D&gt; OXYCODONE AND ASPIRIN

>D> AA	EPIC PHARMA LLC	325MG; 4.8355MG	A040910	001	Jul 16, 2020	Apr	DISC	
>A>	@	325MG; 4.8355MG	A040910	001	Jul 16, 2020	Apr	DISC	
>D>	PERCODAN							
>D> AA	! ENDO OPERATIONS	325MG; 4.8355MG	N007337	007	Aug 05, 2005	Apr	DISC	
>A>	@ +	325MG; 4.8355MG	N007337	007	Aug 05, 2005	Apr	DISC	

ATENOLOL

## TABLET; ORAL

## ATENOLOL

AB		IPCA LABS LTD	25MG	A077877	001	Dec 27, 2006	Jan	CMFD
AB			50MG	A077877	002	Dec 27, 2006	Jan	CMFD
AB			100MG	A077877	003	Dec 27, 2006	Jan	CMFD

ATENOLOL; CHLORTHALIDONE

## TABLET; ORAL

## ATENOLOL AND CHLORTHALIDONE

>D> AB	UNICHEM	100MG; 25MG	A213302	002	Nov 25, 2020	Apr	CHRS	
>A> AB	!	100MG; 25MG	A213302	002	Nov 25, 2020	Apr	CHRS	
>D>	TENORETIC 100							
>D> AB	! TWI PHARMS	100MG; 25MG	N018760	001	Jun 08, 1984	Apr	DISC	
>A>	@ +	100MG; 25MG	N018760	001	Jun 08, 1984	Apr	DISC	
>D>	TENORETIC 50							
>D> AB	+ TWI PHARMS	50MG; 25MG	N018760	002	Jun 08, 1984	Apr	DISC	
>A>	@ +	50MG; 25MG	N018760	002	Jun 08, 1984	Apr	DISC	

ATOMOXETINE HYDROCHLORIDE

## SOLUTION; ORAL

## ATONCY

## +! MAP77

EQ 4MG BASE/ML

N220320 001 Mar 20, 2026 Mar NEWA

ATROPINE SULFATE

## SOLUTION/DROPS; OPHTHALMIC

## ATROPINE SULFATE

>A> AT1	EDENBRIDGE PHARMS	1%	A219013	001	Apr 15, 2026	Apr	NEWA	
---------	-------------------	----	---------	-----	--------------	-----	------	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

## TABLET; ORAL

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	@	PHARMOBEDIANT	0.025MG; 2.5MG	A085762	001		Apr	CAHN
>A>	@	QUAGEN	0.025MG; 2.5MG	A085762	001		Apr	CAHN
>A>	@		0.025MG; 2.5MG	A210571	001	Aug 31, 2018	Feb	CAHN

AXITINIB

TABLET; ORAL

>D>		AXITINIB							
>D>	AB	APOTEX	1MG	A211650	001	Oct 30, 2025	Apr	DISC	
>A>		@	1MG	A211650	001	Oct 30, 2025	Apr	DISC	
>D>	AB		5MG	A211650	002	Oct 30, 2025	Apr	DISC	
>A>		@	5MG	A211650	002	Oct 30, 2025	Apr	DISC	
		INLYTA							
>D>	AB	+ PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr	CTEC	
>A>		+	1MG	N202324	001	Jan 27, 2012	Apr	CTEC	
>D>	AB	+!	5MG	N202324	002	Jan 27, 2012	Apr	CTEC	
>A>		+!	5MG	N202324	002	Jan 27, 2012	Apr	CTEC	

AZACITIDINEPOWDER; INTRAVENOUS, SUBCUTANEOUS  
AZACITIDINE

>D>	AP	AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Apr	DISC	
>A>		@	100MG/VIAL	A211549	001	Feb 03, 2022	Apr	DISC	

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

AZILSARTAN MEDOXOMIL

>A>	AB	LUPIN	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Apr	CMFD	
>A>	AB		EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Apr	CMFD	
>D>		@ LUPIN LTD	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Apr	CMFD	
>D>		@	EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Apr	CMFD	
		EDARBI							
>D>		+ AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CTEC	
>A>	AB	+	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CTEC	
>D>		+!	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CTEC	
>A>	AB	+!	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CTEC	

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

		@ CARLSBAD	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb	CAHN	
AB			EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CAHN	

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

		@ HIKMA	1GM/VIAL	A207069	001	Feb 05, 2026	Feb	DISC	
AP			1GM/VIAL	A207069	001	Feb 05, 2026	Jan	NEWA	
		@	2GM/VIAL	A207069	002	Feb 05, 2026	Feb	DISC	
AP			2GM/VIAL	A207069	002	Feb 05, 2026	Jan	NEWA	

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

		@ PADAGIS US	500 UNITS/GM	A061212	001		Mar	DISC	
--	--	--------------	--------------	---------	-----	--	-----	------	--

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

		@ PADAGIS US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Mar	DISC	
--	--	--------------	---	---------	-----	--	-----	------	--

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

		@ PADAGIS US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Mar	DISC	
--	--	--------------	--	---------	-----	--	-----	------	--

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

		! BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	Mar	CTEC	
		@ PADAGIS US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Mar	DISC	

BACLOFEN

>A>	GRANULE;ORAL								
>A>	LYVISPAAH								
>A>	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Apr	CDFR	
>A>	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Apr	CDFR	
>A>	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Apr	CDFR	
>D>	GRANULES;ORAL								
>D>	LYVISPAAH								
>D>	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Apr	CDFR	
	@ +		5MG/PACKET	N215422	001	Nov 22, 2021	Jan	CAHN	
>D>	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Apr	CDFR	
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jan	CAHN	
>D>	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Apr	CDFR	
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jan	CAHN	
	TABLET;ORAL								
	BACLOFEN								
AB		RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jan	CHRS	

BALSALAZIDE DISODIUM

	CAPSULE;ORAL								
	BALSALAZIDE DISODIUM								
AB		CARNEGIE	750MG	A219422	001	Apr 03, 2025	Feb	CAHN	

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL								
	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE								
	@	APOTEX	5MG; 6.25MG	A078794	001	Aug 21, 2014	Mar	DISC	
	@		10MG; 12.5MG	A078794	002	Aug 21, 2014	Mar	DISC	
	@		20MG; 12.5MG	A078794	003	Aug 21, 2014	Mar	DISC	
	@		20MG; 25MG	A078794	004	Aug 21, 2014	Mar	DISC	
AB	!	SANDOZ	20MG; 25MG	A076631	004	Feb 11, 2004	Jan	CHRS	
	LOTENSIN HCT								
AB	+	VALIDUS PHARMS	20MG; 25MG	N020033	003	May 19, 1992	Jan	CHRS	

BENDAMUSTINE HYDROCHLORIDE

	SOLUTION;INTRAVENOUS								
	BENDAMUSTINE HYDROCHLORIDE								
	+!	AVYXA HOLDINGS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Mar	CAHN	
>D>	@ +	DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Apr	CMFD	
>A>	+!		100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Apr	CMFD	

BENZONATATE

	CAPSULE;ORAL								
	BENZONATATE								
>D>	@	ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019	Apr	CMFD	
>A>	AA		150MG	A211518	002	Feb 22, 2019	Apr	CMFD	
	AA	MARKSANS PHARMA	100MG	A220298	001	Mar 30, 2026	Mar	NEWA	
	AA		200MG	A220298	002	Mar 30, 2026	Mar	NEWA	
>D>	!	THEPHARMANETWORK LLC	150MG	A040627	003	Sep 24, 2014	Apr	CTEC	
>A>	AA	!	150MG	A040627	003	Sep 24, 2014	Apr	CTEC	

BEPOTASTINE BESILATE

	SOLUTION/DROPS;OPHTHALMIC								
	BEPOTASTINE BESILATE								
>D>	AT	APOTEX	1.5%	A206066	001	Mar 05, 2019	Apr	DISC	
>A>	@		1.5%	A206066	001	Mar 05, 2019	Apr	DISC	

BETAMETHASONE DIPROPIONATE

	CREAM;TOPICAL								
	BETAMETHASONE DIPROPIONATE								
AB		AUROBINDO PHARMA LTD	EQ 0.05% BASE	A219348	001	Jan 26, 2026	Jan	NEWA	

BETAMETHASONE VALERATE

	AEROSOL, FOAM;TOPICAL								
	BETAMETHASONE VALERATE								
	@	INGENUS PHARMS LLC	0.12%	A207144	001	May 24, 2017	Feb	CAHN	

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
BETAXOLOL HYDROCHLORIDE

AT	EUROFARMA	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Feb CAHN
----	-----------	--------------	---------	-----	--------------	----------

BIMATOPROSTSOLUTION/DROPS;TOPICAL  
BIMATOPROST

>D>	AT	APOTEX	0.03%	A201894	001	Dec 01, 2014	Apr DISC
>A>		@	0.03%	A201894	001	Dec 01, 2014	Apr DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB	INGENUS PHARMS LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Feb CAHN
----	--------------------	-------------------	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	MICRO LABS	5MG	A218303	001	Mar 09, 2026	Feb NEWA	
AB		10MG	A218303	002	Mar 09, 2026	Feb NEWA	
	@	NATCO PHARMA USA	5MG	A075831	001	Dec 14, 2005	Mar CAHN
	@		10MG	A075831	002	Dec 14, 2005	Mar CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	2.5MG;6.25MG	A217922	001	Jan 21, 2026	Jan NEWA
AB		5MG;6.25MG	A217922	002	Jan 21, 2026	Jan NEWA
AB		10MG;6.25MG	A217922	003	Jan 21, 2026	Jan NEWA
AB	UNIQUE PHARM	2.5MG;6.25MG	A219489	001	Mar 24, 2026	Mar NEWA
AB		5MG;6.25MG	A219489	002	Mar 24, 2026	Mar NEWA
AB		10MG;6.25MG	A219489	003	Mar 24, 2026	Mar NEWA

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	@	CAPLIN ONE LABS	3.5MG/VIAL	A203654	001	Jul 26, 2022	Mar DISC
AP			3.5MG/VIAL	A203654	001	Jul 26, 2022	Jan CAHN

BOSENTAN

TABLET, FOR SUSPENSION;ORAL

BOSENTAN

AB	ZYDUS PHARMS	32MG	A213981	001	Feb 17, 2026	Feb NEWA
----	--------------	------	---------	-----	--------------	----------

BRIGATINIB

TABLET;ORAL

ALUNBRIG

	+	TAKEDA PHARMS USA	90MG	N208772	002	Apr 28, 2017	Jan CHRS
	+		180MG	N208772	003	Oct 02, 2017	Jan CHRS

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AB	GLAND	0.1%	A219219	001	Mar 11, 2026	Feb NEWA	
>A>	AB	MANKIND PHARMA	0.1%	A220398	001	Apr 16, 2026	Apr NEWA
>A>	AB	MICRO LABS	0.1%	A218558	001	May 07, 2026	Apr NEWA

BRIMONIDINE TARTRATE; CARBACHOL

SOLUTION/DROPS;OPHTHALMIC

YUVEZZI

	+	VISUS	0.1%;2.75%	N220142	001	Jan 28, 2026	Jan NEWA
--	---	-------	------------	---------	-----	--------------	----------

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVARACETAM

AP	HAINAN POLY	50MG/5ML (10MG/ML)	A218249	001	Feb 23, 2026	Feb NFTG
AP	MICRO LABS	50MG/5ML (10MG/ML)	A214880	001	Feb 23, 2026	Feb NFTG
AP	MSN	50MG/5ML (10MG/ML)	A214924	001	Feb 23, 2026	Feb NFTG

SOLUTION; INTRAVENOUS								
BRIVIACT								
AP	+	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	Feb CFTG	
SOLUTION; ORAL								
BRIVARACETAM								
AA		ALKEM LABS LTD	10MG/ML	A219772	001	Feb 23, 2026	Feb NEWA	
AA		INDOCO	10MG/ML	A220385	001	Feb 23, 2026	Feb NEWA	
AA		LUPIN	10MG/ML	A220164	001	Feb 23, 2026	Feb NEWA	
AA		MSN	10MG/ML	A214922	001	Feb 19, 2026	Feb NFTG	
AA		REGCON HOLDINGS	10MG/ML	A220385	001	Feb 23, 2026	Mar CAHN	
AA		ZHEJIANG POLY PHARM	10MG/ML	A218494	001	Feb 23, 2026	Feb NEWA	
BRIVIACT								
AA	+	UCB INC	10MG/ML	N205838	001	May 12, 2016	Feb CFTG	
TABLET; ORAL								
BRIVARACETAM								
AB		APOTEX	10MG	A214875	001	Feb 23, 2026	Feb NEWA	
AB			25MG	A214875	002	Feb 23, 2026	Feb NEWA	
AB			50MG	A214875	003	Feb 23, 2026	Feb NEWA	
AB			75MG	A214875	004	Feb 23, 2026	Feb NEWA	
AB			100MG	A214875	005	Feb 23, 2026	Feb NEWA	
AB		AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Jan CMFD	
AB			100MG	A214848	002	Jan 06, 2023	Jan CMFD	
AB		CENTAUR PHARMS PVT	10MG	A220470	001	Feb 23, 2026	Feb NEWA	
AB			25MG	A220470	002	Feb 23, 2026	Feb NEWA	
AB			50MG	A220470	003	Feb 23, 2026	Feb NEWA	
AB			75MG	A220470	004	Feb 23, 2026	Feb NEWA	
AB			100MG	A220470	005	Feb 23, 2026	Feb NEWA	
AB		SUNSHINE	10MG	A214748	001	Jun 09, 2022	Jan CMFD	
AB			25MG	A214748	002	Jun 09, 2022	Jan CMFD	
AB			50MG	A214748	003	Jun 09, 2022	Jan CMFD	
AB			75MG	A214748	004	Jun 09, 2022	Jan CMFD	
AB			100MG	A214748	005	Jun 09, 2022	Jan CMFD	
<u>BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>								
SYRUP; ORAL								
BROMFED-DM								
	@	+	PHARMOBEDIENT	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Jan DISC
<u>BUDESONIDE</u>								
SUSPENSION; INHALATION								
PULMICORT RESPULES								
AN	+	ASTRAZENECA	0.25MG/2ML	N020929	001	Aug 08, 2000	Jan CHRS	
AN	+		0.5MG/2ML	N020929	002	Aug 08, 2000	Jan CHRS	
<u>BUDESONIDE; FORMOTEROL FUMARATE</u>								
AEROSOL, METERED; INHALATION								
SYMBICORT AEROSPHERE								
>A>	+	ASTRAZENECA	0.08MG/INH; 0.0048MG/INH	N216579	002	Apr 27, 2026	Apr NEWA	
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE</u>								
AEROSOL, METERED; INHALATION								
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE								
>A>	AB	TEVA PHARMS USA INC	0.08MG/INH; 0.0045MG/INH	A212212	001	Apr 23, 2026	Apr NEWA	
>A>	AB		0.16MG/INH; 0.0045MG/INH	A212212	002	Apr 23, 2026	Apr NEWA	
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE</u>								
AEROSOL, METERED; INHALATION								
BREZTRI AEROSPHERE								
>A>	+	ASTRAZENECA AB	0.16MG/INH; 0.0048MG/INH; 0.018MG/INH	N212122	002	Apr 27, 2026	Apr NEWA	
<u>BUMETANIDE</u>								
INJECTABLE; INJECTION								
BUMETANIDE								
AP		ANTHEA PHARMA	0.25MG/ML	A220427	001	Feb 26, 2026	Feb NEWA	
TABLET; ORAL								
BUMETANIDE								
AB		MSN	0.5MG	A215362	001	Feb 05, 2026	Jan NEWA	
AB			1MG	A215362	002	Feb 05, 2026	Jan NEWA	
AB			2MG	A215362	003	Feb 05, 2026	Jan NEWA	

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION  
BUPIVACAINE HYDROCHLORIDE

>A>	AP	ANTHEA PHARMA	0.25%	A220493	001	Apr 22, 2026	Apr	NEWA
>A>	AP		0.5%	A220493	002	Apr 22, 2026	Apr	NEWA
>A>	AP		0.75%	A220493	003	Apr 22, 2026	Apr	NEWA

BUPRENORPHINESOLUTION, EXTENDED RELEASE; SUBCUTANEOUS  
BRIXADI

+	!	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	Mar	CHRS
+	!		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	Mar	CHRS
+	!		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	Mar	CHRS
+	!		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	Mar	CHRS
+	!		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	Mar	CHRS
+	!		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	Mar	CHRS

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEFILM; BUCCAL, SUBLINGUAL  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	EQ 2MG BASE; EQ 0.5MG BASE	A219850	001	Jan 21, 2026	Jan	NEWA
AB			EQ 4MG BASE; EQ 1MG BASE	A219850	002	Jan 21, 2026	Jan	NEWA
AB			EQ 8MG BASE; EQ 2MG BASE	A219850	003	Jan 21, 2026	Jan	NEWA
AB			EQ 12MG BASE; EQ 3MG BASE	A219850	004	Jan 21, 2026	Jan	NEWA

BUPROPION HYDROCHLORIDETABLET; ORAL  
BUPROPION HYDROCHLORIDE

AB		SENORES PHARMS	75MG	A075584	001	Feb 07, 2000	Feb	CAHN
AB			100MG	A075584	002	Feb 07, 2000	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL  
BUPROPION HYDROCHLORIDE

>A>	AB1	YICHANG HUMANWELL	100MG	A220529	001	May 04, 2026	Apr	NEWA
>A>	AB1		150MG	A220529	002	May 04, 2026	Apr	NEWA
>A>	AB1		200MG	A220529	003	May 04, 2026	Apr	NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL  
AUVELITY

>A>		+	AXSOME	105MG; 30MG	N215430	002	Apr 30, 2026	Apr	NEWA
-----	--	---	--------	-------------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDECAPSULE; ORAL  
BUCAPSOL

>A>		EPIC PHARMA LLC	5MG	A218628	004	Apr 29, 2026	Apr	NFTG
-----	--	-----------------	-----	---------	-----	--------------	-----	------

TABLET; ORAL  
BUSPIRONE HYDROCHLORIDE  
@ MYLAN

			7.5MG	A076008	002	Jul 08, 2013	Feb	DISC
--	--	--	-------	---------	-----	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATETABLET; ORAL  
ERGOTAMINE TARTRATE AND CAFFEINE

!		MIKART	100MG; 1MG	A040590	001	Sep 16, 2005	Mar	CAHN
---	--	--------	------------	---------	-----	--------------	-----	------

CALCITONIN SALMONINJECTABLE; INJECTION  
CALCITONIN-SALMON

AP		ZYDUS PHARMS	200 IU/ML	A215864	001	Mar 04, 2026	Feb	NEWA
----	--	--------------	-----------	---------	-----	--------------	-----	------

CALCITRIOLCAPSULE; ORAL  
CALCITRIOL

AB		HUMANWELL PURACAP	0.25MCG	A219796	001	Feb 27, 2026	Feb	NEWA
AB			0.5MCG	A219796	002	Feb 27, 2026	Feb	NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

@	LUPIN	667MG	A202127	001	Jul 09, 2015	Mar	DISC
---	-------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

CALCIUM ACETATE

@	PADAGIS US	667MG	A091561	001	Apr 13, 2011	Mar	DISC
---	------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

@	SQUARE PHARMS PLC	100MG/ML	A217463	001	Sep 29, 2025	Mar	DISC
---	-------------------	----------	---------	-----	--------------	-----	------

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

>A>	AP	CAPLIN	1GM/10ML (100MG/ML)	A218840	001	May 04, 2026	Apr	NEWA
>A>	AP		5GM/50ML (100MG/ML)	A218840	002	May 04, 2026	Apr	NEWA
>A>	AP		10GM/100ML (100MG/ML)	A218840	003	May 04, 2026	Apr	NEWA

CANAGLIFLOZIN

TABLET;ORAL

CANAGLIFLOZIN

>A>	AB	APOTEX	100MG	A210449	001	Apr 14, 2026	Apr	NFTG
>A>	AB		300MG	A210449	002	Apr 14, 2026	Apr	NFTG
>A>	AB	AUROBINDO PHARMA LTD	100MG	A210386	001	Apr 20, 2026	Apr	NEWA
>A>		@	100MG	A210386	001	Apr 20, 2026	Apr	DISC
>A>	AB		300MG	A210386	002	Apr 20, 2026	Apr	NEWA
>A>		@	300MG	A210386	002	Apr 20, 2026	Apr	DISC
		INVOKANA						
>D>		+ JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr	CFTG
>A>	AB	+ JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr	CFTG
>D>		+!	300MG	N204042	002	Mar 29, 2013	Apr	CFTG
>A>	AB	+!	300MG	N204042	002	Mar 29, 2013	Apr	CFTG

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	SENORES PHARMS	16MG;12.5MG	A202965	001	Jun 03, 2013	Jan	CAHN
AB		32MG;12.5MG	A202965	002	Jun 03, 2013	Jan	CAHN
AB		32MG;25MG	A202965	003	Jun 03, 2013	Jan	CAHN

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	!	DR REDDYS	500MG	A204345	002	Dec 04, 2020	Jan	CHRS
		XELODA						
	@ +	CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Jan	DISC
	@ +		500MG	N020896	002	Apr 30, 1998	Jan	DISC

CARBAMAZEPINE

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	INGENUS PHARMS LLC	100MG	A216404	001	Dec 02, 2022	Feb	CAHN
AB		200MG	A216404	002	Dec 02, 2022	Feb	CAHN
AB		400MG	A216404	003	Dec 02, 2022	Feb	CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	ALEMBIC	12.5MG;200MG;50MG	A218535	001	Feb 05, 2026	Jan	NEWA
AB		18.75MG;200MG;75MG	A218535	002	Feb 05, 2026	Jan	NEWA
AB		25MG;200MG;100MG	A218535	003	Feb 05, 2026	Jan	NEWA
AB		31.25MG;200MG;125MG	A218535	004	Feb 05, 2026	Jan	NEWA
AB		37.5MG;200MG;150MG	A218535	005	Feb 05, 2026	Jan	NEWA
AB		50MG;200MG;200MG	A218535	006	Feb 05, 2026	Jan	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL  
CARBIDOPA AND LEVODOPA

@	SUN PHARM INDS	25MG;100MG	A077828	001	Aug 23, 2007	Feb	DISC
@		50MG;200MG	A077828	002	Aug 23, 2007	Feb	DISC

CARBOPLATIN

INJECTABLE; INTRAVENOUS  
CARBOPLATIN

@	NOVAST LABS	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Feb	DISC
@		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Feb	DISC
@		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Feb	DISC
@		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Feb	DISC
AP	QILU PHARM HAINAN	50MG/5ML (10MG/ML)	A219999	001	Feb 04, 2026	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A219999	002	Feb 04, 2026	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A219999	003	Feb 04, 2026	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A219999	004	Feb 04, 2026	Jan	NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL  
CARIPRAZINE HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A213982	001	Dec 16, 2025	Jan	DISC
@		EQ 3MG BASE	A213982	002	Dec 16, 2025	Jan	DISC
@		EQ 6MG BASE	A213982	003	Dec 16, 2025	Jan	DISC
	VRAYLAR						
+!	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CTEC
+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CTEC
+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CTEC

CARISOPRODOL

TABLET;ORAL  
CARISOPRODOL

AA	INGENUS PHARMS LLC	350MG	A040823	001	Oct 22, 2008	Feb	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

CARVEDILOL

TABLET;ORAL  
CARVEDILOL

@	LUPIN	3.125MG	A078217	001	Sep 05, 2007	Feb	DISC
@		6.25MG	A078217	002	Sep 05, 2007	Feb	DISC
@		12.5MG	A078217	003	Sep 05, 2007	Feb	DISC
@		25MG	A078217	004	Sep 05, 2007	Feb	DISC

CEFAZOLIN SODIUM

POWDER; INTRAVENOUS  
CEFAZOLIN SODIUM

+!	HQ SPCLT PHARMA	EQ 3GM BASE/VIAL	N211413	002	Mar 08, 2024	Feb	NEWA
----	-----------------	------------------	---------	-----	--------------	-----	------

CEFIXIME

CAPSULE;ORAL  
CEFIXIME

AB	AUROBINDO PHARMA LTD	400MG	A217607	001	Mar 23, 2026	Mar	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL  
CEFIXIME

!	FDC LTD	400MG	A206358	001	Dec 17, 2024	Jan	CMFD
---	---------	-------	---------	-----	--------------	-----	------

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS  
CEFTAROLINE FOSAMIL

AP	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Jan	CMFD
AP		600MG/VIAL	A208075	002	Sep 21, 2021	Jan	CMFD

TEFLARO

AP	+!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	Jan	CTEC
AP	+		600MG/VIAL	N200327	002	Oct 29, 2010	Jan	CTEC

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION  
CEFTRIAZONE

>D>	AP	!	SANDOZ INC	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Apr	DISC
>A>		@		EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Apr	DISC
>D>	AP	!		EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Apr	DISC
>A>		@		EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Apr	DISC

CETIRIZINE HYDROCHLORIDESOLUTION; INTRAVENOUS  
QUZYTIR

>A>	+	!	ESTEVE	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Apr	CAHN
>D>	+	!	JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Apr	CAHN

SOLUTION; ORAL

CETIRIZINE HYDROCHLORIDE

AA			RUBICON RESEARCH	5MG/5ML	A220335	001	Feb 25, 2026	Feb	NEWA
	@		TIME CAP LABS	5MG/5ML	A078757	001	Aug 28, 2009	Mar	CAHN

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS

CETRORELIX ACETATE

>A>	AP		HUMANWELL	EQ 0.25MG BASE/VIAL	A218740	001	Apr 29, 2026	Apr	NEWA
-----	----	--	-----------	---------------------	---------	-----	--------------	-----	------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB			ZYDUS LIFESCIENCES	30MG	A220267	001	Mar 11, 2026	Feb	NEWA
----	--	--	--------------------	------	---------	-----	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	+		BARR	5MG	A084768	001		Mar	CRLD
AB	+			10MG	A083116	001		Mar	CRLD
AB	+	!		25MG	A084769	001		Mar	CRLD
			LIBRIUM						
AB	+		BAUSCH	5MG	A085461	001		Feb	CAHN
AB	+			10MG	A085472	001		Feb	CAHN

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

@	+		SALIX PHARMS	250MG/5ML	N011870	001		Jan	DISC
---	---	--	--------------	-----------	---------	-----	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@			PADAGIS US	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Mar	DISC
---	--	--	------------	----------------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AA	!		GENUS	30MG/ML	A214542	001	Jun 02, 2021	Mar	CTEC
AA	!			100MG/ML	A214542	002	Jun 02, 2021	Mar	CTEC
AA			RUBICON	30MG/ML	A216678	001	Oct 10, 2025	Mar	CTEC
AA				100MG/ML	A216678	002	Oct 10, 2025	Mar	CTEC
			SONAZINE						
AA			SAPTALIS PHARMS	30MG/ML	A080983	004		Mar	CMFD
AA				100MG/ML	A080983	005		Mar	CMFD

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP			MSN	25MG/ML	A216092	001	Jan 26, 2026	Jan	NEWA
----	--	--	-----	---------	---------	-----	--------------	-----	------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB			ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Jan	CAHN
AB				25MG	A212630	002	Nov 29, 2021	Jan	CAHN
AB				50MG	A212630	003	Nov 29, 2021	Jan	CAHN
AB				100MG	A212630	004	Nov 29, 2021	Jan	CAHN
AB				200MG	A212630	005	Nov 29, 2021	Jan	CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	!		ALKEM LABS LTD	50MG	A213412	002	Feb 11, 2020	Mar	CHRS
----	---	--	----------------	------	---------	-----	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	SENORES PHARMS	500MG	A210961	001	Jan 22, 2024	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	MICRO LABS	EQ 4GM RESIN/PACKET	A219318	001	Mar 05, 2026	Feb	NEWA
AB	PHARMOBEDIANT	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Jan	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Jan	CAHN
	CHOLESTYRAMINE LIGHT						
AB	ZYDUS PHARMS	EQ 4GM RESIN/PACKET	A202902	002	Apr 25, 2017	Mar	NEWA

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

AP	SOMERSET THERAPS LLC	EQ 0.004MG CHROMIUM/ML	A218538	001	Nov 18, 2024	Feb	CAHN
----	----------------------	------------------------	---------	-----	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; NASAL

ZETONNA

@ + AZURITY

0.037MG/INH

N202129	001	Jan 20, 2012	Mar	CAHN
---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+! AZURITY

0.05MG/SPRAY

N022004	001	Oct 20, 2006	Mar	CAHN
---------	-----	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

LOPROX

+! EUROFARMA

0.77%

N018748	001	Dec 30, 1982	Feb	CAHN
---------	-----	--------------	-----	------

SUSPENSION; TOPICAL

LOPROX

+! EUROFARMA

0.77%

N019824	001	Dec 30, 1988	Feb	CAHN
---------	-----	--------------	-----	------

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

@ HETERO LABS LTD V

EQ 30MG BASE

A209403	001	Oct 07, 2020	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 60MG BASE

A209403	002	Oct 07, 2020	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 90MG BASE

A209403	003	Oct 07, 2020	Feb	DISC
---------	-----	--------------	-----	------

@ STEVENS J

EQ 30MG BASE

A204364	001	Dec 02, 2021	Feb	CPOT
---------	-----	--------------	-----	------

@

EQ 60MG BASE

A204364	002	Dec 02, 2021	Feb	CPOT
---------	-----	--------------	-----	------

@

EQ 90MG BASE

A204364	003	Dec 02, 2021	Feb	CPOT
---------	-----	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ AMNEAL

EQ 250MG BASE

A075939	002	Jun 09, 2004	Mar	DISC
---------	-----	--------------	-----	------

@

EQ 500MG BASE

A075939	003	Jun 09, 2004	Mar	DISC
---------	-----	--------------	-----	------

@

EQ 750MG BASE

A075939	004	Jun 09, 2004	Mar	DISC
---------	-----	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

@ HENGRUI PHARMA

EQ 2MG BASE/ML

A204960	003	Aug 30, 2017	Feb	DISC
---------	-----	--------------	-----	------

&gt;D&gt;

@ PIRAMAL

EQ 2MG BASE/ML

A212432	001	Mar 11, 2022	Apr	CMFD
---------	-----	--------------	-----	------

&gt;A&gt; AP

EQ 2MG BASE/ML

A212432	001	Mar 11, 2022	Apr	CMFD
---------	-----	--------------	-----	------

&gt;D&gt;

@

EQ 10MG BASE/ML

A212432	002	Mar 11, 2022	Apr	CMFD
---------	-----	--------------	-----	------

&gt;A&gt; AP

EQ 10MG BASE/ML

A212432	002	Mar 11, 2022	Apr	CMFD
---------	-----	--------------	-----	------

CISATRACURIUM BESYLATE PRESERVATIVE FREE

@ HAINAN POLY

EQ 2MG BASE/ML

A216539	001	Aug 27, 2024	Apr	CMFD
---------	-----	--------------	-----	------

&gt;D&gt;

@

EQ 2MG BASE/ML

A216539	001	Aug 27, 2024	Apr	CMFD
---------	-----	--------------	-----	------

&gt;A&gt; AP

@

EQ 10MG BASE/ML

A216539	002	Aug 27, 2024	Apr	CMFD
---------	-----	--------------	-----	------

&gt;D&gt;

@

EQ 10MG BASE/ML

A216539	002	Aug 27, 2024	Apr	CMFD
---------	-----	--------------	-----	------

&gt;A&gt; AP

@ HENGRUI PHARMA

EQ 2MG BASE/ML

A204960	001	Jan 27, 2017	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 10MG BASE/ML

A204960	002	Sep 19, 2017	Feb	DISC
---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

AB	+	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Mar CFTG
AB		AUROBINDO PHARMA LTD	EQ 30MG BASE	A219985	001	Mar 13, 2026	Mar NFTG

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

	@	AMNEAL PHARMS NY	EQ 10MG BASE	A077289	001	Nov 30, 2006	Feb DISC
	@		EQ 20MG BASE	A077289	002	Nov 30, 2006	Feb DISC
	@		EQ 40MG BASE	A077289	003	Nov 30, 2006	Feb DISC

CLADRIBINE

TABLET;ORAL

CLADRIBINE

AB		HOPEWELL PHARMA	10MG	A215547	001	Mar 27, 2026	Mar NEWA
----	--	-----------------	------	---------	-----	--------------	----------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D>	AA		AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Apr DISC
>A>		@		EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Apr DISC
		@	PADAGIS US	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Mar DISC

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1		AUROBINDO PHARMA LTD	EQ 1% BASE	A218942	001	Mar 18, 2026	Mar NEWA
AB1		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Feb CAHN

SOLUTION;TOPICAL

CLINDA-DERM

	@	PADAGIS US	EQ 1% BASE	A063329	001	Sep 30, 1992	Mar DISC
--	---	------------	------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

	@	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Feb CAHN
AT		RISING	EQ 1% BASE	A218300	001	Mar 23, 2026	Mar NEWA

SWAB;TOPICAL

CLINDETS

	@	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Mar DISC
--	---	------------	------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

	@	PADAGIS US	0.05%	A090898	001	Jun 16, 2011	Mar DISC
--	---	------------	-------	---------	-----	--------------	----------

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB		CHARTWELL RX	0.5MG	A074925	001	Sep 30, 1997	Jan CMFD	
AB			1MG	A074925	002	Sep 30, 1997	Jan CMFD	
AB			2MG	A074925	003	Sep 30, 1997	Jan CMFD	
>D>		@	PHARMOBEDIENT	0.5MG	A074940	001	Oct 30, 1997	Apr CAHN
>D>		@		1MG	A074940	002	Oct 30, 1997	Apr CAHN
>D>		@		2MG	A074940	003	Oct 30, 1997	Apr CAHN
>A>		@	QUAGEN	0.5MG	A074940	001	Oct 30, 1997	Apr CAHN
>A>		@		1MG	A074940	002	Oct 30, 1997	Apr CAHN
>A>		@		2MG	A074940	003	Oct 30, 1997	Apr CAHN

CLONIDINE

SYSTEM;TRANSDERMAL

CLONIDINE

	@	DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Feb CAHN
	@		0.2MG/24HR	A076157	002	Aug 18, 2009	Feb CAHN
	@		0.3MG/24HR	A076157	003	Aug 18, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

	@	ROSEMONT	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Mar CAHN
	@		EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

! TP ANDA HOLDINGS 0.05MG A070923 004 Apr 06, 2026 Mar NFTG

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ NATCO PHARMA USA 3.75MG A071509 001 Oct 19, 1987 Mar CAHN

@ 7.5MG A071510 001 Oct 19, 1987 Mar CAHN

@ 15MG A071511 001 Oct 19, 1987 Mar CAHN

COBICISTAT

TABLET;ORAL

TYBOST

@ + GILEAD SCIENCES INC 150MG N203094 001 Sep 24, 2014 Mar DISC

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+! JANSSEN PRODS 150MG;EQ 675MG BASE N205395 002 Mar 21, 2025 Mar CHRS

TABLET, FOR SUSPENSION;ORAL

PREZCOBIX PED

+! JANSSEN PRODS 90MG;EQ 600MG BASE N220092 001 Feb 27, 2026 Feb NEWA

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB MICRO LABS 0.6MG A212880 001 Feb 17, 2026 Feb NEWA

TABLET;ORAL

COLCHICINE

AB MACLEODS PHARMS LTD 0.6MG A210633 001 Feb 13, 2026 Feb NEWA

COPPER HISTIDINATE

POWDER;SUBCUTANEOUS

ZYCUBO

+! SENTYNL THERAPS INC 2.9MG/VIAL N211241 001 Jan 12, 2026 Jan NEWA

CROTAMITON

CREAM;TOPICAL

EURAX

>D> @ + JOURNEY 10% N006927 001 Apr CMFD

>A> +! 10% N006927 001 Apr CMFD

LOTION;TOPICAL

CROTAN

>D> AT LEGACY PHARMA 10% A087204 001 Apr CTEC

>A> 10% A087204 001 Apr CTEC

>A> ! 10% A087204 001 Apr CHRS

>D> EURAX

>D> AT +! JOURNEY 10% N009112 003 Apr DISC

>A> @ + 10% N009112 003 Apr DISC

CUPRIC CHLORIDE

INJECTABLE;INJECTION

CUPRIC CHLORIDE

@ AMNEAL EQ 0.4MG COPPER/ML A217287 001 Jan 26, 2026 Mar DISC

AP EQ 0.4MG COPPER/ML A217287 001 Jan 26, 2026 Jan NEWA

>D> AP RK PHARMA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 Apr CAHN

>A> AP STIRA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 Apr CAHN

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

@ HAINAN POLY 500MG/VIAL A218632 001 Dec 26, 2024 Jan DISC

@ 1GM/VIAL A218632 002 Dec 26, 2024 Jan DISC

@ 2GM/VIAL A218632 003 Dec 26, 2024 Jan DISC

CYCLOSPORINE

	EMULSION;OPHTHALMIC CYCLOSPORINE						
AB	TWI PHARMS	0.05%	A209064	001	Jan 21, 2026	Jan	NEWA
	INJECTABLE; INJECTION CYCLOSPORINE						
	@ PADAGIS US	50MG/ML	A065151	001	Oct 07, 2003	Mar	DISC

CYPROHEPTADINE HYDROCHLORIDE

	SYRUP; ORAL CYPROHEPTADINE HYDROCHLORIDE						
AA	ST JOHN PHARM	2MG/5ML	A209108	001	Oct 16, 2018	Jan	CAHN
	TABLET; ORAL CYPROHEPTADINE HYDROCHLORIDE						
	@ ANVI	4MG	A087129	001		Mar	CAHN
AA	INGENUS PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Feb	CAHN

DALBAVANCIN HYDROCHLORIDE

	POWDER; INTRAVENOUS DALBAVANCIN HYDROCHLORIDE						
AP	LONG GROVE PHARMS	EQ 500MG BASE/VIAL	A218602	001	Feb 26, 2026	Feb	NEWA

DAPAGLIFLOZIN

	TABLET; ORAL DAPAGLIFLOZIN						
AB	AIZANT	5MG	A211523	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211523	002	Apr 06, 2026	Mar	NFTG
AB	AJANTA PHARMA LTD	5MG	A211482	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211482	002	Apr 06, 2026	Mar	NFTG
AB	ALEMBIC	5MG	A211560	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211560	002	Apr 06, 2026	Mar	NFTG
AB	ALKEM LABS LTD	5MG	A211545	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211545	002	Apr 06, 2026	Mar	NFTG
AB	AUROBINDO PHARMA	5MG	A211468	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211468	002	Apr 06, 2026	Mar	NFTG
AB	BIOCON PHARMA	5MG	A211470	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211470	002	Apr 06, 2026	Mar	NFTG
AB	CIPLA	5MG	A211535	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211535	002	Apr 06, 2026	Mar	NFTG
AB	INVENTIA	5MG	A211156	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211156	002	Apr 06, 2026	Mar	NFTG
AB	LUPIN	5MG	A211531	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211531	002	Apr 06, 2026	Mar	NFTG
AB	MACLEODS PHARMS LTD	5MG	A211506	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211506	002	Apr 06, 2026	Mar	NFTG
AB	MICRO LABS	5MG	A211467	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211467	002	Apr 06, 2026	Mar	NFTG
AB	MSN	5MG	A211478	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211478	002	Apr 06, 2026	Mar	NFTG
AB	SANDOZ	5MG	A211312	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211312	002	Apr 06, 2026	Mar	NFTG
AB	TEVA PHARMS USA	5MG	A211541	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211541	002	Apr 06, 2026	Mar	NFTG
AB	ZYDUS PHARMS	5MG	A211582	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211582	002	Apr 06, 2026	Mar	NFTG
	FARXIGA						
AB	+ ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CFTG
AB	+!	10MG	N202293	002	Jan 08, 2014	Mar	CFTG

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
AB	ALKEM LABS LTD	5MG; 500MG	A211563	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211563	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211563	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211563	004	Apr 06, 2026	Mar	NFTG
AB	AUROBINDO PHARMA	5MG; 500MG	A211489	001	Apr 06, 2026	Mar	NFTG
AB		5MG; 1GM	A211489	002	Apr 06, 2026	Mar	NFTG
AB		10MG; 500MG	A211489	003	Apr 06, 2026	Mar	NFTG
AB		10MG; 1GM	A211489	004	Apr 06, 2026	Mar	NFTG
AB	CIPLA	5MG; 1GM	A211595	001	Apr 06, 2026	Mar	NFTG
AB	CIPLA LTD	5MG; 500MG	A211536	001	Apr 06, 2026	Mar	NFTG

## TABLET, EXTENDED RELEASE;ORAL

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE							
AB		10MG;500MG	A211536	002	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211536	003	Apr 06, 2026	Mar	NFTG
AB	LUPIN	5MG;500MG	A211579	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211579	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211579	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211579	004	Apr 06, 2026	Mar	NFTG
AB	MACLEODS PHARMS LTD	5MG;500MG	A211559	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211559	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211559	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211559	004	Apr 06, 2026	Mar	NFTG
AB	MICRO LABS	5MG;500MG	A211466	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211466	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211466	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211466	004	Apr 06, 2026	Mar	NFTG
AB	MSN	5MG;500MG	A211479	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211479	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211479	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211479	004	Apr 06, 2026	Mar	NFTG
AB	SUN PHARM	5MG;1GM	A211491	001	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211491	002	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211491	003	Apr 06, 2026	Mar	NFTG
AB	TEVA PHARMS USA INC	2.5MG;1GM	A211583	001	Apr 06, 2026	Mar	NFTG
AB		5MG;500MG	A211583	002	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211583	003	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211583	004	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211583	005	Apr 06, 2026	Mar	NFTG
<u>XIGDUO XR</u>							
AB	+ ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017	Mar	CFTG
AB	+	5MG;500MG	N205649	001	Oct 29, 2014	Mar	CFTG
AB	+	5MG;1GM	N205649	002	Oct 29, 2014	Mar	CFTG
AB	+	10MG;500MG	N205649	003	Oct 29, 2014	Mar	CFTG
AB	+	10MG;1GM	N205649	004	Oct 29, 2014	Mar	CFTG

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

## TABLET;ORAL

DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE							
AB	! MSN	10MG;EQ 5MG BASE	A211533	001	Apr 06, 2026	Mar	NFTG
AB	TORRENT	10MG;EQ 5MG BASE	A211537	001	Apr 06, 2026	Mar	NFTG

DAPSONE

## TABLET;ORAL

DAPSONE							
AB	ZYDUS LIFESCIENCES	25MG	A220103	001	Feb 26, 2026	Feb	NEWA
AB		100MG	A220103	002	Feb 26, 2026	Feb	NEWA

DAPTOMYCIN

## POWDER; INTRAVENOUS

DAPTOMYCIN							
@	HENGRUI PHARMA	500MG/VIAL	A212022	001	Aug 22, 2019	Jan	DISC

DASIGLUCAGON HYDROCHLORIDE

## SOLUTION; SUBCUTANEOUS

ZEGALOGUE							
@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Feb	DISC
@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Feb	DISC

DECITABINE

## INJECTABLE; INTRAVENOUS

DECITABINE							
@	NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Feb	DISC

DEFERIPRONE

## TABLET;ORAL

FERRIPROX							
>D>	AB + CHIESI	500MG	N021825	001	Oct 14, 2011	Apr	DISC
>A>	@ +	500MG	N021825	001	Oct 14, 2011	Apr	DISC

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION  
 DEFEROXAMINE MESYLATE  
 @ HIKMA  
 @

500MG/VIAL  
 2GM/VIAL

A078086 001 May 30, 2007 Mar DISC  
 A078086 002 May 30, 2007 Mar DISC

DEFLAZACORT

SUSPENSION; ORAL  
 DEFLAZACORT

AB SUN PHARM INDS INC 22.75MG/ML

A219930 001 Jan 27, 2026 Jan NEWA

DEHYDRATED ALCOHOL

SOLUTION; INTRA-ARTERIAL  
 ABLYSINOL

AP @ + BPI LABS 99% (1ML)  
 @ +! 99% (5ML)

N207987 001 Jun 21, 2018 Jan CAIN  
 N207987 002 Jun 21, 2018 Jan CAIN

DEHYDRATED ALCOHOL  
 AP ACCORD HLTHCARE 99% (5ML)  
 AP BRECKENRIDGE 99% (5ML)  
 AP INGENUS PHARMS LLC 99% (5ML)  
 AP XGEN PHARMS 99% (5ML)

A217845 001 Jun 23, 2025 Jan CAIN  
 A219444 001 Jun 23, 2025 Jan CAIN  
 A219569 001 Jul 09, 2025 Jan CAIN  
 A219400 001 Jun 23, 2025 Jan CAIN

SOLUTION; INTRAVENOUS  
 DEHYDRATED ALCOHOL  
 +! ROYAL PHARMS

98% (5ML)

N214988 001 Oct 23, 2025 Jan CAIN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL  
 DESIPRAMINE HYDROCHLORIDE

AB @ HERITAGE 10MG  
 @ 25MG  
 @ 50MG  
 @ 75MG  
 @ 100MG  
 @ 150MG  
 AB INGENUS PHARMS LLC 10MG  
 AB 25MG  
 AB 50MG  
 AB 75MG  
 AB 100MG  
 AB 150MG

A207433 001 May 05, 2016 Jan DISC  
 A207433 002 May 05, 2016 Jan DISC  
 A207433 003 May 05, 2016 Jan DISC  
 A207433 004 May 05, 2016 Jan DISC  
 A207433 005 May 05, 2016 Jan DISC  
 A207433 006 May 05, 2016 Jan DISC  
 A204963 001 Dec 26, 2017 Feb CAHN  
 A204963 002 Dec 26, 2017 Feb CAHN  
 A204963 003 Dec 26, 2017 Feb CAHN  
 A204963 004 Dec 26, 2017 Feb CAHN  
 A204963 005 Dec 26, 2017 Feb CAHN  
 A204963 006 Dec 26, 2017 Feb CAHN

DESLORATADINE

TABLET; ORAL  
 DESLORATADINE

AB @ NATCO PHARMA USA 5MG

A078351 001 Feb 10, 2012 Mar CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION  
 DESMOPRESSIN ACETATE

AP CAPLIN 0.004MG/ML

A219981 001 Feb 27, 2026 Feb NEWA

SOLUTION; ORAL  
 DESMODA

AB +! ETON 0.05MG/ML

N219873 001 Feb 25, 2026 Feb NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28  
 DESOGESTREL AND ETHINYL ESTRADIOL

AB ANNORA PHARMA 0.15MG; 0.03MG

A219761 001 Mar 18, 2026 Mar NEWA

DESONIDE

AEROSOL, FOAM; TOPICAL  
 VERDESO

>D> @ + ALMIRALL 0.05%  
 >A> @ + GENUS 0.05%

N021978 001 Sep 19, 2006 Apr CAHN  
 N021978 001 Sep 19, 2006 Apr CAHN

LOTION; TOPICAL  
 DESONIDE

>D> @ PAI HOLDINGS PHARM 0.05%  
 >A> @ VERTICE 0.05%

A207855 001 Sep 28, 2017 Apr CAHN  
 A207855 001 Sep 28, 2017 Apr CAHN

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

>D>	@	SCIEGEN PHARMS	0.05%	A203787	001	Jan 06, 2017	Apr	CMFD
>A>	AB		0.05%	A203787	001	Jan 06, 2017	Apr	CMFD
>D>	@		0.25%	A203234	001	Jun 12, 2015	Apr	CMFD
>A>	AB		0.25%	A203234	001	Jun 12, 2015	Apr	CMFD

GEL; TOPICAL

DESOXIMETASONE

@	PADAGIS US	0.05%	A077552	001	Jan 09, 2006	Mar	DISC
---	------------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB		PLATINUM	EQ 50MG BASE	A204805	001	May 07, 2019	Mar	CAHN
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Mar	CAHN
AB		YICHANG HUMANWELL	EQ 25MG BASE	A220460	001	Mar 10, 2026	Feb	NEWA
AB			EQ 50MG BASE	A220460	002	Mar 10, 2026	Feb	NEWA
AB			EQ 100MG BASE	A220460	003	Mar 10, 2026	Feb	NEWA

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

+	!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983	Jan	CRLD
---	---	-------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

DEXAMETHASONE

		PANGEA	0.25MG	A088149	001	Apr 28, 1983	Mar	CMFD
--	--	--------	--------	---------	-----	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

@		CAPLIN	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Jan	CAHN
---	--	--------	-------------------	---------	-----	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

@		PADAGIS US	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062938	001	Jul 31, 1989	Mar	DISC
---	--	------------	---	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

IGALMI

+		BIOXCEL	EQ 0.18MG BASE	N215390	002	Apr 05, 2022	Jan	CHRS
---	--	---------	----------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	AP	BAXTER HLTHCARE CORP	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A208103	001	Apr 15, 2026	Apr	NEWA
>D>	AP	CAPLIN	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Apr	DISC
>A>		@	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Apr	DISC
	AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Jan	CAHN
	AP	DR REDDYS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A220315	001	Feb 25, 2026	Feb	NEWA
	AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A220315	002	Feb 25, 2026	Feb	NEWA
	AP	KNACK	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A218675	001	Mar 09, 2026	Feb	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	5MG	A202580	002	Aug 25, 2015	Mar	CMS1
	@		10MG	A202580	003	Aug 25, 2015	Mar	CMS1
	@		15MG	A202580	004	Aug 25, 2015	Mar	CMS1
	@		20MG	A202580	005	Dec 21, 2015	Mar	CMS1
	@		25MG	A202580	006	May 04, 2021	Mar	CMS1
	@		35MG	A202580	007	May 04, 2021	Mar	CMS1
	@		40MG	A202580	008	Aug 25, 2015	Mar	CMS1
>D>	AB	MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Apr	CAHN
>D>	AB		10MG	A078992	002	Nov 23, 2021	Apr	CAHN
>D>	AB		15MG	A078992	003	Nov 18, 2013	Apr	CAHN

CAPSULE, EXTENDED RELEASE;ORALDEXMETHYLPHENIDATE HYDROCHLORIDE

>D>	AB		30MG	A078992	004	Nov 18, 2013	Apr	CAHN
>D>	AB		20MG	A078992	005	Nov 23, 2021	Apr	CAHN
>D>	AB		40MG	A078992	006	Nov 23, 2021	Apr	CAHN
>A>	AB	PLATINUM	5MG	A078992	001	Nov 23, 2021	Apr	CAHN
>A>	AB		10MG	A078992	002	Nov 23, 2021	Apr	CAHN
>A>	AB		15MG	A078992	003	Nov 18, 2013	Apr	CAHN
>A>	AB		30MG	A078992	004	Nov 18, 2013	Apr	CAHN
>A>	AB		20MG	A078992	005	Nov 23, 2021	Apr	CAHN
>A>	AB		40MG	A078992	006	Nov 23, 2021	Apr	CAHN

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORALDEXTROAMPHETAMINE SULFATE

>D>	@	PHARMOBEDIANT	5MG	A206735	001	Jan 27, 2016	Apr	CAHN
>D>	@		10MG	A206735	002	Jan 27, 2016	Apr	CAHN
>D>	@		15MG	A206735	003	Jan 27, 2016	Apr	CAHN
>A>	@	QUAGEN	5MG	A206735	001	Jan 27, 2016	Apr	CAHN
>A>	@		10MG	A206735	002	Jan 27, 2016	Apr	CAHN
>A>	@		15MG	A206735	003	Jan 27, 2016	Apr	CAHN
	@	STRIDES PHARMA INTL	5MG	A205673	001	Oct 31, 2017	Jan	DISC
	@		10MG	A205673	002	Oct 31, 2017	Jan	DISC
	@		15MG	A205673	003	Oct 31, 2017	Jan	DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDESYRUP;ORALPROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		HETERO LABS LTD III	15MG/5ML;6.25MG/5ML	A218264	001	Mar 12, 2026	Mar	NEWA
----	--	---------------------	---------------------	---------	-----	--------------	-----	------

DIAZEPAMTABLET;ORALDIAZEPAM

	@	STRIDES PHARMA INTL	2MG	A077749	001	Mar 31, 2006	Jan	DISC
	@		5MG	A077749	002	Mar 31, 2006	Jan	DISC
	@		10MG	A077749	003	Mar 31, 2006	Jan	DISC

DICLOFENAC POTASSIUMCAPSULE;ORALZIPSOR

AB		+! ASSERTIO SPECLTY	25MG	N022202	001	Jun 16, 2009	Feb	CAHN
----	--	---------------------	------	---------	-----	--------------	-----	------

FOR SOLUTION;ORALCAMBIA

AB		+! ASSERTIO SPECLTY	50MG	N022165	001	Jun 17, 2009	Feb	CAHN
----	--	---------------------	------	---------	-----	--------------	-----	------

TABLET;ORALDICLOFENAC POTASSIUM

AB		INGENUS PHARMS LLC	50MG	A215585	001	Oct 08, 2021	Feb	CAHN
----	--	--------------------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUMGEL;TOPICALDICLOFENAC SODIUM

	@	AMNEAL	3%	A200936	001	Oct 28, 2013	Mar	DISC
--	---	--------	----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORALDICLOFENAC SODIUM

AB		INGENUS PHARMS LLC	100MG	A216275	001	Sep 23, 2022	Feb	CAHN
----	--	--------------------	-------	---------	-----	--------------	-----	------

DIFAMILASTOINTMENT;TOPICALADQUEY

	+!	ACROTECH BIOPHARMA	1%	N219474	001	Feb 12, 2026	Feb	NEWA
--	----	--------------------	----	---------	-----	--------------	-----	------

DIFLUPREDNATEEMULSION;OPHTHALMICDIFLUPREDNATE

AB		ALEMBIC	0.05%	A213774	001	Jan 26, 2026	Jan	NEWA
----	--	---------	-------	---------	-----	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION		LANOXIN					
AP	+!	AZURITY	0.25MG/ML	N009330	002		Mar CAHN
		LANOXIN PEDIATRIC					
	+!	AZURITY	0.1MG/ML	N009330	004		Mar CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION		DIHYDROERGOTAMINE MESYLATE					
	@	PADAGIS US	1MG/ML	A040475	001	Apr 28, 2003	Mar DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		DILTIAZEM HYDROCHLORIDE					
AB3		MACLEODS PHARMS LTD	120MG	A218744	001	Feb 27, 2026	Feb NEWA
AB3			180MG	A218744	002	Feb 27, 2026	Feb NEWA
AB3			240MG	A218744	003	Feb 27, 2026	Feb NEWA
AB3			300MG	A218744	004	Feb 27, 2026	Feb NEWA
AB3			360MG	A218744	005	Feb 27, 2026	Feb NEWA
TABLET; ORAL		DILTIAZEM HYDROCHLORIDE					
	@	ZYDUS LIFESCIENCES	30MG	A219253	001	Aug 08, 2025	Jan DISC
	@		60MG	A219253	002	Aug 08, 2025	Jan DISC
	@		90MG	A219253	003	Aug 08, 2025	Jan DISC
	@		120MG	A219253	004	Aug 08, 2025	Jan DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL		DIMETHYL FUMARATE					
	@	MYLAN	120MG	A210531	001	Aug 17, 2020	Mar DISC
	@		240MG	A210531	002	Aug 17, 2020	Mar DISC

DISULFIRAM

TABLET; ORAL		DISULFIRAM					
	@	NATCO PHARMA USA	250MG	A203916	001	Mar 04, 2015	Mar CAHN
	@		500MG	A203916	002	Mar 04, 2015	Mar CAHN

DOCETAXEL

INJECTABLE; INJECTION		DOCETAXEL					
	@	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Feb CAHN
	@		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb DISC
AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb CAHN
	@		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb DISC
AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb CAHN

DOFETILIDE

CAPSULE; ORAL		DOFETILIDE					
	@	INGENUS PHARMS LLC	0.125MG	A212410	001	Dec 27, 2019	Feb CAHN
	@		0.25MG	A212410	002	Dec 27, 2019	Feb CAHN
	@		0.5MG	A212410	003	Dec 27, 2019	Feb CAHN
	@	STRIDES PHARMA INTL	0.125MG	A208519	001	Oct 09, 2018	Jan DISC
	@		0.25MG	A208519	002	Oct 09, 2018	Jan DISC
	@		0.5MG	A208519	003	Oct 09, 2018	Jan DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL		DONEPEZIL HYDROCHLORIDE					
	@	LUPIN	23MG	A202782	001	Oct 30, 2015	Feb DISC

>A>		<u>DORAVIRINE; ISLATRAVIR</u>					
>A>		TABLET; ORAL					
>A>		IDVYNZO					
>A>	+!	MSD	100MG;0.25MG	N216964	001	Apr 20, 2026	Apr NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	UNIQUE	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar	CAHN
AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar	CAHN
AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar	CAHN
AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar	CAHN
AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar	CAHN

CREAM;TOPICAL

DOXEPIN HYDROCHLORIDE

>A>	AB	SUN PHARMA CANADA	5%	A213919	001	Apr 28, 2026	Apr	NEWA
-----	----	-------------------	----	---------	-----	--------------	-----	------

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

>D>	AP	CAPLIN	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Apr	DISC
>A>	@		4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Apr	DISC
	AP		4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan	CAHN
>A>			2MCG/ML (2MCG/ML)	A200926	002	Sep 04, 2014	Apr	NEWA
>A>	@		2MCG/ML (2MCG/ML)	A200926	002	Sep 04, 2014	Apr	DISC
	@	EUGIA PHARMA	4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Mar	DISC
	@	HIKMA	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Mar	DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE

AB	QILU PHARM HAINAN	20MG/10ML (2MG/ML)	A219881	001	Feb 03, 2026	Jan	NEWA
AB		50MG/25ML (2MG/ML)	A219881	002	Feb 03, 2026	Jan	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	AIPING PHARM INC	40MG	A219978	001	Oct 01, 2025	Jan	CAHN
----	------------------	------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

	@	AVET LIFESCIENCES	EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb	DISC
AP			EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb	NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

	@	APOTEX	EQ 75MG BASE	A209243	001	Apr 15, 2019	Jan	DISC
	@		EQ 150MG BASE	A209243	002	Apr 15, 2019	Jan	DISC

TABLET, DELAYED RELEASE;ORAL

DORYX

>D>								
>D>	+	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC
>A>	@ +		EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC
>D>	AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr	DISC
>A>	@ +		EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr	DISC

DRONABINOL

SOLUTION;ORAL

SYNDROS

@ + WELLHOUSE PHARMA

5MG/ML

N205525	001	Mar 23, 2017	Jan	CAHN
---------	-----	--------------	-----	------

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

@ LUPIN

EQ 400MG BASE

A205904	001	Jan 31, 2024	Mar	DISC
---------	-----	--------------	-----	------

MULTAQ

+! SANOFI AVENTIS US

EQ 400MG BASE

N022425	001	Jul 01, 2009	Mar	CTEC
---------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

+! ALMATICA

EQ 80MG BASE

N219131	001	Feb 27, 2026	Feb	NEWA
---------	-----	--------------	-----	------

+

EQ 90MG BASE

N219131	002	Feb 27, 2026	Feb	NEWA
---------	-----	--------------	-----	------

+

EQ 120MG BASE

N219131	003	Feb 27, 2026	Feb	NEWA
---------	-----	--------------	-----	------

ECONAZOLE NITRATECREAM; TOPICAL  
ECONAZOLE NITRATE

AB	AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Mar	CMFD
----	----------------------	----	---------	-----	--------------	-----	------

EDARAVONESOLUTION; INTRAVENOUS  
EDARAVONE

>D>	AP	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	DISC
>A>	@		60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	DISC
>D>	AP	GLAND	60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	DISC
>A>	@		60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	DISC
>D>	AP	! PHARMOBEDIENT	60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Apr	CTEC
>A>	!		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Apr	CTEC
		RADICAVA						
>A>	@ +	SHIONOGI	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CAHN
>A>	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CAHN
>A>	@ +		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	DISC
>D>	@ +	TANABE PHARMA	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CAHN
>D>	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CAHN
		SUSPENSION; ORAL						
		RADICAVA ORS						
>D>	+	! KK BCJ-94	105MG/5ML	N215446	001	May 12, 2022	Apr	CAHN
>A>	+	! SHIONOGI	105MG/5ML	N215446	001	May 12, 2022	Apr	CAHN

EFINACONAZOLESOLUTION; TOPICAL  
EFINACONAZOLE

AB	ALEMBIC	10%	A212027	001	Feb 23, 2026	Feb	NEWA
AB	NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Mar	CAHN

ELETRIPTAN HYDROBROMIDETABLET; ORAL  
ELETRIPTAN HYDROBROMIDE

@	CARLSBAD	EQ 20MG BASE	A209680	001	Jul 13, 2020	Feb	CAHN
@		EQ 40MG BASE	A209680	002	Jul 13, 2020	Feb	CAHN

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

>A>		GRANULE; ORAL						
>A>		TRIKAFTA (COPACKAGED)						
>A>	+	VERTEX PHARMS INC	80MG, 60MG, 40MG; 59.5MG	N217660	001	Apr 26, 2023	Apr	CDFR
>A>	+	!	100MG, 75MG, 50MG; 75MG	N217660	002	Apr 26, 2023	Apr	CDFR
>D>		GRANULES; ORAL						
>D>		TRIKAFTA (COPACKAGED)						
>D>	+	VERTEX PHARMS INC	80MG, 60MG, 40MG; 59.5MG	N217660	001	Apr 26, 2023	Apr	CDFR
>D>	+	!	100MG, 75MG, 50MG; 75MG	N217660	002	Apr 26, 2023	Apr	CDFR

ELIGLUSTAT TARTRATECAPSULE; ORAL  
ELIGLUSTAT TARTRATE

@	CIPLA	EQ 84MG BASE	A212369	001	Dec 10, 2024	Feb	DISC
---	-------	--------------	---------	-----	--------------	-----	------

ELTROMBOPAG OLAMINETABLET; ORAL  
ELTROMBOPAG OLAMINE

>A>	AB	AIZANT	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	Apr	NEWA
>A>	AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	Apr	NEWA
>A>	AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	Apr	NEWA
>A>	AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	Apr	NEWA
	AB	AMNEAL	EQ 12.5MG ACID	A212884	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A212884	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A212884	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A212884	004	Jan 14, 2026	Jan	NEWA
	AB	DR REDDYS	EQ 12.5MG ACID	A219121	001	Mar 16, 2026	Mar	NEWA
	AB		EQ 25MG ACID	A219121	002	Mar 16, 2026	Mar	NEWA
	AB		EQ 50MG ACID	A219121	003	Mar 16, 2026	Mar	NEWA
	AB		EQ 75MG ACID	A219121	004	Mar 16, 2026	Mar	NEWA
>A>	AB	HIKMA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Apr	CAHN
>A>	AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Apr	CAHN
>A>	AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Apr	CAHN
>A>	AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Apr	CAHN

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB	MSN	EQ 12.5MG ACID	A220250	001	Jan 14, 2026	Jan	NEWA
AB		EQ 25MG ACID	A220250	002	Jan 14, 2026	Jan	NEWA
AB		EQ 50MG ACID	A220250	003	Jan 14, 2026	Jan	NEWA
AB		EQ 75MG ACID	A220250	004	Jan 14, 2026	Jan	NEWA
AB	SOMERSET THERAPS LLC	EQ 12.5MG ACID	A219638	001	Jan 14, 2026	Jan	NEWA
AB		EQ 25MG ACID	A219638	002	Jan 14, 2026	Jan	NEWA
AB		EQ 50MG ACID	A219638	003	Jan 14, 2026	Jan	NEWA
AB		EQ 75MG ACID	A219638	004	Jan 14, 2026	Jan	NEWA
>D>	ZENARA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Apr	CAHN
AB		EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Mar	NEWA
>D>	AB	EQ 25MG ACID	A220033	002	Apr 08, 2026	Apr	CAHN
AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Mar	NEWA
>D>	AB	EQ 50MG ACID	A220033	003	Apr 08, 2026	Apr	CAHN
AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Mar	NEWA
>D>	AB	EQ 75MG ACID	A220033	004	Apr 08, 2026	Apr	CAHN
AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Mar	NEWA
AB	ZYDUS PHARMS	EQ 12.5MG ACID	A216281	001	Jan 14, 2026	Jan	NEWA
AB		EQ 25MG ACID	A216281	002	Jan 14, 2026	Jan	NEWA
AB		EQ 50MG ACID	A216281	003	Jan 14, 2026	Jan	NEWA
AB		EQ 75MG ACID	A216281	004	Jan 14, 2026	Jan	NEWA

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

AB	APOTEX	200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jan	NFTG
AB	ODEFSEY						
AB	+! GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jan	CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	LAURUS	200MG;EQ 25MG BASE;300MG	A220232	001	Mar 04, 2026	Feb	NEWA
----	--------	--------------------------	---------	-----	--------------	-----	------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

AB	@ LUPIN	200MG;EQ 25MG BASE	A213926	001	Dec 13, 2024	Mar	DISC
AB	MACLEODS PHARMS LTD	200MG;EQ 25MG BASE	A214216	001	Apr 07, 2026	Mar	NEWA

ENSIFENTRINE

SUSPENSION; INHALATION

OHTUVAYRE

>A>	+! MSD	3MG/2.5ML	N217389	001	Jun 26, 2024	Apr	CAHN
>D>	+! VERONA PHARMA	3MG/2.5ML	N217389	001	Jun 26, 2024	Apr	CAHN

ENTECAVIR

TABLET;ORAL

ENTECAVIR

	@ PHARMADAX	0.5MG	A212106	001	Aug 10, 2020	Mar	CAHN
	@	1MG	A212106	002	Aug 10, 2020	Mar	CAHN

ENZALUTAMIDE

TABLET;ORAL

ENZALUTAMIDE

>A>	AB	SANDOZ	40MG	A216068	001	Apr 20, 2026	Apr	NFTG
>A>	AB		80MG	A216068	002	Apr 20, 2026	Apr	NFTG
		XTANDI						
>D>	+	ASTELLAS	40MG	N213674	001	Aug 04, 2020	Apr	CFTG
>A>	AB	+	40MG	N213674	001	Aug 04, 2020	Apr	CFTG
>D>	+	!	80MG	N213674	002	Aug 04, 2020	Apr	CFTG
>A>	AB	+	80MG	N213674	002	Aug 04, 2020	Apr	CFTG

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EPHEDRINE SULFATE

AP2	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A219991	001	Mar 19, 2026	Mar	NEWA
-----	--------------------	--------------------	---------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
EPINASTINE HYDROCHLORIDE

>D>	AT	APOTEX	0.05%	A090919	001	Oct 31, 2011	Apr	DISC
>A>	@		0.05%	A090919	001	Oct 31, 2011	Apr	DISC
>D>	AT	! SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Apr	CTEC
>A>		!	0.05%	A090951	001	Oct 31, 2011	Apr	CTEC

EPINEPHRINESOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
EPINEPHRINE

+!	BAXTER HLTHCARE CORP	1MG/ML (1MG/ML)	N220626	001	Mar 30, 2026	Mar	NEWA
+!		30MG/30ML (1MG/ML)	N220626	002	Mar 30, 2026	Mar	NEWA

EPINEPHRINE BITARTRATESOLUTION;INTRAVENOUS  
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N218475	002	Mar 16, 2026	Mar	NEWA
----	----------------------	--------------------------------------	---------	-----	--------------	-----	------

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDESOLUTION;INJECTION  
FLAVALTA

+!	DEPROCO	EQ 0.017MG BASE/1.7ML (EQ 0.01MG BASE/ML);34MG/1.7ML (20MG/ML)	N216564	001	Mar 19, 2026	Mar	NEWA
----	---------	--	---------	-----	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>D>	@	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Apr	CRLD
>A>	@ +		0.01MG/ML;1%	A080406	001		Apr	CRLD

EPLONTERSEN SODIUMSOLUTION;SUBCUTANEOUS  
WAINUA

>A>	+!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	002	Apr 15, 2026	Apr	NEWA
-----	----	----------------	---	---------	-----	--------------	-----	------

ERIBULIN MESYLATESOLUTION;INTRAVENOUS  
ERIBULIN MESYLATE

AP	FORMOSA LABS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar	NEWA
AP	XGEN PHARMS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar	CAHN

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS;ORAL  
ERYTHROMYCIN

AB	CARNEGIE	250MG	A062746	001	Dec 22, 1986	Feb	CAHN
----	----------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

ERYTHROMYCIN

AB	CARNEGIE	250MG	A061621	001		Feb	CAHN
AB		500MG	A061621	002		Feb	CAHN

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB	CARNEGIE	250MG	A062298	001		Feb	CAHN
AB		333MG	A062298	003	Mar 29, 1982	Feb	CAHN
AB	!	500MG	A062298	002		Feb	CAHN

ERYTHROMYCIN ETHYLSUCCINATETABLET;ORAL  
E.E.S. 400

BX	@	CARNEGIE	EQ 400MG BASE	A061905	001		Feb	CAHN
BX	!		EQ 400MG BASE	A061905	002	Aug 12, 1982	Feb	CAHN
BX	!	CARNEGIE	EQ 400MG BASE	A061904	001		Feb	CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

>A>	AB	MICRO LABS	EQ 5MG BASE	A091655	001	Apr 22, 2026	Apr	NEWA
>A>	AB		EQ 10MG BASE	A091655	002	Apr 22, 2026	Apr	NEWA
>A>	AB		EQ 20MG BASE	A091655	003	Apr 22, 2026	Apr	NEWA

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	+	ABBVIE	0.01%	A086069	001	Jan 31, 1984	Mar	CAHN
----	---	--------	-------	---------	-----	--------------	-----	------

GEL;TRANSDERMAL

ESTRADIOL

AB		SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Feb	CAHN
AB			0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Feb	CAHN
AB			0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Feb	CAHN
AB			0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Feb	CAHN
AB			0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Feb	CAHN
AB		XIROMED	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jan	CAHN
AB			0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jan	CAHN
AB			0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022	Jan	CAHN

GEL, METERED;TRANSDERMAL

ESTRADIOL

AB		LONG GROVE PHARMS	0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026	Jan	NEWA
----	--	-------------------	---------------------------	---------	-----	--------------	-----	------

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

+	MILLICENT MFG PR	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

+	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998	Mar	CHRS
---	------------------	-------------------------	---------	-----	--------------	-----	------

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

>D>	AB	LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Apr	DISC
>A>		@	1MG	A091124	001	Sep 13, 2011	Apr	DISC
>D>	AB		2MG	A091124	002	Sep 13, 2011	Apr	DISC
>A>		@	2MG	A091124	002	Sep 13, 2011	Apr	DISC
>D>	AB		3MG	A091124	003	Sep 13, 2011	Apr	DISC
>A>		@	3MG	A091124	003	Sep 13, 2011	Apr	DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

>D>	AB	XIROMED	0.05MG;1MG	A204704	001	Feb 09, 2016	Apr	CHRS	
>A>	AB	!	0.05MG;1MG	A204704	001	Feb 09, 2016	Apr	CHRS	
>D>		KELNOR 1/50							
>D>	AB	!	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Apr	DISC
>A>		@		0.05MG;1MG	A072723	001	Dec 30, 1991	Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

QUARTETTE

AB	+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar	CAHN
----	---	--------------------	---	---------	-----	--------------	-----	------

TABLET;ORAL-28

MYZILRA

>D>								
>D>	AB	PH HEALTH	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	Apr	DISC
>A>		@	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	Apr	DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

>D>		GILDAGIA							
>D>	AB	PH HEALTH	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Apr	DISC	
>A>		@	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Apr	DISC	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

>D>		GILDESS 24 FE							
>D>	AB	PH HEALTH	0.02MG;1MG	A090293	001	Dec 01, 2014	Apr	DISC	
>A>		@	0.02MG;1MG	A090293	001	Dec 01, 2014	Apr	DISC	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

PREVIFEM

>D>									
>D>	AB	PH HEALTH	0.035MG;0.25MG	A076334	001	Jan 09, 2004	Apr	DISC	
>A>		@	0.035MG;0.25MG	A076334	001	Jan 09, 2004	Apr	DISC	

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

>D>	AB	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Apr	DISC	
>A>		@	250MG	A200892	001	Sep 25, 2012	Apr	DISC	

ETODOLAC

TABLET; ORAL

ETODOLAC

		@	SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jan	CAHN
--	--	---	----------------	-------	---------	-----	--------------	-----	------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

AB	!	MYLAN	50MG	A075635	001	Sep 19, 2001	Jan	CTEC	
----	---	-------	------	---------	-----	--------------	-----	------	--

VEPESID

AB	+	ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jan	CMFD	
----	---	---------------------	------	---------	-----	--------------	-----	------	--

INJECTABLE; INJECTION

ETOPOSIDE

@ NATCO PHARMA USA

@

INJECTABLE; INTRAVENOUS

AVOPEF

+! AVYXA HOLDINGS

SOLUTION; INTRAVENOUS

AVOPEF

+! AVYXA HOLDINGS

TABLET, FOR SUSPENSION; ORAL

EVEROLIMUS

AB		EUGIA PHARMA	0.25MG	A219533	001	Feb 25, 2026	Feb	NEWA	
----	--	--------------	--------	---------	-----	--------------	-----	------	--

AB			0.5MG	A219533	002	Feb 25, 2026	Feb	NEWA	
----	--	--	-------	---------	-----	--------------	-----	------	--

AB			0.75MG	A219533	003	Feb 25, 2026	Feb	NEWA	
----	--	--	--------	---------	-----	--------------	-----	------	--

AB			1MG	A219533	004	Feb 25, 2026	Feb	NEWA	
----	--	--	-----	---------	-----	--------------	-----	------	--

	@	PH HEALTH	2.5MG	A207934	001	Dec 09, 2019	Jan	DISC	
--	---	-----------	-------	---------	-----	--------------	-----	------	--

	@		5MG	A207934	002	Dec 09, 2019	Jan	DISC	
--	---	--	-----	---------	-----	--------------	-----	------	--

	@		7.5MG	A207934	003	Dec 09, 2019	Jan	DISC	
--	---	--	-------	---------	-----	--------------	-----	------	--

	@		10MG	A207934	004	Dec 09, 2020	Jan	DISC	
--	---	--	------	---------	-----	--------------	-----	------	--

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

@ WATSON LABS INC

@

@

@

@

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Feb	CAHN
AB	CONTRACT PHARMACAL	40MG/5ML	A219603	001	Mar 09, 2026	Feb	NEWA

TABLET;ORAL

FAMOTIDINE

AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan	CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan	CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB	ZYDUS LIFESCIENCES	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb	CAHN
----	--------------------	--------------	---------	-----	--------------	-----	------

FENOFIBRATE

CAPSULE;ORAL

LIPOFEN

@ + CIPHER PHARMS INC 100MG

N021612 002 Jan 11, 2006 Jan CRLD

TABLET;ORAL

FENOFIBRATE

AB	MACLEODS PHARMS LTD	54MG	A210379	001	Jan 21, 2026	Jan	NEWA
AB		160MG	A210379	002	Jan 21, 2026	Jan	NEWA

TRIGLIDE

@ JAGOTEC 50MG

N021350 001 May 07, 2005 Jan CAHN

@ + 160MG

N021350 002 May 07, 2005 Jan CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

@ + ROSEMONT 35MG

N022418 001 Aug 14, 2009 Mar CAHN

@ + 105MG

N022418 002 Aug 14, 2009 Mar CAHN

FERRIC CITRATE

TABLET;ORAL

AURYXIA

AB	+! KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Feb	CFTG
----	--------------------	---------------	---------	-----	--------------	-----	------

FERRIC CITRATE

AB	TEVA PHARMS USA	EQ 210MG IRON	A212563	001	Mar 11, 2026	Feb	NFTG
----	-----------------	---------------	---------	-----	--------------	-----	------

FERUMOXYTOL

SOLUTION;INTRAVENOUS

FERABRIGHT

>A>	+! AZURITY	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Apr	CAHN
-----	------------	--------------------------------------	---------	-----	--------------	-----	------

>A>	+!	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Apr	CAHN
-----	----	--------------------------------------	---------	-----	--------------	-----	------

>D>	+! COVIS	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Apr	CAHN
-----	----------	--------------------------------------	---------	-----	--------------	-----	------

>D>	+!	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Apr	CAHN
-----	----	--------------------------------------	---------	-----	--------------	-----	------

FERAHEME

>A>	AB	+! AZURITY	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Apr	CAHN
-----	----	------------	--------------------------------------	---------	-----	--------------	-----	------

>D>	AB	+! COVIS	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Apr	CAHN
-----	----	----------	--------------------------------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

@ DR REDDYS LABS LTD 30MG

A076502 001 Apr 11, 2006 Mar DISC

@ 60MG

A076502 002 Apr 11, 2006 Mar DISC

@ 180MG

A076502 003 Apr 11, 2006 Mar DISC

@ RISING 60MG

A077081 003 Apr 11, 2008 Mar DISC

@ 180MG

A077081 001 Apr 16, 2007 Mar DISC

@ TEVA 30MG

A076447 001 Sep 01, 2005 Mar DISC

@ 60MG

A076447 002 Sep 01, 2005 Mar DISC

@ 180MG

A076447 003 Sep 01, 2005 Mar DISC

FIDAXOMICIN

TABLET; ORAL

FIDAXOMICIN

AB	APOTEX	200MG	A219559	001	Feb 02, 2026	Jan	NEWA
AB	TORRENT	200MG	A220374	001	Jan 27, 2026	Jan	NEWA

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

>D>	@ +	FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Apr	CMFD
>A>	+	!	0.3%	N206307	001	Dec 17, 2014	Apr	CMFD

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

>A>	AB	ALEMBIC	EQ 0.5MG BASE	A207974	001	Apr 24, 2026	Apr	NEWA
-----	----	---------	---------------	---------	-----	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>A>	AB	OMSAV PHARMA	50MG	A218093	001	Apr 22, 2026	Apr	NEWA
>A>	AB		100MG	A218093	002	Apr 22, 2026	Apr	NEWA
>A>	AB		150MG	A218093	003	Apr 22, 2026	Apr	NEWA

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+! LANTHEUS

1.4-135mCi/ML

N204677	001	Mar 19, 2014	Mar	CAHN
---------	-----	--------------	-----	------

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	UNIQUE	50MG	A076957	001	Sep 28, 2005	Mar	CAHN
AB		100MG	A076957	002	Sep 28, 2005	Mar	CAHN
AB		150MG	A076957	004	Feb 27, 2017	Mar	CAHN
AB		200MG	A076957	003	Sep 28, 2005	Mar	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

@ + CAPLIN ONE LABS

50MG/2ML (25MG/ML)

N022137	001	Sep 21, 2007	Jan	CAHN
---------	-----	--------------	-----	------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

>D>		NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	DISC
>A>	@		4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	DISC

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB	HIBROW HLTHCARE	0.1MG	A220308	001	Feb 10, 2026	Jan	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

@ HIKMA

0.5MG/5ML (0.1MG/ML)

A076787	002	Oct 12, 2004	Mar	DISC
---------	-----	--------------	-----	------

@

1MG/10ML (0.1MG/ML)

A076787	001	Oct 12, 2004	Mar	DISC
---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

AT	+	!	EUROFARMA	0.01%	N012787	004	Feb	CAHN
AT	+	!		0.025%	N012787	002	Feb	CAHN
AT	+	!		0.025%	N012787	005	Feb	CAHN

SYNALAR-HP

@ EUROFARMA

0.2%

N016161	002		Feb	CAHN
---------	-----	--	-----	------

OINTMENT; TOPICAL

SYNALAR

AT	+	!	EUROFARMA	0.025%	N013960	001	Feb	CAHN
----	---	---	-----------	--------	---------	-----	-----	------

SOLUTION;TOPICAL		SYNALAR							
AT	+!	EUROFARMA	0.01%	N015296	001			Feb	CAHN
<u>FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE</u>									
CREAM;TOPICAL		NEO-SYNALAR							
	!	EUROFARMA	0.025%;EQ 3.5MG BASE/GM	A060700	001			Feb	CAHN
<u>FLUORESCEIN SODIUM</u>									
INJECTABLE;INTRAVENOUS		FLUORESCEIN SODIUM							
>A>	AP	BPI LABS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A220046	001	Apr 30, 2026		Apr	NEWA
>D>		!	NEXUS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Apr	CHRS
>A>				EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Apr	CHRS
<u>FLUOROMETHOLONE</u>									
SUSPENSION/DROPS;OPHTHALMIC		FLUOROMETHOLONE							
AB		DIFGEN PHARMS	0.1%	A218819	001	Feb 12, 2026		Jan	NEWA
<u>FLUOROURACIL</u>									
SOLUTION;INTRAVENOUS		FAVLYXA							
	+!	AVYXA HOLDINGS	250MG/10ML (25MG/ML)	N220201	001	Feb 20, 2026		Feb	NEWA
<u>FLUOXETINE HYDROCHLORIDE</u>									
CAPSULE;ORAL		FLUOXETINE HYDROCHLORIDE							
AB1		SENORES PHARMS	EQ 10MG BASE	A075049	001	Aug 02, 2001		Feb	CAHN
AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002		Feb	CAHN
AB			EQ 40MG BASE	A075049	003	Jan 29, 2002		Feb	CAHN
	@	STRIDES PHARMA INTL	EQ 10MG BASE	A076922	001	Dec 16, 2004		Jan	DISC
	@		EQ 20MG BASE	A076922	002	Dec 16, 2004		Jan	DISC
	@		EQ 40MG BASE	A076922	003	Dec 16, 2004		Jan	DISC
SOLUTION;ORAL		FLUOXETINE HYDROCHLORIDE							
>D>	AA	AUROBINDO PHARMA	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009		Apr	CHRS
>A>	AA	!		EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Apr	CHRS
>D>	AA	!	PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	Apr	DISC
>A>		@		EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	Apr	DISC
TABLET;ORAL		FLUOXETINE HYDROCHLORIDE							
	@	LUPIN	EQ 60MG BASE	A211632	001	Feb 08, 2019		Mar	DISC
<u>FLUPHENAZINE HYDROCHLORIDE</u>									
TABLET;ORAL		FLUPHENAZINE HYDROCHLORIDE							
	@	BRECKENRIDGE	1MG	A216891	001	Nov 15, 2022		Feb	DISC
	@		2.5MG	A216891	002	Nov 15, 2022		Feb	DISC
	@		5MG	A216891	003	Nov 15, 2022		Feb	DISC
	@		10MG	A216891	004	Nov 15, 2022		Feb	DISC
AB		ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021		Jan	CAHN
AB			2.5MG	A215141	002	Oct 20, 2021		Jan	CAHN
AB			5MG	A215141	003	Oct 20, 2021		Jan	CAHN
AB			10MG	A215141	004	Oct 20, 2021		Jan	CAHN
<u>FLURAZEPAM HYDROCHLORIDE</u>									
CAPSULE;ORAL		FLURAZEPAM HYDROCHLORIDE							
	@	HIKMA INTL PHARMS	15MG	A071108	002	Dec 08, 1986		Feb	CMS1
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE</u>									
POWDER;INHALATION		BREO ELLIPTA							
	+!	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023		Jan	CHRS

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION  
FLOVENT HFA

AB	+	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004	Feb CFTG
AB		FLUTICASONE PROPIONATE		A219602	001	Mar 03, 2026	Feb NFTG
		GLENMARK SPECILT	0.044MG/INH				

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION  
AIRDUO RESPICLICK

	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan CHRS
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan CHRS
		FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE					
	@	RESPIRENT PHARMS	0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Mar DISC
AB			0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Jan NEWA
	@		0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Mar DISC
AB			0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Jan NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL  
FLUVOXAMINE MALEATE

>A>	AB	APPCO	100MG	A220328	001	Apr 30, 2026	Apr NEWA
>A>	AB		150MG	A220328	002	Apr 30, 2026	Apr NEWA

FOLIC ACID

SOLUTION; ORAL  
QUIOFIC

	+	CMP DEV LLC	0.2MG/ML	N216395	001	Jan 26, 2026	Jan NEWA
	+	SOLUBIOMIX	0.2MG/ML	N216395	001	Jan 26, 2026	Mar CAHN

TABLET; ORAL

AA	+	WATSON LABS	1MG	A080680	001		Feb CHRS
----	---	-------------	-----	---------	-----	--	----------

FONDAPARINUX SODIUM

SOLUTION; SUBCUTANEOUS  
ARIXTRA

AP	+	MYLAN IRELAND LTD	2.5MG/0.5ML (2.5MG/0.5ML)	N021345	001	Dec 07, 2001	Mar CPOT
AP	+		2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jan CDFR
AP	+		5MG/0.4ML (5MG/0.4ML)	N021345	002	May 28, 2004	Mar CPOT
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Jan CDFR
AP	+		7.5MG/0.6ML (7.5MG/0.6ML)	N021345	003	May 28, 2004	Mar CPOT
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jan CDFR
AP	+		10MG/0.8ML (10MG/0.8ML)	N021345	004	May 28, 2004	Mar CPOT
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Jan CDFR
		FONDAPARINUX SODIUM					
	@	BRIGHTGENE	2.5MG/0.5ML (2.5MG/0.5ML)	A218312	001	Dec 18, 2024	Mar CPOT
	@		2.5MG/0.5ML	A218312	001	Dec 18, 2024	Jan CDFR
AP		DR REDDYS LABS LTD	2.5MG/0.5ML (2.5MG/0.5ML)	A091316	001	Jul 11, 2011	Mar CPOT
AP			2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jan CDFR
AP			5MG/0.4ML (5MG/0.4ML)	A091316	002	Jul 11, 2011	Mar CPOT
AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jan CDFR
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A091316	003	Jul 11, 2011	Mar CPOT
AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jan CDFR
AP			10MG/0.8ML (10MG/0.8ML)	A091316	004	Jul 11, 2011	Mar CPOT
AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jan CDFR
AP		EUGIA PHARMA	2.5MG/0.5ML (2.5MG/0.5ML)	A206918	001	Dec 26, 2017	Mar CPOT
AP			2.5MG/0.5ML	A206918	001	Dec 26, 2017	Jan CDFR
AP			5MG/0.4ML (5MG/0.4ML)	A206918	002	Dec 26, 2017	Mar CPOT
AP			5MG/0.4ML	A206918	002	Dec 26, 2017	Jan CDFR
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A206918	003	Dec 26, 2017	Mar CPOT
AP			7.5MG/0.6ML	A206918	003	Dec 26, 2017	Jan CDFR
AP			10MG/0.8ML (10MG/0.8ML)	A206918	004	Dec 26, 2017	Mar CPOT
AP			10MG/0.8ML	A206918	004	Dec 26, 2017	Jan CDFR
	@	HANGZHOU ZHONGMEI	2.5MG/0.5ML (2.5MG/0.5ML)	A216493	001	Aug 19, 2024	Mar CPOT
	@		2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jan CDFR
	@		5MG/0.4ML (5MG/0.4ML)	A216493	002	Aug 19, 2024	Mar CPOT
	@		5MG/0.4ML	A216493	002	Aug 19, 2024	Jan CDFR
	@		7.5MG/0.6ML (7.5MG/0.6ML)	A216493	003	Aug 19, 2024	Mar CPOT
	@		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jan CDFR
	@		10MG/0.8ML (10MG/0.8ML)	A216493	004	Aug 19, 2024	Mar CPOT

SOLUTION;SUBCUTANEOUS  
FONDAPARINUX SODIUM

	@		10MG/0.8ML	A216493	004	Aug 19, 2024	Jan CDFR
AP	HENGRUI PHARMA		2.5MG/0.5ML (2.5MG/0.5ML)	A206812	001	May 15, 2018	Mar CPOT
AP			2.5MG/0.5ML	A206812	001	May 15, 2018	Jan CDFR
AP			5MG/0.4ML (5MG/0.4ML)	A206812	002	May 15, 2018	Mar CPOT
AP			5MG/0.4ML	A206812	002	May 15, 2018	Jan CDFR
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A206812	003	May 15, 2018	Mar CPOT
AP			7.5MG/0.6ML	A206812	003	May 15, 2018	Jan CDFR
AP			10MG/0.8ML (10MG/0.8ML)	A206812	004	May 15, 2018	Mar CPOT
AP			10MG/0.8ML	A206812	004	May 15, 2018	Jan CDFR
AP	SCINOPHARM TAIWAN		2.5MG/0.5ML (2.5MG/0.5ML)	A208615	001	Nov 14, 2018	Mar CPOT
AP			2.5MG/0.5ML	A208615	001	Nov 14, 2018	Jan CDFR
AP			5MG/0.4ML (5MG/0.4ML)	A208615	002	Nov 14, 2018	Mar CPOT
AP			5MG/0.4ML	A208615	002	Nov 14, 2018	Jan CDFR
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A208615	003	Nov 14, 2018	Mar CPOT
AP			7.5MG/0.6ML	A208615	003	Nov 14, 2018	Jan CDFR
AP			10MG/0.8ML (10MG/0.8ML)	A208615	004	Nov 14, 2018	Mar CPOT
AP			10MG/0.8ML	A208615	004	Nov 14, 2018	Jan CDFR

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE  
@ CAPLIN

		EQ 150MG BASE/VIAL	A203939	001	Dec 08, 2020	Jan CAHN
--	--	--------------------	---------	-----	--------------	----------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL  
FOSFOMYCIN TROMETHAMINE

AA	AUCTA	EQ 3GM BASE/PACKET	A217772	001	Apr 09, 2026	Mar NEWA
----	-------	--------------------	---------	-----	--------------	----------

FROVATRIPTAN SUCCINATE

TABLET;ORAL  
FROVA  
@ + ENDO OPERATIONS  
FROVATRIPTAN SUCCINATE

		EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Feb DISC
AB	! RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Feb CHRS

FULVESTRANT

SOLUTION;INTRAMUSCULAR  
CLIGAVYX

>A>	@ AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Apr CTNA
>D>	FULVESTRANT					
>D>	@ AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Apr CTNA
	@ EUGIA PHARMA	250MG/5ML (50MG/ML)	A215169	001	Jun 30, 2023	Mar DISC

FUROSEMIDE

INJECTABLE;INJECTION  
FUROSEMIDE

AP	MICRO LABS	10MG/ML	A218188	001	Jan 08, 2026	Jan NEWA
----	------------	---------	---------	-----	--------------	----------

GABAPENTIN

CAPSULE;ORAL  
GABAPENTIN

AB	PRINSTON INC	100MG	A219814	001	Mar 06, 2026	Feb NEWA
AB		300MG	A219814	002	Mar 06, 2026	Feb NEWA
AB		400MG	A219814	003	Mar 06, 2026	Feb NEWA
	RELGAABI					
AB	SCIEGEN PHARMS	100MG	A204989	001	Feb 18, 2016	Mar CTNA
		200MG	A204989	004	Mar 06, 2026	Mar CTNA
		200MG	A204989	004	Mar 06, 2026	Feb NEWA
AB		300MG	A204989	002	Feb 18, 2016	Mar CTNA
AB		400MG	A204989	003	Feb 18, 2016	Mar CTNA

GALANTAMINE HYDROBROMIDE

TABLET;ORAL  
GALANTAMINE HYDROBROMIDE

AB	SENORES PHARMS	EQ 4MG BASE	A077593	001	Sep 11, 2008	Jan CAHN
AB		EQ 8MG BASE	A077593	002	Sep 11, 2008	Jan CAHN
AB		EQ 12MG BASE	A077593	003	Sep 11, 2008	Jan CAHN

GANAXOLONESUSPENSION;ORAL  
ZTALMY

+! IMMEDICA PHARMA 50MG/ML N215904 001 Jun 01, 2022 Mar CAHN

GANIRELIX ACETATEINJECTABLE; INJECTION  
GANIRELIX ACETATE

@ TRIS PHARMA INC 250MCG/0.5ML A219454 001 Jun 27, 2025 Mar DISC

GEFITINIBTABLET;ORAL  
GEFITINIB

	@	APOTEX	250MG	A209532	001	Sep 23, 2022	Jan	DISC
>D>	AB	CIPLA	250MG	A211826	001	May 16, 2025	Apr	DISC
>A>	@		250MG	A211826	001	May 16, 2025	Apr	DISC

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

@	NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb	DISC
@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb	DISC
@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb	DISC

GENTAMICIN SULFATESOLUTION/DROPS;OPHTHALMIC  
GENTAMICIN SULFATE

@ PADAGIS US EQ 0.3% BASE A065121 001 Jan 30, 2004 Mar DISC

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS  
GLATIRAMER ACETATE

AP		HYBIO	20MG/ML	A213382	001	Feb 11, 2026	Jan	NEWA
AP			40MG/ML	A214022	001	Feb 11, 2026	Jan	NEWA

GLECAPREVIR; PIBRENTASVIRPELLETS;ORAL  
MAVYRET

+! ABBVIE 50MG/PACKET;20MG/PACKET N215110 001 Jun 10, 2021 Mar CPOT

GLIPIZIDETABLET;ORAL  
GLIPIZIDE

AB		GRAVITI PHARMS	5MG	A219159	001	Mar 04, 2026	Feb	NEWA
AB			10MG	A219159	002	Mar 04, 2026	Feb	NEWA
	!	RUBICON RESEARCH	15MG	A214874	004	Feb 04, 2026	Jan	NFTG

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET;ORAL  
GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		IMPAX	1.25MG;250MG	A076345	001	Feb 18, 2004	Mar	CAHN
AB			2.5MG;500MG	A076345	002	Feb 18, 2004	Mar	CAHN
AB			5MG;500MG	A076345	003	Feb 18, 2004	Mar	CAHN

GLYCEROL PHENYLBUTYRATELIQUID;ORAL  
GLYCEROL PHENYLBUTYRATE

>A>	AA	AUROBINDO PHARMA	1.1GM/ML	A220313	001	Apr 15, 2026	Apr	NEWA
>A>	AA	LUPIN	1.1GM/ML	A207694	001	Apr 30, 2026	Apr	NEWA
>A>	AA	MSN	1.1GM/ML	A219540	001	Apr 15, 2026	Apr	NEWA
>A>	AA	NAVINTA LLC	1.1GM/ML	A220568	001	Apr 23, 2026	Apr	NEWA
>A>	AA	TEVA PHARMS INC	1.1GM/ML	A218738	001	Apr 15, 2026	Apr	NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION  
GLYCOPYRROLATE

>A>	AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Apr	CAHN
>D>	AP	UMEDICA	0.2MG/ML	A212591	001	Oct 13, 2021	Apr	CAHN

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

>D>		GLYCOPYRRONIUM TOSYLATE							
>D>	AB	PADAGIS US	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Apr	DISC	
>A>		@	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Apr	DISC	
	AB		EQ 2.4% BASE	A214448	001	Apr 03, 2026	Mar	NFTG	
		QBREXZA							
>D>	AB	+! JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Apr	CTEC	
>A>		+!	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Apr	CTEC	
	AB	+!	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Mar	CFTG	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOSPORIN

		@ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060582	001		Jan	DISC	
--	--	------------------	---	---------	-----	--	-----	------	--

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

	AB	ASCENT PHARMS INC	EQ 1MG BASE	A220675	001	Mar 24, 2026	Mar	NEWA	
	AB		EQ 2MG BASE	A220675	002	Mar 24, 2026	Mar	NEWA	
	AB	RUBICON RESEARCH	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar	CTEC	
	AB		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar	CTEC	

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

HALOBETASOL PROPIONATE

		! PADAGIS ISRAEL	0.05%	A215266	001	Aug 11, 2023	Feb	CTEC	
AB		!	0.05%	A215266	001	Aug 11, 2023	Feb	CHRS	
		LEXETTE							
		@ + MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Feb	DISC	

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	AB	AIPING PHARM INC	0.5MG	A071130	004	Apr 08, 2026	Mar	NEWA	
	AB		1MG	A071130	005	Apr 08, 2026	Mar	NEWA	
	AB		20MG	A071130	006	Apr 08, 2026	Mar	NEWA	
>D>	AB	MYLAN	20MG	A070278	003	Jul 16, 2009	Apr	DISC	
>A>		@	20MG	A070278	003	Jul 16, 2009	Apr	DISC	

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

		+! PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Feb	CMFD	
--	--	-----------	----------------	---------	-----	--------------	-----	------	--

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

		@ PADAGIS US	1.5MG/5ML;5MG/5ML	A205731	001	Feb 15, 2017	Mar	DISC	
--	--	--------------	-------------------	---------	-----	--------------	-----	------	--

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

		@ HERITAGE	10MG	A086242	001	Feb 04, 2010	Mar	DISC	
		@	25MG	A086242	003		Mar	DISC	
		@	50MG	A086242	002		Mar	DISC	
		@	100MG	A086242	004	Feb 04, 2010	Mar	DISC	
		@ STRIDES PHARMA INTL	10MG	A087836	001	Oct 05, 1982	Jan	DISC	
		@	25MG	A086961	002		Jan	DISC	
		@	50MG	A086962	001		Jan	DISC	
		@	100MG	A088391	001	Sep 27, 1983	Jan	DISC	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

		@ STRIDES PHARMA INTL	25MG;25MG	A088957	001	Oct 21, 1985	Jan	DISC	
		@	50MG;50MG	A088946	001	Oct 21, 1985	Jan	DISC	

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE  
 AB INGENUS PHARMS LLC 37.5MG;20MG A215586 001 Apr 06, 2022 Feb CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>A> @ CHARTWELL RX 12.5MG;150MG A201524 001 Feb 27, 2013 Apr CAHN  
 >A> @ 12.5MG;300MG A201524 002 Feb 27, 2013 Apr CAHN  
 >D> @ LUPIN LTD 12.5MG;150MG A201524 001 Feb 27, 2013 Apr CAHN  
 >D> @ 12.5MG;300MG A201524 002 Feb 27, 2013 Apr CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@ STRIDES PHARMA INTL 15MG;250MG A070614 002 Feb 02, 1987 Jan CMS1  
 @ 25MG;250MG A070614 003 Feb 02, 1987 Jan CMS1  
 @ 30MG;500MG A070614 004 Feb 02, 1987 Jan CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB ALEMBIC 25MG;100MG A202870 002 Nov 06, 2013 Feb CHRS  
 AB ! MYLAN 50MG;100MG A076792 003 Aug 20, 2004 Feb CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A> AB MICRO LABS 12.5MG;20MG A206371 001 Apr 13, 2026 Apr NEWA  
 >A> AB 12.5MG;40MG A206371 002 Apr 13, 2026 Apr NEWA  
 >A> AB 25MG;40MG A206371 003 Apr 13, 2026 Apr NEWA  
 AB SCIEGEN PHARMS 12.5MG;20MG A208465 001 Mar 31, 2026 Mar NEWA  
 AB 12.5MG;40MG A208465 002 Mar 31, 2026 Mar NEWA  
 AB 25MG;40MG A208465 003 Mar 31, 2026 Mar NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>A> AB SCIEGEN PHARMS 12.5MG;80MG A204687 001 Apr 23, 2026 Apr NEWA  
 >A> AB 12.5MG;160MG A204687 002 Apr 23, 2026 Apr NEWA  
 >A> AB 12.5MG;320MG A204687 003 Apr 23, 2026 Apr NEWA  
 >A> AB 25MG;160MG A204687 004 Apr 23, 2026 Apr NEWA  
 >A> AB 25MG;320MG A204687 005 Apr 23, 2026 Apr NEWA

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

AB APPCO 5MG A220329 001 Feb 25, 2026 Feb NEWA  
 AB 10MG A220329 002 Feb 25, 2026 Feb NEWA  
 AB 20MG A220329 003 Feb 25, 2026 Feb NEWA

HYDROCORTISONE BUTYRATE

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE

! TARO 0.1% A076842 001 Dec 27, 2004 Feb CTEC  
 AB ! 0.1% A076842 001 Dec 27, 2004 Feb CHRS  
 LOCOID  
 @ + PRECISION DERMAT 0.1% N018652 001 Oct 29, 1982 Feb DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

HYDROCORTISONE SODIUM SUCCINATE

AP APOTEX EQ 100MG BASE/VIAL A219856 001 Feb 05, 2026 Jan NEWA  
 >A> AP ZYDUS PHARMS EQ 100MG BASE/VIAL A217191 001 May 07, 2026 Apr NEWA

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

@	PADAGIS ISRAEL	0.2%	A075666	001	May 24, 2000	Mar	DISC
---	----------------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID-HP

>D>	@ +	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Apr	CMFD
>A>	AP	+	10MG/ML	N019034	001	Jan 11, 1984	Apr	CMFD

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	AB		AMNEAL PHARM	10MG	A040808	001	Sep 24, 2008	Apr	DISC
>A>		@		10MG	A040808	001	Sep 24, 2008	Apr	DISC
>D>	AB			25MG	A040808	002	Sep 24, 2008	Apr	DISC
>A>		@		25MG	A040808	002	Sep 24, 2008	Apr	DISC
>D>	AB			50MG	A040808	003	Sep 24, 2008	Apr	DISC
>A>		@		50MG	A040808	003	Sep 24, 2008	Apr	DISC

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

>D>	AB		PHARMOBEDIENT	1GM	A218994	001	Dec 20, 2024	Apr	CAHN
>A>	AB		TORRENT	1GM	A218994	001	Dec 20, 2024	Apr	CAHN

ICOTROKINRA HYDROCHLORIDE

TABLET; ORAL

ICOTYDE

+	JANSSEN BIOTECH	EQ 200MG BASE	N220149	001	Mar 17, 2026	Mar	NEWA
---	-----------------	---------------	---------	-----	--------------	-----	------

IDELALISIB

TABLET; ORAL

IDELALISIB

AB		NATCO	100MG	A216921	001	Feb 17, 2026	Feb	NFTG
AB			150MG	A216921	002	Feb 17, 2026	Feb	NFTG
		ZYDELIG						
AB	+	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Feb	CFTG
AB	+	+	150MG	N205858	002	Jul 23, 2014	Feb	CFTG

IMATINIB MESYLATE

TABLET; ORAL

GLEVEEC

AB	+	NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003	Mar	CHRS
AB	+		EQ 400MG BASE	N021588	002	Apr 18, 2003	Mar	CHRS
		IMATINIB MESYLATE						
	@	SUN PHARM	EQ 100MG BASE	A078340	001	Dec 03, 2015	Feb	DISC
	@		EQ 400MG BASE	A078340	002	Dec 03, 2015	Feb	DISC

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

INDIUM IN-111 PENTETREOTIDE KIT

>D>	AP		SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Apr	DISC
>A>		@		3mCi/ML	A212785	001	Jul 01, 2024	Apr	DISC
		OCTREOSCAN							
>D>	AP	+	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Apr	CTEC
>A>		+		3mCi/ML	N020314	001	Jun 02, 1994	Apr	CTEC

IOMEPROL

SOLUTION; INTRA-ARTERIAL

IOMERVU

+	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Feb	CMFD
+		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Feb	CMFD

SOLUTION; INTRA-ARTERIAL

## IOMERVU

+	!		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Feb	CMFD
+	!		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Feb	CMFD

SOLUTION; INTRAVENOUS

## IOMERVU

+	!	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Feb	CMFD
+	!		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Feb	CMFD
+	!		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Feb	CMFD
+	!		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Feb	CMFD

IPRATROPIUM BROMIDE

## AEROSOL, METERED; INHALATION

## ATROVENT HFA

AB	+	!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004	Feb	CFTG
AB			ARMSTRONG PHARMS	0.021MG/INH	A217953	001	Feb 23, 2026	Feb	NFTG

ISOSORBIDE MONONITRATE

## TABLET; ORAL

## ISOSORBIDE MONONITRATE

>A>	AB		ANI PHARMS	10MG	A075147	002	Mar 27, 2026	Apr	NEWA
	AB			20MG	A075147	001	Nov 27, 1998	Mar	CMFD

ISOSULFAN BLUE

## SOLUTION; SUBCUTANEOUS

## ISOSULFAN BLUE

!	!	MYLAN INSTITUTIONAL	10MG/ML (10MG/ML)	A090874	002	Jan 28, 2026	Jan	NFTG
!	!		30MG/3ML (10MG/ML)	A090874	003	Jan 28, 2026	Jan	NFTG

ISOTRETINOIN

## CAPSULE; ORAL

## ISOTRETINOIN

@		AMNEAL PHARMS NY	10MG	A216097	001	Oct 07, 2025	Mar	DISC
@			20MG	A216097	002	Oct 07, 2025	Mar	DISC
@			25MG	A216097	003	Oct 07, 2025	Mar	DISC
@			30MG	A216097	004	Oct 07, 2025	Mar	DISC
@			35MG	A216097	005	Oct 07, 2025	Mar	DISC
@			40MG	A216097	006	Oct 07, 2025	Mar	DISC

IVABRADINE

## SOLUTION; ORAL

## CORLANOR

@	+	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Mar	DISC
---	---	-----------	------------------	---------	-----	--------------	-----	------

IVABRADINE HYDROCHLORIDE

## TABLET; ORAL

## CORLANOR

@	+	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan	DISC
@	+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan	DISC

## IVABRADINE HYDROCHLORIDE

AB	!	INGENUS PHARMS LLC	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan	CHRS
----	---	--------------------	---------------	---------	-----	--------------	-----	------

IVERMECTIN

## TABLET; ORAL

## IVERMECTIN

AB		AJANTA PHARMA LTD	3MG	A218509	001	Apr 07, 2026	Mar	NEWA
AB		E5 PHARMA	3MG	A216808	001	Mar 09, 2026	Feb	NEWA
AB		ZYDUS LIFESCIENCES	3MG	A216863	001	Feb 26, 2026	Feb	NEWA

KETAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## KETAMINE HYDROCHLORIDE

>D>	AP		CAPLIN	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Apr	DISC
>A>		@		EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Apr	DISC

KETOCONAZOLE

CREAM; TOPICAL  
KETOCONAZOLE

@ PADAGIS US 2% A215185 001 Nov 17, 2021 Jan DISC

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC  
ACULAR LS

>D> AT +! ABBVIE 0.4% N021528 001 May 30, 2003 Apr CTEC  
>A> + 0.4% N021528 001 May 30, 2003 Apr CTEC

KETOROLAC TROMETHAMINE

>D> AT APOTEX 0.4% A077308 001 Nov 05, 2009 Apr DISC  
>A> @ 0.4% A077308 001 Nov 05, 2009 Apr DISC

LABETALOL HYDROCHLORIDE

TABLET; ORAL  
LABETALOL HYDROCHLORIDE

AB APPCO 400MG A209603 004 Oct 18, 2024 Mar CTEC  
AB HERITAGE PHARMA 400MG A074787 004 Mar 26, 2026 Mar NEWA

LACOSAMIDE

SOLUTION; INTRAVENOUS  
LACOSAMIDE

AP ANTHEA PHARMA 200MG/20ML (10MG/ML) A220268 001 Jan 21, 2026 Jan NEWA  
AP GLENMARK PHARMS 200MG/20ML (10MG/ML) A220268 001 Jan 21, 2026 Mar CAHN

SOLUTION; ORAL

LACOSAMIDE

@ APOTEX 10MG/ML A206355 001 Sep 26, 2022 Feb DISC  
AA INDOCO 10MG/ML A220386 001 Jan 29, 2026 Jan NEWA  
AA REGCON HOLDINGS 10MG/ML A220386 001 Jan 29, 2026 Jan CAHN

LAMIVUDINE

TABLET; ORAL  
LAMIVUDINE

@ LUPIN 150MG A205217 001 Dec 18, 2014 Jan DISC  
@ 300MG A205217 002 Dec 18, 2014 Jan DISC

LAMOTRIGINE

TABLET; ORAL  
LAMOTRIGINE

>D> AB LUPIN LTD 25MG A078691 001 Jun 01, 2010 Apr DISC  
>A> @ 25MG A078691 001 Jun 01, 2010 Apr DISC  
>D> AB 100MG A078691 002 Jun 01, 2010 Apr DISC  
>A> @ 100MG A078691 002 Jun 01, 2010 Apr DISC  
>D> AB 150MG A078691 003 Jun 01, 2010 Apr DISC  
>A> @ 150MG A078691 003 Jun 01, 2010 Apr DISC  
>D> AB 200MG A078691 004 Jun 01, 2010 Apr DISC  
>A> @ 200MG A078691 004 Jun 01, 2010 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

>D> AB PH HEALTH 25MG A201791 001 Jan 18, 2013 Apr DISC  
>A> @ 25MG A201791 001 Jan 18, 2013 Apr DISC  
>D> AB 50MG A201791 002 Jan 18, 2013 Apr DISC  
>A> @ 50MG A201791 002 Jan 18, 2013 Apr DISC  
>D> AB 100MG A201791 003 Jan 18, 2013 Apr DISC  
>A> @ 100MG A201791 003 Jan 18, 2013 Apr DISC  
>D> AB 200MG A201791 004 Jan 18, 2013 Apr DISC  
>A> @ 200MG A201791 004 Jan 18, 2013 Apr DISC  
>D> AB 250MG A201791 005 Jan 18, 2013 Apr DISC  
>A> @ 250MG A201791 005 Jan 18, 2013 Apr DISC  
>D> AB 300MG A201791 006 Jan 18, 2013 Apr DISC  
>A> @ 300MG A201791 006 Jan 18, 2013 Apr DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

AB ALEMBIC 25MG A217278 001 Feb 25, 2026 Feb NEWA  
AB 50MG A217278 002 Feb 25, 2026 Feb NEWA  
AB 100MG A217278 003 Feb 25, 2026 Feb NEWA  
AB 200MG A217278 004 Feb 25, 2026 Feb NEWA  
AB TORRENT 25MG A217100 001 Jan 08, 2026 Jan NEWA  
AB 50MG A217100 002 Jan 08, 2026 Jan NEWA  
AB 100MG A217100 003 Jan 08, 2026 Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE

AB 200MG A217100 004 Jan 08, 2026 Jan NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC  
LATANOPROST

@ CARNEGIE 0.005% A202077 001 Feb 11, 2013 Feb CAHN

LENALIDOMIDE

CAPSULE;ORAL  
LENALIDOMIDE

AB ALVOGEN 2.5MG A210480 005 Mar 06, 2023 Jan CAHN  
 AB 5MG A210480 001 Aug 31, 2022 Jan CAHN  
 AB 10MG A210480 002 Aug 31, 2022 Jan CAHN  
 AB 15MG A210480 003 Aug 31, 2022 Jan CAHN  
 AB 20MG A210480 006 Mar 06, 2023 Jan CAHN  
 AB 25MG A210480 004 Aug 31, 2022 Jan CAHN  
 AB CIPLA 5MG A213165 001 Feb 02, 2026 Jan NEWA  
 AB 10MG A213165 002 Feb 02, 2026 Jan NEWA  
 AB 15MG A213165 003 Feb 02, 2026 Jan NEWA  
 AB 20MG A213165 004 Feb 02, 2026 Jan NEWA  
 AB 25MG A213165 005 Feb 02, 2026 Jan NEWA  
 AB @ TORRENT 2.5MG A213405 005 Feb 10, 2026 Mar DISC  
 AB 2.5MG A213405 005 Feb 10, 2026 Jan NEWA  
 @ 5MG A213405 006 Feb 10, 2026 Mar DISC  
 AB 5MG A213405 006 Feb 10, 2026 Jan NEWA  
 @ 15MG A213405 004 Nov 04, 2025 Mar DISC

LEUCOVORIN CALCIUM

SOLUTION;INTRAMUSCULAR, INTRAVENOUS  
LEUCOVORIN CALCIUM

@ INGENUS PHARMS LLC EQ 500MG BASE/50ML (EQ 10MG BASE/ML) A210917 001 Nov 23, 2018 Feb CAHN

## VYKOURA

+! AVYXA HOLDINGS EQ 50MG BASE/5ML (EQ 10MG BASE/ML) N220406 001 Feb 03, 2026 Feb NEWA  
 +! EQ 350MG BASE/35ML (EQ 10MG BASE/ML) N220406 002 Feb 03, 2026 Feb NEWA  
 +! EQ 500MG BASE/50ML (EQ 10MG BASE/ML) N220406 003 Feb 03, 2026 Feb NEWA

## TABLET;ORAL

## LEUCOVORIN CALCIUM

>A> AB INGENUS PHARMS LLC EQ 5MG BASE A211132 001 Jul 30, 2020 Apr CAHN  
 >A> AB EQ 10MG BASE A211132 002 Jul 30, 2020 Apr CAHN  
 >A> AB EQ 15MG BASE A211132 003 Jul 30, 2020 Apr CAHN  
 >A> AB EQ 25MG BASE A211132 004 Jul 30, 2020 Apr CAHN  
 >D> AB NOVAST LABS EQ 5MG BASE A211132 001 Jul 30, 2020 Apr CAHN  
 >D> AB EQ 10MG BASE A211132 002 Jul 30, 2020 Apr CAHN  
 >D> AB EQ 15MG BASE A211132 003 Jul 30, 2020 Apr CAHN  
 >D> AB EQ 25MG BASE A211132 004 Jul 30, 2020 Apr CAHN

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS  
LEUPROLIDE ACETATE

AP SOMERSET THERAPS LLC 14MG/2.8ML (1MG/0.2ML) A213829 001 Aug 13, 2021 Feb CAHN

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS  
CAMCEVI ETM

+! ACCORD EQ 21MG BASE N219745 001 Aug 25, 2025 Jan CAHN

LEVETIRACETAM

SOLUTION;ORAL  
LEVETIRACETAM

AA ANDA REPOSITORY 100MG/ML A218080 001 Nov 21, 2025 Mar CAHN

## TABLET;ORAL

## LEVETIRACETAM

AB SENORES PHARMS 250MG A076920 001 Jan 15, 2009 Jan CAHN  
 AB 500MG A076920 002 Jan 15, 2009 Jan CAHN  
 AB 750MG A076920 003 Jan 15, 2009 Jan CAHN  
 AB 1GM A078904 001 Jan 15, 2009 Jan CAHN

LEVOLEUCOVORIN CALCIUMSOLUTION; INTRAVENOUS  
LEVOLEUCOVORIN CALCIUM

@	AMNEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Mar	DISC
---	--------	---	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

>D>	EUTHYROX						
>D>	AB2	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr DISC
>A>	@		0.025MG	N021292	001	May 31, 2002	Apr DISC
>D>	AB2		0.05MG	N021292	002	May 31, 2002	Apr DISC
>A>	@		0.05MG	N021292	002	May 31, 2002	Apr DISC
>D>	AB2		0.075MG	N021292	003	May 31, 2002	Apr DISC
>A>	@		0.075MG	N021292	003	May 31, 2002	Apr DISC
>D>	AB2		0.088MG	N021292	004	May 31, 2002	Apr DISC
>A>	@		0.088MG	N021292	004	May 31, 2002	Apr DISC
>D>	AB2		0.1MG	N021292	005	May 31, 2002	Apr DISC
>A>	@		0.1MG	N021292	005	May 31, 2002	Apr DISC
>D>	AB2		0.112MG	N021292	006	May 31, 2002	Apr DISC
>A>	@		0.112MG	N021292	006	May 31, 2002	Apr DISC
>D>	AB2		0.125MG	N021292	007	May 31, 2002	Apr DISC
>A>	@		0.125MG	N021292	007	May 31, 2002	Apr DISC
>D>	AB2		0.137MG	N021292	008	May 31, 2002	Apr DISC
>A>	@		0.137MG	N021292	008	May 31, 2002	Apr DISC
>D>	AB2		0.15MG	N021292	009	May 31, 2002	Apr DISC
>A>	@		0.15MG	N021292	009	May 31, 2002	Apr DISC
>D>	AB2		0.175MG	N021292	010	May 31, 2002	Apr DISC
>A>	@		0.175MG	N021292	010	May 31, 2002	Apr DISC
>D>	AB2		0.2MG	N021292	011	May 31, 2002	Apr DISC
>A>	@		0.2MG	N021292	011	May 31, 2002	Apr DISC

LIDOCAINEPATCH; TOPICAL  
LIDOCAINE

AB	USPHARMA	5%	A207059	001	Feb 09, 2026	Mar	CMFD
	@	5%	A207059	001	Feb 09, 2026	Feb	DISC
AB		5%	A207059	001	Feb 09, 2026	Jan	NEWA

LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
LIDOCAINE HYDROCHLORIDE

AP	ANTHEA PHARMA	2%	A219535	002	Feb 06, 2026	Jan	NEWA
AP	VIWIT PHARM	1%	A220071	001	Mar 19, 2026	Mar	NEWA
AP		2%	A220071	002	Mar 19, 2026	Mar	NEWA

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

AT	QUAGEN	2%	A218676	001	Mar 20, 2026	Mar	NEWA
----	--------	----	---------	-----	--------------	-----	------

LINERIXIBAT

TABLET; ORAL

LYNAVOY

+	!	GLAXOSMITHKLINE	40MG	N220295	001	Mar 17, 2026	Mar	NEWA
---	---	-----------------	------	---------	-----	--------------	-----	------

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

LIRAGLUTIDE

AP1	BIOCON PHARMA	18MG/3ML (6MG/ML)	A215245	001	Mar 11, 2026	Feb	NEWA
AP2		18MG/3ML (6MG/ML)	A217063	001	Feb 24, 2026	Feb	NEWA
AP1	FRESENIUS KABI USA	18MG/3ML (6MG/ML)	A212552	001	Mar 30, 2026	Mar	NEWA
AP2	ORBICULAR	18MG/3ML (6MG/ML)	A217234	001	Feb 24, 2026	Feb	NEWA
AP1		18MG/3ML (6MG/ML)	A217590	001	Jan 14, 2026	Jan	NEWA

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

AA	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Mar	CMFD
----	--------------------	------------------------	---------	-----	--------------	-----	------

LOMITAPIDE MESYLATE

CAPSULE;ORAL  
JUXTAPID

+	CHIESI	EQ 2MG BASE	N203858	007	Feb 25, 2026	Feb	NEWA
+	!	EQ 30MG BASE	N203858	004	Apr 23, 2015	Mar	CHRS

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL  
ALTOPREV

@	AZURITY	10MG	N021316	001	Jun 26, 2002	Mar	CAHN
@ +		20MG	N021316	002	Jun 26, 2002	Mar	CAHN
@ +		40MG	N021316	003	Jun 26, 2002	Mar	CAHN
@ +		60MG	N021316	004	Jun 26, 2002	Mar	CAHN

LUBIPROSTONE

CAPSULE;ORAL  
LUBIPROSTONE

AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan	CMFD
AB		24MCG	A209450	002	Nov 30, 2021	Jan	CMFD

MACIMORELIN ACETATE

FOR SOLUTION;ORAL  
MACRILEN

@ +	AETERNA ZENTARIS	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	Jan	CAHN
-----	------------------	--------------------	---------	-----	--------------	-----	------

MACITENTAN

TABLET;ORAL  
MACITENTAN

AB	APOTEX	10MG	A211195	001	Jan 09, 2024	Mar	CMFD
>D>	@ SEASONS BIOTECH	10MG	A211026	001	Dec 03, 2025	Apr	CMFD
>A>	AB	10MG	A211026	001	Dec 03, 2025	Apr	CMFD
>D>	@ TORRENT	10MG	A211107	001	Aug 05, 2024	Apr	CMFD
>A>	AB	10MG	A211107	001	Aug 05, 2024	Apr	CMFD
>D>	@ ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	Apr	CMFD
>A>	AB	10MG	A211224	001	Apr 06, 2021	Apr	CMFD

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL  
MAFENIDE ACETATE

@	INGENUS PHARMS LLC	5%	A206716	001	Jul 31, 2017	Feb	CAHN
---	--------------------	----	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE;INJECTION  
MAGNESIUM SULFATE

!	BAXTER HLTHCARE CORP	3GM/100ML (30MG/ML)	A211966	004	Jan 08, 2026	Jan	NFTG
	MAGNESIUM SULFATE IN PLASTIC CONTAINER						
@	MYLAN LABS LTD	2GM/50ML (40MG/ML)	A209911	001	Sep 14, 2018	Mar	DISC

MARAVIROC

TABLET;ORAL  
MARAVIROC

>D>	AB	RHODES PHARMS	150MG	A216143	001	Nov 04, 2025	Apr	DISC
>A>	@		150MG	A216143	001	Nov 04, 2025	Apr	DISC
>D>	AB		300MG	A216143	002	Nov 04, 2025	Apr	DISC
>A>	@		300MG	A216143	002	Nov 04, 2025	Apr	DISC

MECLIZINE HYDROCHLORIDE

TABLET;ORAL  
MECLIZINE HYDROCHLORIDE

AA	SENORES PHARMS	12.5MG	A087128	002		Feb	CAHN
AA		25MG	A087128	001		Feb	CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL  
MEMANTINE HYDROCHLORIDE

AA	MEDLEY PHARMS	2MG/ML	A210319	001	Aug 31, 2020	Mar	CAHN
----	---------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL  
MEMANTINE HYDROCHLORIDE

AB	!	DR REDDYS LABS LTD	10MG	A090048	002	Apr 14, 2010	Mar	CHRS
AB		RENATA	5MG	A209527	001	May 07, 2018	Feb	CAHN
AB			10MG	A209527	002	May 07, 2018	Feb	CAHN

TABLET;ORAL

NAMENDA

@ +	ABBVIE	5MG	N021487	001	Oct 16, 2003	Mar	DISC
@ +		10MG	N021487	002	Oct 16, 2003	Mar	DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

POLOCAINE

!	FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986	Jan	CHRS
!		2%	A089410	001	Dec 01, 1986	Jan	CHRS

POLOCAINE-MPF

!	FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986	Jan	CHRS
!		1.5%	A089408	001	Dec 01, 1986	Jan	CHRS
!		2%	A089409	001	Dec 01, 1986	Jan	CHRS

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

MESALAMINE

AB	DIFGEN PHARMS	250MG	A219997	001	Mar 10, 2026	Feb	NFTG
AB		500MG	A219997	002	Mar 10, 2026	Feb	NEWA

PENTASA

AB	+ TAKEDA PHARMS USA	250MG	N020049	001	May 10, 1993	Feb	CFTG
----	---------------------	-------	---------	-----	--------------	-----	------

ENEMA;RECTAL

MESALAMINE

AB	KLM LABS PVT	4GM/60ML	A220016	001	Mar 31, 2026	Mar	NEWA
----	--------------	----------	---------	-----	--------------	-----	------

MESNA

INJECTABLE;INTRAVENOUS

MESNA

AP	EUGIA PHARMA	100MG/ML	A220518	001	Jan 27, 2026	Jan	NEWA
----	--------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

MESNA

AB	INGENUS PHARMS LLC	400MG	A218871	001	Jan 13, 2025	Feb	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

METAXALONE

TABLET;ORAL

METAXALONE

@	INGENUS PHARMS LLC	800MG	A213836	001	Oct 21, 2020	Feb	CAHN
---	--------------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB	CHARTWELL	625MG	A075972	005	Jan 24, 2002	Jan	CTEC
AB		750MG	A075972	004	Jan 24, 2002	Jan	CTEC
AB	SCIEGEN PHARMS	625MG	A203769	004	Feb 09, 2026	Jan	NEWA
AB		750MG	A203769	005	Feb 09, 2026	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

>A>	@	ALLIED	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
>A>	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN
	@	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Mar	DISC
	@		750MG	A078596	002	Jan 03, 2008	Mar	DISC
	@	APOTEX	500MG	A213356	001	Dec 13, 2021	Feb	DISC
	@		1GM	A213356	002	Dec 13, 2021	Feb	DISC
>D>	AB1	MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Apr	CAHN
>D>	AB		750MG	A202306	002	Feb 23, 2017	Apr	CAHN
>A>	AB1	PLATINUM	500MG	A202306	001	Feb 23, 2017	Apr	CAHN
>A>	AB		750MG	A202306	002	Feb 23, 2017	Apr	CAHN
>D>	@	RK PHARMA	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
	@		500MG	A215629	001	Jun 20, 2023	Jan	DISC
>D>	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN
	@		1GM	A215629	002	Jun 20, 2023	Jan	DISC
>A>	@	SENORES PHARMS	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
>A>	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

>A>	AB	APOTEX	500MG;EQ 50MG BASE	A202426	001	Apr 30, 2026	Apr	NEWA
>A>	AB		1GM;EQ 50MG BASE	A202426	002	Apr 30, 2026	Apr	NEWA

METHADONE HYDROCHLORIDE

SOLUTION;ORAL  
METHADONE HYDROCHLORIDE

AA	VISTAPHARM LLC	5MG/5ML	A090707	001	Jun 30, 2010	Feb	CMFD
----	----------------	---------	---------	-----	--------------	-----	------

METHAZOLAMIDE

TABLET;ORAL  
METHAZOLAMIDE

AB	AJANTA PHARMA LTD	25MG	A217408	001	Feb 09, 2026	Jan	NEWA
AB		50MG	A217408	002	Feb 09, 2026	Jan	NEWA
>D>	@ ATHEM	25MG	A040102	001	Aug 28, 1996	Apr	CAHN
>D>	@	50MG	A040102	002	Aug 28, 1996	Apr	CAHN
>A>	@ POM PHARMA	25MG	A040102	001	Aug 28, 1996	Apr	CAHN
>A>	@	50MG	A040102	002	Aug 28, 1996	Apr	CAHN

METHENAMINE HIPPURATE

TABLET;ORAL  
METHENAMINE HIPPURATE

AB	INGENUS PHARMS LLC	1GM	A210068	001	Nov 27, 2020	Feb	CAHN
----	--------------------	-----	---------	-----	--------------	-----	------

METHOCARBAMOL

TABLET;ORAL  
METHOCARBAMOL

AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Mar	CAHN
AA		750MG	A203550	002	Feb 08, 2017	Mar	CAHN
AA	HLTHCARE	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION  
METHOTREXATE SODIUM

>A>	AP	ALEMBIC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A220225	001	Apr 15, 2026	Apr	NEWA
>A>	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A220225	002	Apr 15, 2026	Apr	NEWA
>A>	AP	HETERO LABS LTD VI	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A219865	001	Apr 30, 2026	Apr	NEWA
>D>	!	HIKMA	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Apr	CTEC
>A>	AP	!	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Apr	CTEC
			METHOTREXATE SODIUM PRESERVATIVE FREE					
	@	CAPLIN ONE LABS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Mar	DISC
	AP		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan	CAHN
	@		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Mar	DISC
	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan	CAHN
	@		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Mar	DISC
	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan	CAHN
>D>	@	EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Apr	CMFD
>A>	AP		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Apr	CMFD
>D>	@		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Apr	CMFD
>A>	AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Apr	CMFD
>D>	@		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Apr	CMFD
>A>	AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Apr	CMFD
>D>	@		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Apr	CMFD
>A>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Apr	CMFD

TABLET;ORAL  
METHOTREXATE SODIUM

@	DAITO	EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Mar	DISC
---	-------	---------------	---------	-----	--------------	-----	------

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>A>	@	QUAGEN	125MG	A 070535	001	Jan 02, 1987	Apr	CAHN
>A>	@		250MG	A 070536	001	Jan 02, 1987	Apr	CAHN
>A>	@		500MG	A 070537	001	Jan 02, 1987	Apr	CAHN
>D>	@	STRIDES PHARMA INTL	125MG	A 070535	001	Jan 02, 1987	Apr	CAHN
>D>	@		250MG	A 070536	001	Jan 02, 1987	Apr	CAHN
>D>	@		500MG	A 070537	001	Jan 02, 1987	Apr	CAHN

METHYLENE BLUE

SOLUTION; INTRAVENOUS

METHYLENE BLUE

!	ZYDUS LIFESCIENCES	5MG/ML (5MG/ML)	A 215636	003	Feb 02, 2026	Jan	NFTG
!		100MG/10ML (10MG/ML)	A 215636	004	Mar 31, 2026	Mar	NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1		DR REDDYS LABS SA	60MG	A 078458	004	Jun 23, 2016	Feb	CHRS
AB1	!	GRANULES	60MG	A 211796	005	May 23, 2019	Feb	CHRS

TABLET, CHEWABLE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	@	QUAGEN	2.5MG	A 204954	001	Jan 26, 2017	Apr	CAHN
>A>	@		5MG	A 204954	002	Jan 26, 2017	Apr	CAHN
>A>	@		10MG	A 204954	003	Jan 26, 2017	Apr	CAHN
>D>	@	STRIDES PHARMA	2.5MG	A 204954	001	Jan 26, 2017	Apr	CAHN
>D>	@		5MG	A 204954	002	Jan 26, 2017	Apr	CAHN
>D>	@		10MG	A 204954	003	Jan 26, 2017	Apr	CAHN

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

@	INGENUS PHARMS LLC	4MG	A 210985	001	Jan 09, 2019	Feb	CAHN
---	--------------------	-----	----------	-----	--------------	-----	------

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB		CAPLIN	40MG/ML	A 220556	001	Jan 26, 2026	Jan	NEWA
AB			80MG/ML	A 220556	002	Jan 26, 2026	Jan	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SPRAY, METERED; NASAL

GIMOTI

+	!	QOL MEDCL	EQ 15MG BASE/SPRAY	N 209388	001	Jun 19, 2020	Feb	CAHN
---	---	-----------	--------------------	----------	-----	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	STRIDES PHARMA INTL	EQ 10MG BASE	A 070581	001	Oct 17, 1985	Jan	DISC
---	---------------------	--------------	----------	-----	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

@	MYLAN PHARMS INC	EQ 200MG TARTRATE	A 202033	004	Dec 15, 2011	Mar	DISC
---	------------------	-------------------	----------	-----	--------------	-----	------

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

AB		ZYDUS LIFESCIENCES	0.75%	A 220095	001	Feb 13, 2026	Feb	NEWA
----	--	--------------------	-------	----------	-----	--------------	-----	------

INJECTABLE; INJECTION

METRO I.V. IN PLASTIC CONTAINER

@	+	B BRAUN	500MG/100ML	N 018900	001	Sep 29, 1983	Jan	DISC
---	---	---------	-------------	----------	-----	--------------	-----	------

METRONIDAZOLE IN PLASTIC CONTAINER

AP	!	INFORLIFE	500MG/100ML	A 206191	001	Feb 25, 2019	Jan	CHRS
----	---	-----------	-------------	----------	-----	--------------	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	150MG	A 214352	001	Jan 25, 2021	Feb	CAHN
AB			200MG	A 214352	002	Jan 25, 2021	Feb	CAHN
AB			250MG	A 214352	003	Jan 25, 2021	Feb	CAHN
AB		MACLEODS PHARMS LTD	150MG	A 219987	001	Mar 23, 2026	Mar	NEWA

CAPSULE;ORAL

## MEXILETINE HYDROCHLORIDE

AB		200MG	A219987	002	Mar 23, 2026	Mar	NEWA
AB		250MG	A219987	003	Mar 23, 2026	Mar	NEWA

MICAFUNGIN SODIUM

## INJECTABLE;INTRAVENOUS

## MICAFUNGIN SODIUM

AP	ASPIRO	EQ 50MG BASE/VIAL	A220296	001	Mar 17, 2026	Mar	NEWA
AP		EQ 100MG BASE/VIAL	A220296	002	Mar 17, 2026	Mar	NEWA
AP	HISUN PHARM HANGZHOU	EQ 50MG BASE/VIAL	A219712	001	Jan 21, 2026	Jan	NEWA
AP		EQ 100MG BASE/VIAL	A219712	002	Jan 21, 2026	Jan	NEWA
AP	YICHANG HUMANWELL	EQ 50MG BASE/VIAL	A219518	001	Feb 24, 2026	Feb	NEWA
AP		EQ 100MG BASE/VIAL	A219518	002	Feb 24, 2026	Feb	NEWA

MIDODRINE HYDROCHLORIDE

## TABLET;ORAL

## MIDODRINE HYDROCHLORIDE

>D>	AB	IMPAX PHARMS	2.5MG	A076449	001	May 27, 2004	Apr	DISC
>A>	@		2.5MG	A076449	001	May 27, 2004	Apr	DISC
>D>	AB		5MG	A076449	002	May 27, 2004	Apr	DISC
>A>	@		5MG	A076449	002	May 27, 2004	Apr	DISC
>D>	AB		10MG	A076449	003	Dec 16, 2005	Apr	DISC
>A>	@		10MG	A076449	003	Dec 16, 2005	Apr	DISC
	AB	UNIQUE	2.5MG	A207613	001	Nov 02, 2018	Mar	CAHN
	AB		5MG	A207613	002	Nov 02, 2018	Mar	CAHN
	AB		10MG	A207613	003	Nov 02, 2018	Mar	CAHN

MIGLITOL

## TABLET;ORAL

## MIGLITOL

!	ORIENT PHARMA	25MG	A203965	001	Feb 24, 2015	Mar	CAHN
		50MG	A203965	002	Feb 24, 2015	Mar	CAHN
		100MG	A203965	003	Feb 24, 2015	Mar	CAHN

MILNACIPRAN HYDROCHLORIDE

## TABLET;ORAL

## MILNACIPRAN HYDROCHLORIDE

AB	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Jan	CMFD
AB		25MG	A205081	002	Apr 22, 2016	Jan	CMFD
AB		50MG	A205081	003	Apr 22, 2016	Jan	CMFD
AB		100MG	A205081	004	Apr 22, 2016	Jan	CMFD
AB	BRECKENRIDGE	12.5MG	A205071	001	Jan 27, 2016	Jan	CMFD
AB		25MG	A205071	002	Jan 27, 2016	Jan	CMFD
AB		50MG	A205071	003	Jan 27, 2016	Jan	CMFD
AB		100MG	A205071	004	Jan 27, 2016	Jan	CMFD
AB	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Feb	CMFD
AB		25MG	A205147	002	Oct 03, 2024	Feb	CMFD
AB		50MG	A205147	003	Oct 03, 2024	Feb	CMFD
AB		100MG	A205147	004	Oct 03, 2024	Feb	CMFD
	SAVELLA						
AB	+ ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan	CTEC
AB	+	25MG	N022256	002	Jan 14, 2009	Jan	CTEC
AB	+!	50MG	N022256	003	Jan 14, 2009	Jan	CTEC
AB	+	100MG	N022256	004	Jan 14, 2009	Jan	CTEC

MILRINONE LACTATE

## INJECTABLE;INJECTION

## MILRINONE LACTATE

@	HIKMA	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Mar	DISC
---	-------	----------------	---------	-----	--------------	-----	------

MILSAPERIDONE

## TABLET;ORAL

## BYSANTI

+	!	VANDA PHARMS INC	1MG	N220358	001	Feb 20, 2026	Feb	NEWA
	+		2MG	N220358	002	Feb 20, 2026	Feb	NEWA
	+		4MG	N220358	003	Feb 20, 2026	Feb	NEWA
	+		6MG	N220358	004	Feb 20, 2026	Feb	NEWA
	+		8MG	N220358	005	Feb 20, 2026	Feb	NEWA
	+		10MG	N220358	006	Feb 20, 2026	Feb	NEWA
	+		12MG	N220358	007	Feb 20, 2026	Feb	NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
MINOCYCLINE HYDROCHLORIDE

>D>	AB	CHARTWELL RX	EQ 45MG BASE	A 091424	001	Nov 30, 2011	Apr	CAHN
>D>	AB		EQ 55MG BASE	A 091424	002	Nov 30, 2011	Apr	CAHN
>D>	AB		EQ 90MG BASE	A 091424	003	Nov 30, 2011	Apr	CAHN
>D>	AB		EQ 135MG BASE	A 091424	004	Nov 30, 2011	Apr	CAHN
>A>	AB	LUPIN	EQ 45MG BASE	A 091424	001	Nov 30, 2011	Apr	CAHN
>A>	AB		EQ 55MG BASE	A 091424	002	Nov 30, 2011	Apr	CAHN
>A>	AB		EQ 90MG BASE	A 091424	003	Nov 30, 2011	Apr	CAHN
>A>	AB		EQ 135MG BASE	A 091424	004	Nov 30, 2011	Apr	CAHN

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL  
MIRABEGRON

AB		ALKEM LABS LTD	8MG/ML	A 219323	001	Jan 20, 2026	Jan	NFTG
		MYRBETRIQ GRANULES						
AB		+! APGDI	8MG/ML	N 213801	001	Mar 25, 2021	Jan	CFTG
		TABLET, EXTENDED RELEASE;ORAL						
		MIRABEGRON						
>A>	AB	DEVA HOLDING AS	25MG	A 219941	001	May 01, 2026	Apr	NEWA
>A>	AB		50MG	A 219941	002	May 01, 2026	Apr	NEWA

MIRTAZAPINE

TABLET;ORAL  
MIRTAZAPINE

AB		NOVITIUM PHARMA	7.5MG	A 219919	001	Feb 02, 2026	Jan	NEWA
AB			15MG	A 219919	002	Feb 02, 2026	Jan	NEWA
AB			30MG	A 219919	003	Feb 02, 2026	Jan	NEWA
AB			45MG	A 219919	004	Feb 02, 2026	Jan	NEWA

MITAPIVAT SULFATE

TABLET;ORAL  
AQVESME

		+! AGIOS PHARMS INC	EQ 100MG BASE	N 216196	004	Dec 23, 2025	Jan	NEWA
--	--	---------------------	---------------	----------	-----	--------------	-----	------

MOMETASONE FUROATE

IMPLANT;IMPLANTATION  
SINUVA

		+! INTERSECT ENT INC	1.35MG	N 209310	001	Dec 08, 2017	Mar	CHRS
--	--	----------------------	--------	----------	-----	--------------	-----	------

OINTMENT;TOPICAL  
MOMETASONE FUROATE

>D>		@ ENCUBE	0.1%	A 076481	001	Nov 14, 2003	Apr	CMFD
>A>	AB		0.1%	A 076481	001	Nov 14, 2003	Apr	CMFD

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL  
MONTELUKAST SODIUM

		@ AMNEAL PHARMS	EQ 4MG BASE	A 205107	001	Sep 04, 2020	Mar	DISC
		@	EQ 5MG BASE	A 205107	002	Sep 04, 2020	Mar	DISC
AB		SENORES PHARMS	EQ 4MG BASE	A 201581	001	Aug 06, 2012	Jan	CAHN
AB			EQ 5MG BASE	A 201581	002	Aug 06, 2012	Jan	CAHN

MORPHINE SULFATE

SOLUTION;ORAL  
MORPHINE SULFATE

		@ PADAGIS US	100MG/5ML	A 201574	001	Aug 06, 2012	Mar	DISC
		@ TRIS PHARMA INC	10MG/5ML	A 203518	001	May 12, 2015	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

		@ STRIDES PHARMA INTL	15MG	A 075295	001	Oct 28, 1998	Jan	DISC
		@	30MG	A 075295	002	Oct 28, 1998	Jan	DISC
		@	60MG	A 075295	003	Oct 28, 1998	Jan	DISC
		@	100MG	A 075295	004	Sep 15, 2000	Jan	DISC
		@	200MG	A 075295	005	Sep 15, 2000	Jan	DISC

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

@	FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Feb	DISC
---	---------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 400MG BASE	A209143	001	Mar 02, 2026	Feb	NEWA
>D> AB	TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Apr	DISC
>A>	@	EQ 400MG BASE	A200160	001	Apr 03, 2014	Apr	DISC

MUPIROCINOINTMENT;TOPICAL  
CENTANY

@	PADAGIS US	2%	N050788	001	Dec 04, 2002	Mar	DISC
---	------------	----	---------	-----	--------------	-----	------

MYCOPHENOLATE SODIUMTABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLATE SODIUM

@	RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Jan	DISC
@		EQ 360MG BASE	A091248	001	Jan 08, 2014	Jan	DISC
@	TWI PHARMS	EQ 180MG BASE	A214289	001	Nov 03, 2021	Mar	DISC
@		EQ 360MG BASE	A214289	002	Nov 03, 2021	Mar	DISC

NABUMETONETABLET;ORAL  
NABUMETONE

!	LGM PHARMA	1GM	A203166	003	Aug 30, 2019	Jan	CHRS
---	------------	-----	---------	-----	--------------	-----	------

NAFTIFINE HYDROCHLORIDECREAM;TOPICAL  
NAFTIFINE HYDROCHLORIDE

@	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb	DISC
---	--------	----	---------	-----	--------------	-----	------

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

@	AMNEAL	1%	A206165	001	Mar 20, 2019	Mar	DISC
---	--------	----	---------	-----	--------------	-----	------

NAFTIN

+	!	LEGACY PHARMA	1%	N019356	001	Jun 18, 1990	Mar	CTEC
---	---	---------------	----	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDESPRAY;NASAL  
REZENOPY

+	!	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Jan	CMFD
---	---	-----------	------------	---------	-----	--------------	-----	------

NAPROXENSUSPENSION;ORAL  
NAPROXEN

@	AUROBINDO PHARMA	25MG/ML	A216504	001	Oct 03, 2025	Mar	DISC
---	------------------	---------	---------	-----	--------------	-----	------

NARATRIPTAN HYDROCHLORIDETABLET;ORAL  
NARATRIPTAN

@	PADAGIS US	EQ 1MG BASE	A091326	001	Jul 08, 2010	Mar	DISC
@		EQ 2.5MG BASE	A091326	002	Jul 08, 2010	Mar	DISC

NAVEPEGITIDEPOWDER;SUBCUTANEOUS  
YUWIWEL

+	!	ASCENDIS	1.3MG/VIAL	N219164	001	Feb 27, 2026	Feb	NEWA
+	!		2.8MG/VIAL	N219164	002	Feb 27, 2026	Feb	NEWA
+	!		5.5MG/VIAL	N219164	003	Feb 27, 2026	Feb	NEWA

NEBIVOLOL HYDROCHLORIDETABLET;ORAL  
NEBIVOLOL HYDROCHLORIDE

@	TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar	DISC
@		EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar	DISC
@		EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar	DISC
@		EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar	DISC

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

>D> AA AARXION ANDA HLDING 500MG A065220 001 Jul 28, 2006 Apr CAHN  
 >A> AA SOLARIS PHARMA CORP 500MG A065220 001 Jul 28, 2006 Apr CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

@ WATSON LABS EQ 40MG BASE/ML;200,000 UNITS/ML A062664 001 Apr 08, 1986 Jan DISC  
 ! XGEN PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A065106 001 Jan 31, 2006 Jan CTEC  
 AT ! EQ 40MG BASE/ML;200,000 UNITS/ML A065106 001 Jan 31, 2006 Jan CHRS  
 ! EQ 40MG BASE/ML;200,000 UNITS/ML A065108 001 Jan 31, 2006 Jan CTEC  
 AT ! EQ 40MG BASE/ML;200,000 UNITS/ML A065108 001 Jan 31, 2006 Jan CHRS  
 NEOSPORIN G.U. IRRIGANT  
 @ MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A060707 001 Jan DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

@ HIKMA 3MG/3ML (1MG/ML) A216206 001 Jul 13, 2022 Mar DISC  
 NIVAGEN PHARMS INC 5MG/10ML (0.5MG/ML) A212627 001 Nov 03, 2022 Mar CAHN  
 AP 10MG/10ML (1MG/ML) A212627 002 Nov 03, 2022 Mar CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

@ NAVINTA LLC 20MG A218638 001 Jun 25, 2025 Mar DISC  
 @ 30MG A218638 002 Jun 25, 2025 Mar DISC  
 AB SENORES PHARMS 20MG A215377 001 Jul 17, 2023 Jan CAHN  
 AB 30MG A215377 002 Jul 17, 2023 Jan CAHN

INJECTABLE;INJECTION

CARDENE

AP + CHIESI 25MG/10ML (2.5MG/ML) N019734 001 Jan 30, 1992 Jan CMFD  
 AP NICARDIPINE HYDROCHLORIDE SOMERSET THERAPS LLC 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009 Jan CAHN

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB ! HERITAGE PHARMA 10MG A202644 001 Apr 25, 2013 Mar CHRS  
 PROCARDIA  
 @ + PFIZER 10MG N018482 001 Mar DISC

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>D> AB2 NOVAST LABS 90MG A210614 003 Mar 12, 2019 Apr CHRS  
 >A> AB2 ! 90MG A210614 003 Mar 12, 2019 Apr CHRS  
 @ PHARMADAX 30MG A216019 001 Nov 18, 2022 Mar CAHN  
 @ 60MG A216019 002 Nov 18, 2022 Mar CAHN  
 PROCARDIA XL  
 >D> AB2 +! PFIZER 90MG N019684 003 Sep 06, 1989 Apr DISC  
 >A> @ + 90MG N019684 003 Sep 06, 1989 Apr DISC

NILUTAMIDE

TABLET;ORAL

NILANDRON

>D> AB +! ADVANZ PHARMA 150MG N020169 002 Apr 30, 1999 Apr DISC  
 >A> @ + 150MG N020169 002 Apr 30, 1999 Apr DISC

NILUTAMIDE

>D> AB ANI PHARMS 150MG A207631 001 Jul 15, 2016 Apr CHRS  
 >A> AB ! 150MG A207631 001 Jul 15, 2016 Apr CHRS  
 >A> ! 150MG A207631 001 Jul 15, 2016 Apr CTEC

NINTEDANIB ESYLATE

CAPSULE;ORAL

NINTEDANIB ESYLATE

AB	APOTEX	EQ 100MG BASE	A 219227	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 219227	002	Apr 02, 2026	Mar	NFTG
AB	CIPLA	EQ 100MG BASE	A 212609	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 212609	002	Apr 02, 2026	Mar	NFTG
AB	DEXCEL	EQ 100MG BASE	A 219819	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 219819	002	Apr 02, 2026	Mar	NFTG
AB	DR REDDYS	EQ 100MG BASE	A 219283	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 219283	002	Apr 02, 2026	Mar	NFTG
AB	SANDOZ	EQ 100MG BASE	A 216915	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 216915	002	Apr 02, 2026	Mar	NFTG
	OFEV						
AB	+ BOEHRINGER INGELHEIM	EQ 100MG BASE	N 205832	001	Oct 15, 2014	Mar	CFTG
AB	+!	EQ 150MG BASE	N 205832	002	Oct 15, 2014	Mar	CFTG

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL

OGSIVEO

@ + SPRINGWORKS

EQ 50MG BASE

N 217677 001 Nov 27, 2023 Mar DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

>D>	@	AMTA	8.5MG	A 216606	001	Apr 10, 2023	Apr	CMFD
>A>	AB		8.5MG	A 216606	001	Apr 10, 2023	Apr	CMFD
>D>	AB	MYLAN	8.5MG	A 091001	001	Jan 26, 2011	Apr	DISC
>A>	@		8.5MG	A 091001	001	Jan 26, 2011	Apr	DISC
>D>	AB		17MG	A 091001	002	Jan 26, 2011	Apr	DISC
>A>	@		17MG	A 091001	002	Jan 26, 2011	Apr	DISC
>D>	!		20MG	A 079051	001	Jul 25, 2008	Apr	DISC
>A>	@		20MG	A 079051	001	Jul 25, 2008	Apr	DISC
>D>			25.5MG	A 091001	003	Jan 26, 2011	Apr	DISC
>A>	@		25.5MG	A 091001	003	Jan 26, 2011	Apr	DISC
>D>			30MG	A 079051	002	Jul 25, 2008	Apr	DISC
>A>	@		30MG	A 079051	002	Jul 25, 2008	Apr	DISC
	@		34MG	A 091001	004	Jan 26, 2011	Feb	DISC
>D>	!		40MG	A 079051	003	Jul 25, 2008	Apr	DISC
>A>	@		40MG	A 079051	003	Jul 25, 2008	Apr	DISC
	SULAR							
>D>	AB	+! AZURITY	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC
>A>		+!	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC
>A>	AB	+!	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC
	AB	+!	8.5MG	N 020356	008	Jan 02, 2008	Feb	CAHN
	@ +		10MG	N 020356	001	Feb 02, 1995	Feb	CAHN
	AB	+!	17MG	N 020356	007	Jan 02, 2008	Feb	CAHN
	@ +		20MG	N 020356	002	Feb 02, 1995	Feb	CAHN
	@ +		25.5MG	N 020356	006	Jan 02, 2008	Feb	CAHN
	@ +		30MG	N 020356	003	Feb 02, 1995	Feb	CAHN
	+!		34MG	N 020356	005	Jan 02, 2008	Feb	CAHN
	@ +		40MG	N 020356	004	Feb 02, 1995	Feb	CAHN
	+!	COVIS	34MG	N 020356	005	Jan 02, 2008	Feb	CTEC

NITRIC OXIDE

GAS; INHALATION

NOXIVENT

	@	VERO BIOTECH INC	100PPM	A 207141	001	Oct 02, 2018	Mar	CAHN
AA			800PPM	A 207141	002	Oct 02, 2018	Mar	CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

>D>	AB	AMNEAL PHARMS	25MG/5ML	A 201679	001	May 11, 2011	Apr	DISC
>A>	@		25MG/5ML	A 201679	001	May 11, 2011	Apr	DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

>D>	@	ATHEM	25MG	A 074336	001	Jan 25, 1995	Apr	CAHN
>D>	@		50MG	A 074336	002	Jan 25, 1995	Apr	CAHN
>D>	@		100MG	A 074336	003	Jan 25, 1995	Apr	CAHN
>A>	@	POM PHARMA	25MG	A 074336	001	Jan 25, 1995	Apr	CAHN
>A>	@		50MG	A 074336	002	Jan 25, 1995	Apr	CAHN
>A>	@		100MG	A 074336	003	Jan 25, 1995	Apr	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		CREEKWOOD PHARMS	75MG;25MG	A 220269	001	Apr 07, 2026	Mar	NEWA
----	--	------------------	-----------	----------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

	+	USPHARMA	0.1MG/HR	N 020145	001	Apr 04, 1995	Jan	CHRS
	+		0.2MG/HR	N 020145	002	Apr 04, 1995	Jan	CHRS
	+		0.3MG/HR	N 020145	003	Apr 04, 1995	Jan	CHRS
	+		0.6MG/HR	N 020145	005	Apr 04, 1995	Jan	CHRS
	+		0.8MG/HR	N 020145	006	Apr 04, 1995	Jan	CHRS
AB2		MYLAN TECHNOLOGIES	0.1MG/HR	A 074559	004	Feb 06, 1998	Jan	CHRS
AB2			0.2MG/HR	A 074559	003	Aug 30, 1996	Jan	CHRS
AB2			0.6MG/HR	A 074559	001	Aug 30, 1996	Jan	CHRS

OINTMENT; INTRA-ANAL

NITROGLYCERIN

AB	!	COSETTE	0.4%	A 216103	001	Feb 16, 2024	Mar	CHRS
	@ +	ABBVIE	0.4%	N 021359	001	Jun 21, 2011	Mar	DISC

NOREPINEPHRINE BITARTRATE

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

	+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N 214313	004	Feb 06, 2026	Feb	NEWA
	+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N 214313	005	Feb 06, 2026	Feb	NEWA
	+	!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N 214313	006	Feb 06, 2026	Feb	NEWA
AP	+	!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N 214313	003	Nov 21, 2023	Mar	CFTG
AP			SAGENT	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	A 220483	001	Mar 26, 2026	Mar	NFTG

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB		INGENUS PHARMS LLC	5MG	A 206490	001	Nov 05, 2018	Feb	CAHN
----	--	--------------------	-----	----------	-----	--------------	-----	------

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL

SPINRAZA

>A>	+	!	BIOGEN IDEC	EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML)	N 209531	002	Mar 27, 2026	Apr	NEWA
>A>	+	!		EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N 209531	003	Mar 27, 2026	Apr	NEWA

NYSTATIN

SUSPENSION;ORAL

NILSTAT

AA	+		CHARTWELL MOLECULES	100,000 UNITS/ML	N 050299	001		Mar	CMFD
AA			SCIEGEN PHARMS	100,000 UNITS/ML	A 062832	001	Dec 27, 1991	Jan	CAHN
AA			STERANCO HLTHCARE	100,000 UNITS/ML	A 220367	001	Feb 05, 2026	Jan	NEWA

OFLOXACINSOLUTION/DROPS;OPHTHALMIC  
OFLOXACIN

AT	MICRO LABS	0.3%	A218557	001	Apr 08, 2026	Mar	NEWA
----	------------	------	---------	-----	--------------	-----	------

OLANZAPINEPOWDER;INTRAMUSCULAR  
OLANZAPINE

AP	AM REGENT	10MG/VIAL	A201741	001	Mar 20, 2012	Jan	CDFR
AP	ANTHEA PHARMA	10MG/VIAL	A220323	001	Mar 05, 2026	Feb	NEWA
AP	ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Jan	CDFR
AP	EUGIA PHARMA	10MG/VIAL	A210968	001	Oct 22, 2020	Jan	CDFR
AP	OMNIVIUM PHARMS	10MG/VIAL	A219048	001	Jan 23, 2026	Jan	NEWA
AP	QILU	10MG/VIAL	A218116	001	May 16, 2025	Jan	CDFR
AP	SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Jan	CDFR
AP	UBI	10MG/VIAL	A211072	001	Jun 11, 2025	Jan	CDFR

ZYPREXA

AP	+! CHEPLAPHARM	10MG/VIAL	N021253	001	Mar 29, 2004	Jan	CDFR
----	----------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL  
OLANZAPINE

AB	SUNSHINE	2.5MG	A206238	001	Nov 19, 2018	Feb	CMFD
AB		5MG	A206238	002	Nov 19, 2018	Feb	CMFD
AB		7.5MG	A206238	003	Nov 19, 2018	Feb	CMFD
AB		10MG	A206238	004	Nov 19, 2018	Feb	CMFD
AB		15MG	A206238	005	Nov 19, 2018	Feb	CMFD
AB		20MG	A206238	006	Nov 19, 2018	Feb	CMFD
AB	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Jan	CMFD
AB		5MG	A091434	002	Apr 23, 2012	Jan	CMFD
AB		7.5MG	A091434	003	Apr 23, 2012	Jan	CMFD
AB		10MG	A091434	004	Apr 23, 2012	Jan	CMFD
AB		15MG	A091434	005	Apr 23, 2012	Jan	CMFD
AB		20MG	A091434	006	Apr 23, 2012	Jan	CMFD

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL  
OMEGA-3-ACID ETHYL ESTERS

>D>	AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Apr	DISC
>A>	@		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Apr	DISC
>D>	AB	APOTEX	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Apr	DISC
>A>	@		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Apr	DISC

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL  
OMEPRAZOLE

>D>	AB	GLENMARK PHARMS LTD	20MG	A091672	002	Oct 31, 2014	Apr	CHRS
>A>	AB	!	20MG	A091672	002	Oct 31, 2014	Apr	CHRS
>D>	AB		40MG	A091672	003	Oct 31, 2014	Apr	CHRS
>A>	AB	!	40MG	A091672	003	Oct 31, 2014	Apr	CHRS
>D>	AB	! SANDOZ	20MG	A075757	002	Jan 28, 2003	Apr	CHRS
>A>	AB		20MG	A075757	002	Jan 28, 2003	Apr	CHRS
>D>	AB	!	40MG	A076515	001	Jan 21, 2009	Apr	CHRS
>A>	AB		40MG	A076515	001	Jan 21, 2009	Apr	CHRS

OMEPRAZOLE MAGNESIUMFOR SUSPENSION, DELAYED RELEASE;ORAL  
PRILOSEC

+	AZURITY	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Feb	CAHN
+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Feb	CAHN

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL  
ONDANSETRON HYDROCHLORIDE

AA PHARM ASSOC EQ 4MG BASE/5ML A078127 001 Jun 25, 2007 Feb CMFD

>A> ORFORGLIPRON CALCIUM

>A> TABLET;ORAL  
>A> FOUNDAYO

>A> + ELI LILLY AND CO EQ 0.8MG BASE N220934 001 Apr 01, 2026 Apr NEWA  
>A> + EQ 2.5MG BASE N220934 002 Apr 01, 2026 Apr NEWA  
>A> + EQ 5.5MG BASE N220934 003 Apr 01, 2026 Apr NEWA  
>A> + EQ 9MG BASE N220934 004 Apr 01, 2026 Apr NEWA  
>A> + EQ 14.5MG BASE N220934 005 Apr 01, 2026 Apr NEWA  
>A> +! EQ 17.2MG BASE N220934 006 Apr 01, 2026 Apr NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL  
OSELTAMIVIR PHOSPHATE

>D> AB CEDIPROF INC EQ 30MG BASE A217451 001 Dec 03, 2024 Apr DISC  
>A> @ EQ 30MG BASE A217451 001 Dec 03, 2024 Apr DISC  
>D> AB EQ 45MG BASE A217451 002 Dec 03, 2024 Apr DISC  
>A> @ EQ 45MG BASE A217451 002 Dec 03, 2024 Apr DISC  
>D> AB EQ 75MG BASE A217451 003 Dec 03, 2024 Apr DISC  
>A> @ EQ 75MG BASE A217451 003 Dec 03, 2024 Apr DISC  
>D> AB UPSHER SMITH LABS EQ 30MG BASE A213437 001 Jan 22, 2026 Apr DISC  
>A> @ EQ 30MG BASE A213437 001 Jan 22, 2026 Apr DISC  
AB EQ 30MG BASE A213437 001 Jan 22, 2026 Jan NEWA  
>D> AB EQ 45MG BASE A213437 002 Jan 22, 2026 Apr DISC  
>A> @ EQ 45MG BASE A213437 002 Jan 22, 2026 Apr DISC  
AB EQ 45MG BASE A213437 002 Jan 22, 2026 Jan NEWA  
>D> AB EQ 75MG BASE A213437 003 Jan 22, 2026 Apr DISC  
>A> @ EQ 75MG BASE A213437 003 Jan 22, 2026 Apr DISC  
AB EQ 75MG BASE A213437 003 Jan 22, 2026 Jan NEWA

OXALIPLATIN

INJECTABLE; INTRAVENOUS  
OXALIPLATIN

>D> AP ACTAVIS 50MG/10ML (5MG/ML) A204880 001 Mar 05, 2018 Apr DISC  
>A> @ 50MG/10ML (5MG/ML) A204880 001 Mar 05, 2018 Apr DISC  
>D> AP 100MG/20ML (5MG/ML) A204880 002 Mar 05, 2018 Apr DISC  
>A> @ 100MG/20ML (5MG/ML) A204880 002 Mar 05, 2018 Apr DISC  
>D> AP HENGRUI PHARMA 50MG/10ML (5MG/ML) A203869 001 Jun 18, 2014 Apr DISC  
>A> @ 50MG/10ML (5MG/ML) A203869 001 Jun 18, 2014 Apr DISC  
>D> AP 100MG/20ML (5MG/ML) A203869 002 Jun 18, 2014 Apr DISC  
>A> @ 100MG/20ML (5MG/ML) A203869 002 Jun 18, 2014 Apr DISC  
>D> AP NOVAST LABS 100MG/20ML (5MG/ML) A207562 002 Oct 16, 2018 Apr DISC  
>A> @ 100MG/20ML (5MG/ML) A207562 002 Oct 16, 2018 Apr DISC  
AP SHANDONG 50MG/10ML (5MG/ML) A219765 001 Jan 15, 2026 Jan NEWA  
AP 100MG/20ML (5MG/ML) A219765 002 Jan 15, 2026 Jan NEWA  
>D> AP +! TEVA PHARMS 50MG/10ML (5MG/ML) N022160 001 Aug 07, 2009 Apr DISC  
>A> @ + 50MG/10ML (5MG/ML) N022160 001 Aug 07, 2009 Apr DISC  
>D> AP +! 100MG/20ML (5MG/ML) N022160 002 Aug 07, 2009 Apr DISC  
>A> @ + 100MG/20ML (5MG/ML) N022160 002 Aug 07, 2009 Apr DISC

OXCARBAZEPINE

SUSPENSION;ORAL  
OXCARBAZEPINE

AB STERANCO HLTHCARE 300MG/5ML A220281 001 Mar 09, 2026 Feb NEWA

TABLET;ORAL  
OXCARBAZEPINE

AB EPIC PHARMA LLC 150MG A219556 001 Mar 02, 2026 Feb NEWA  
AB 300MG A219556 002 Mar 02, 2026 Feb NEWA  
AB 600MG A219556 003 Mar 02, 2026 Feb NEWA  
>A> AB UMEDICA LABS PVT 150MG A218341 001 Apr 29, 2026 Apr NEWA  
>A> AB 300MG A218341 002 Apr 29, 2026 Apr NEWA  
>A> AB 600MG A218341 003 Apr 29, 2026 Apr NEWA

OXICONAZOLE NITRATE

LOTION;TOPICAL  
OXISTAT

>D>	+	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	DISC
>A>	@	+	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	DISC

OXYBUTYNIN CHLORIDE

TABLET;ORAL  
OXYBUTYNIN CHLORIDE

AB	!	NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017	Jan	CHRS
AB	!	RISING	2.5MG	A209025	002	Feb 07, 2023	Feb	CTEC
AB		STRIDES PHARMA INTL	2.5MG	A075079	002	Mar 10, 2026	Feb	NEWA
AB			5MG	A075079	001	Oct 31, 1997	Jan	CHRS

TABLET, EXTENDED RELEASE;ORAL  
OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	15MG	A207138	003	Feb 29, 2016	Jan	CHRS
AB	!	ZYDUS PHARMS	15MG	A202332	003	Jun 26, 2017	Jan	CHRS

OZENOXACIN

CREAM;TOPICAL  
XEPI

@	+	LNHC	1%	N208945	001	Dec 11, 2017	Jan	CAHN
---	---	------	----	---------	-----	--------------	-----	------

PACLITAXEL

INJECTABLE;INJECTION  
PACLITAXEL

@		NATCO PHARMA USA	6MG/ML	A091540	001	Sep 29, 2011	Mar	CAHN
---	--	------------------	--------	---------	-----	--------------	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL  
PALIPERIDONE

AB		AJANTA PHARMA LTD	3MG	A218514	002	Jun 26, 2024	Mar	CMFD
AB			6MG	A218514	003	Jun 26, 2024	Mar	CMFD
AB			9MG	A218514	004	Jun 26, 2024	Mar	CMFD
>D>	AB	APOTEX	3MG	A203279	001	Jan 26, 2026	Apr	DISC
>A>	@		3MG	A203279	001	Jan 26, 2026	Apr	DISC
AB			3MG	A203279	001	Jan 26, 2026	Jan	NEWA
>D>	AB		6MG	A203279	002	Jan 26, 2026	Apr	DISC
>A>	@		6MG	A203279	002	Jan 26, 2026	Apr	DISC
AB			6MG	A203279	002	Jan 26, 2026	Jan	NEWA
>D>	AB		9MG	A203279	003	Jan 26, 2026	Apr	DISC
>A>	@		9MG	A203279	003	Jan 26, 2026	Apr	DISC
AB			9MG	A203279	003	Jan 26, 2026	Jan	NEWA
	@	RK PHARMA	1.5MG	A203802	001	Sep 24, 2015	Jan	DISC
	@		3MG	A203802	002	Sep 24, 2015	Jan	DISC
	@		6MG	A203802	003	Sep 24, 2015	Jan	DISC
	@		9MG	A203802	004	Sep 24, 2015	Jan	DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
INVEGA HAFYERA

+	!	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Jan	CHRS
+	!		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Jan	CHRS

INVEGA SUSTENNA

+	!	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Mar	CHRS
+	!		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Mar	CHRS
+	!		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CHRS
+	!		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Mar	CHRS

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS  
PANTOPRAZOLE SODIUM

>A>	AP	@	PHARMOBEDIANT	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Jan	CAHN
		@	SHUANGCHENG	EQ 40MG BASE/VIAL	A219973	001	Apr 22, 2026	Apr	NEWA

PARICALCITOL

CAPSULE;ORAL  
ZEMPLAR

>D>	AB	+	ABBVIE	2MCG	N021606	002	May 26, 2005	Apr	DISC
>A>	@	+		2MCG	N021606	002	May 26, 2005	Apr	DISC

## SOLUTION; INTRAVENOUS

## PARICALCITOL

>D>	AP	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	DISC
>A>	@		0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	DISC
>D>	AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	DISC
>A>	@		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	DISC
>D>	AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	DISC
>A>	@		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	DISC
	@	EUGIA PHARMA	0.002MG/ML (0.002MG/ML)	A205982	001	Oct 09, 2018	Jan	DISC
	@		0.005MG/ML (0.005MG/ML)	A205982	002	Oct 09, 2018	Jan	DISC
	@		0.01MG/2ML (0.005MG/ML)	A205982	003	Oct 09, 2018	Jan	DISC

PAROXETINE HYDROCHLORIDE

## SUSPENSION; ORAL

## PAROXETINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 10MG BASE/5ML	A219954	001	Mar 05, 2026	Feb	NEWA
AB	!	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Feb	CTEC

## TABLET, EXTENDED RELEASE; ORAL

## PAROXETINE HYDROCHLORIDE

AB		ALEMBIC	EQ 12.5MG BASE	A217280	003	Mar 26, 2026	Mar	NEWA
----	--	---------	----------------	---------	-----	--------------	-----	------

PENTAMIDINE ISETHIONATE

## FOR SOLUTION; INHALATION

## PENTAMIDINE ISETHIONATE

>A>	AN	PAI HOLDINGS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr	CAHN
>D>	AN	SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr	CAHN

## INJECTABLE; INJECTION

## PENTAMIDINE ISETHIONATE

>A>	AP	PAI HOLDINGS	300MG/VIAL	A206666	001	Sep 28, 2017	Apr	CAHN
>D>	AP	PHARMOBEDIANT	300MG/VIAL	A206982	001	Mar 17, 2022	Apr	DISC
>A>	@		300MG/VIAL	A206982	001	Mar 17, 2022	Apr	DISC
>D>	AP	SETON PHARMS	300MG/VIAL	A206666	001	Sep 28, 2017	Apr	CAHN

PHENTERMINE HYDROCHLORIDE

## TABLET; ORAL

## PHENTERMINE HYDROCHLORIDE

@		INGENUS PHARMS LLC	37.5MG	A091451	001	Sep 21, 2012	Feb	CAHN
---	--	--------------------	--------	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

## SOLUTION; INTRAVENOUS

## PHENYLEPHRINE HYDROCHLORIDE

AP1		BAXTER HLTHCARE CORP	10MG/ML (10MG/ML)	A217032	001	Apr 03, 2026	Mar	NEWA
AP1			50MG/5ML (10MG/ML)	A217032	002	Apr 03, 2026	Mar	NEWA
AP1			100MG/10ML (10MG/ML)	A217032	003	Apr 03, 2026	Mar	NEWA
AP1		HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Jan	CMFD
AP1			50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Jan	CMFD
AP1			100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Jan	CMFD

PHYTONADIONE

## INJECTABLE; INJECTION

## PHYTONADIONE

AB1		ALEMBIC	1MG/0.5ML	A216444	001	Sep 08, 2025	Mar	CTEC
AB1		AMNEAL	1MG/0.5ML	A216601	001	Nov 04, 2025	Mar	CTEC
AB2		BAXTER HLTHCARE CORP	1MG/0.5ML	A216852	001	Feb 26, 2026	Mar	CTEC
AB			1MG/0.5ML	A216852	001	Feb 26, 2026	Feb	NEWA
AB2	!	CIPLA	1MG/0.5ML	A214596	001	Apr 22, 2022	Mar	CTEC
AB1			1MG/0.5ML	A214966	001	Jan 03, 2025	Mar	CTEC
AB1	+	INTL MEDICATION	1MG/0.5ML	A083722	001		Mar	CTEC
AB1		ORBICULAR	1MG/0.5ML	A216298	001	Mar 13, 2026	Mar	CTEC
AB			1MG/0.5ML	A216298	001	Mar 13, 2026	Mar	NEWA
AB1		SUNNY	10MG/ML	A215090	001	Jan 09, 2026	Jan	NEWA

## TABLET; ORAL

## PHYTONADIONE

AB		SINOTHERAPEUTICS INC	5MG	A220454	001	Feb 26, 2026	Feb	NEWA
----	--	----------------------	-----	---------	-----	--------------	-----	------

PIFLUFOLASTAT F-18

## SOLUTION; INTRAVENOUS

## PYLARIFY TRUVU

+	!	APHELION	1mCi/mL-120mCi/mL	N220089	001	Mar 06, 2026	Mar	NEWA
---	---	----------	-------------------	---------	-----	--------------	-----	------

PILOCARPINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
PILOCARPINE HYDROCHLORIDE

>D>	AB	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr	CHRS
>A>	AB	!	1.25%	A217733	001	Apr 28, 2025	Apr	CHRS
>A>		!	1.25%	A217733	001	Apr 28, 2025	Apr	CTEC
>D>		VUITY						
>D>	AB	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr	DISC
>A>		@ +	1.25%	N214028	001	Oct 28, 2021	Apr	DISC

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	5MG	A212377	001	Aug 13, 2019	Jan	CAHN
AB			7.5MG	A212377	002	Aug 13, 2019	Jan	CAHN
		@ PADAGIS US	5MG	A076746	001	Nov 16, 2004	Mar	DISC

PIMOZIDE

TABLET;ORAL

PIMOZIDE

>A>	AB	NOVITIUM PHARMA	1MG	A219897	001	Apr 13, 2026	Apr	NEWA
>A>	AB		2MG	A219897	002	Apr 13, 2026	Apr	NEWA
>D>		PH HEALTH	1MG	A204521	001	Sep 28, 2015	Apr	CTEC
>A>	AB		1MG	A204521	001	Sep 28, 2015	Apr	CTEC
>D>		!	2MG	A204521	002	Sep 28, 2015	Apr	CTEC
>A>	AB	!	2MG	A204521	002	Sep 28, 2015	Apr	CTEC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP	SANDOZ	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065363	001	Oct 21, 2010	Apr	DISC
>A>		@	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065363	001	Oct 21, 2010	Apr	DISC
>D>	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065363	002	Oct 21, 2010	Apr	DISC
>A>		@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065363	002	Oct 21, 2010	Apr	DISC
>D>	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065363	003	Oct 21, 2010	Apr	DISC
>A>		@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065363	003	Oct 21, 2010	Apr	DISC

PIRFENIDONE

CAPSULE;ORAL

PIRFENIDONE

>A>	AB	AUROBINDO PHARMA	267MG	A212597	001	Apr 20, 2026	Apr	NEWA
-----	----	------------------	-------	---------	-----	--------------	-----	------

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL

PIVYA

+!	ALEMBIC THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Jan	CAHN
----	----------------	---------------	---------	-----	--------------	-----	------

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

@	TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)	A205197	001	Jul 24, 2023	Mar	DISC
---	---------------------	----------------------	---------	-----	--------------	-----	------

PODOFILOX

GEL;TOPICAL

CONDYLOX

@ +	ALLERGAN	0.5%	N020529	001	Mar 13, 1997	Jan	DISC
!	PADAGIS US	0.5%	A211871	001	Nov 22, 2023	Jan	CHRS
		0.5%	A211871	001	Nov 22, 2023	Jan	CTEC

SOLUTION;TOPICAL

CONDYLOX

>D>								
>D>	AT	+! TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Apr	DISC
>A>		@ +	0.5%	N019795	001	Dec 13, 1990	Apr	DISC
	AT	+!	0.5%	N019795	001	Dec 13, 1990	Feb	CAHN
>D>	AT	PADAGIS US	0.5%	A075600	001	Jan 29, 2002	Apr	CHRS
>A>	AT	!	0.5%	A075600	001	Jan 29, 2002	Apr	CHRS
>A>		!	0.5%	A075600	001	Jan 29, 2002	Apr	CTEC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

TRILYTE

>D>	@	AUROBINDO PHARMA USA	420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	A076491	001	Feb 05, 2004	Apr	CMFD
>A>	AA		420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	A076491	001	Feb 05, 2004	Apr	CMFD

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

>D>	@	QUAGEN	120GM/PACKET;1.49GM/PACKET;3.3 6GM/PACKET;2.92GM/PACKET;11.36 GM/PACKET	N018983	005	Oct 26, 1984	Apr	CRLD
>A>	@ +		120GM/PACKET;1.49GM/PACKET;3.3 6GM/PACKET;2.92GM/PACKET;11.36 GM/PACKET	N018983	005	Oct 26, 1984	Apr	CRLD
>D>	@		227.1GM/PACKET;2.82GM/PACKET;6 .36GM/PACKET;5.53GM/PACKET;21. 5GM/PACKET	N018983	004	Oct 26, 1984	Apr	CRLD
>A>	@ +		227.1GM/PACKET;2.82GM/PACKET;6 .36GM/PACKET;5.53GM/PACKET;21. 5GM/PACKET	N018983	004	Oct 26, 1984	Apr	CRLD
>D>	@		227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Apr	CRLD
>A>	@ +		227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Apr	CRLD
>D>	@		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Apr	CRLD
>A>	@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Apr	CRLD
>D>	@		360GM/PACKET;4.47GM/PACKET;10. 08GM/PACKET;8.76GM/PACKET;34.0 8GM/PACKET	N018983	006	Oct 26, 1984	Apr	CRLD
>A>	@ +		360GM/PACKET;4.47GM/PACKET;10. 08GM/PACKET;8.76GM/PACKET;34.0 8GM/PACKET	N018983	006	Oct 26, 1984	Apr	CRLD
>A>	@ +	STRIDES PHARMA INTL	120GM/PACKET;1.49GM/PACKET;3.3 6GM/PACKET;2.92GM/PACKET;11.36 GM/PACKET	N018983	005	Oct 26, 1984	Apr	CAHN
>A>	@ +		227.1GM/PACKET;2.82GM/PACKET;6 .36GM/PACKET;5.53GM/PACKET;21. 5GM/PACKET	N018983	004	Oct 26, 1984	Apr	CAHN
>A>	@ +		227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Apr	CAHN
>A>	@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Apr	CAHN
>A>	@ +		360GM/PACKET;4.47GM/PACKET;10. 08GM/PACKET;8.76GM/PACKET;34.0 8GM/PACKET	N018983	006	Oct 26, 1984	Apr	CAHN
COLYTE WITH FLAVOR PACKS								
>D>	@	QUAGEN	240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	CRLD
>A>	@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	CRLD
>A>	@ +	STRIDES PHARMA INTL	240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	CAHN
COLYTE-FLAVORED								
>D>	@	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr	CRLD
>A>	@ +		227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr	CRLD
>D>	@		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr	CRLD
>A>	@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr	CRLD
>A>	@ +	STRIDES PHARMA INTL	227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr	CAHN
>A>	@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr	CAHN
PEG 3350 AND ELECTROLYTES								
>D>		NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CHRS
>A>	!		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CHRS

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

AB	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	CMFD
AB		2MG	A210164	002	Jun 11, 2024	Jan	CMFD
AB		3MG	A210164	003	Jun 11, 2024	Jan	CMFD
AB		4MG	A210164	004	Jun 11, 2024	Jan	CMFD
AB	BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Jan	CMFD
AB		2MG	A210111	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210111	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210111	004	Oct 30, 2020	Jan	CMFD
AB	EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Jan	CMFD
AB		2MG	A210249	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210249	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210249	004	Oct 30, 2020	Jan	CMFD
AB	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Jan	CMFD
AB		2MG	A210236	002	Sep 26, 2024	Jan	CMFD
AB		3MG	A210236	003	Sep 26, 2024	Jan	CMFD
AB		4MG	A210236	004	Sep 26, 2024	Jan	CMFD
AB	TEVA PHARMS USA	1MG	A209956	001	May 04, 2022	Jan	CMFD
AB		2MG	A209956	002	May 04, 2022	Jan	CMFD
AB		3MG	A209956	003	May 04, 2022	Jan	CMFD
AB		4MG	A209956	004	May 04, 2022	Jan	CMFD
	POMALYST						
AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Jan	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Jan	CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Jan	CTEC

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

	+!	TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	Jan	CHRS
	+		EQ 45MG BASE	N203469	002	Dec 14, 2012	Jan	CHRS

POSACONAZOLE

SOLUTION; INTRAVENOUS

NOXAFIL

	@ +	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Jan	DISC
		POSACONAZOLE						
AP	!	GLAND	300MG/16.7ML (18MG/ML)	A217553	001	Dec 26, 2023	Jan	CHRS
		TABLET, DELAYED RELEASE; ORAL						
		POSACONAZOLE						
>A>	AB	WELDING	100MG	A216326	001	Jun 20, 2023	Apr	CAHN
>D>	AB	WESTMINSTER PHARMS	100MG	A216326	001	Jun 20, 2023	Apr	CAHN

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

	@	EXELA PHARMA	2MEQ/ML	A206203	001	Dec 29, 2015	Jan	DISC
--	---	--------------	---------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

	@	PADAGIS US	8MEQ	A200185	001	May 18, 2011	Mar	DISC
	@		10MEQ	A200185	002	May 18, 2011	Mar	DISC

FOR SOLUTION; ORAL

POKONZA

>A>		+ GENUS	15MEQ	N208019	004	Nov 12, 2025	Apr	NEWA
		INJECTABLE; INJECTION						
		POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER						
	@ +	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989	Mar	DISC

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS

POTASSIUM PHOSPHATES

AP	CAPLIN	1.18GM/5ML (236MG/ML); 1.12GM/5ML	A220373	001	Mar 12, 2026	Mar	NEWA
AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML	A220373	002	Mar 12, 2026	Mar	NEWA
AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML	A220373	003	Mar 12, 2026	Mar	NEWA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

@	SENORES PHARMS	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan CAHN
@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan CAHN

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	SENORES PHARMS	10MG	A077491	002	Oct 23, 2006	Feb CAHN
AB		20MG	A077491	003	Oct 23, 2006	Feb CAHN
AB		40MG	A077491	004	Oct 23, 2006	Feb CAHN
AB		80MG	A077491	001	Feb 11, 2008	Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

>A>	AA	+! PAI HOLDINGS	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Apr CAHN
>D>	AA	+! SETON PHARM	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Apr CAHN

PREGABALIN

CAPSULE; ORAL

PREGABALIN

AB	FOURRTS LABS	25MG	A218529	001	Feb 24, 2026	Feb NEWA	
AB		50MG	A218529	002	Feb 24, 2026	Feb NEWA	
AB		75MG	A218529	003	Feb 24, 2026	Feb NEWA	
AB		100MG	A218529	004	Feb 24, 2026	Feb NEWA	
AB		150MG	A218529	005	Feb 24, 2026	Feb NEWA	
AB		200MG	A218529	006	Feb 24, 2026	Feb NEWA	
AB		225MG	A218529	007	Feb 24, 2026	Feb NEWA	
AB		300MG	A218529	008	Feb 24, 2026	Feb NEWA	
AB	RENATA	50MG	A210585	001	Dec 26, 2019	Feb CAHN	
AB		75MG	A210585	002	Dec 26, 2019	Feb CAHN	
AB		100MG	A210585	003	Dec 26, 2019	Feb CAHN	
AB		150MG	A210585	004	Dec 26, 2019	Feb CAHN	
AB		200MG	A210585	005	Dec 26, 2019	Feb CAHN	
AB		300MG	A210585	006	Dec 26, 2019	Feb CAHN	
>A>	AB	UNICHEM	25MG	A219593	001	Apr 30, 2026	Apr NEWA
>A>	AB		50MG	A219593	002	Apr 30, 2026	Apr NEWA
>A>	AB		75MG	A219593	003	Apr 30, 2026	Apr NEWA
>A>	AB		100MG	A219593	004	Apr 30, 2026	Apr NEWA
>A>	AB		150MG	A219593	005	Apr 30, 2026	Apr NEWA
>A>	AB		200MG	A219593	006	Apr 30, 2026	Apr NEWA
>A>	AB		225MG	A219593	007	Apr 30, 2026	Apr NEWA
>A>	AB		300MG	A219593	008	Apr 30, 2026	Apr NEWA

SOLUTION; ORAL

PREGABALIN

AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Mar CAHN
----	--------	---------	---------	-----	--------------	----------

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS LLC	EQ 15MG BASE	A206043	001	Jun 23, 2016	Feb CAHN
----	--------------------	--------------	---------	-----	--------------	----------

PRIMIDONE

TABLET; ORAL

PRIMIDONE

AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Feb CAHN
AB		250MG	A218366	002	Jan 23, 2024	Feb CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	!	GLAND	100MG/ML	A218135	001	Jul 22, 2024	Jan CHRS
AP	!		500MG/ML	A218135	002	Jul 22, 2024	Jan CHRS
AP		HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jan CHRS
	@		500MG/ML	A089070	001	Feb 12, 1986	Jan DISC

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION  
PROCHLORPERAZINE EDISYLATE

@	AMNEAL	EQ 5MG BASE/ML	A214192	001	Nov 28, 2022	Feb	DISC
---	--------	----------------	---------	-----	--------------	-----	------

PROGESTERONE

GEL; VAGINAL

CRINONE

>D>							
>D>	+!	ABBVIE	4%	N020701	001	Jul 31, 1997	Apr DISC
>A>	@	+	4%	N020701	001	Jul 31, 1997	Apr DISC

INSERT; VAGINAL

PROGESTERONE

>A>	AB	GLENMARK PHARMS	100MG	A216363	001	Apr 08, 2026	Apr CAHN
>D>	AB	GLENMARK PHARMS LTD	100MG	A216363	001	Apr 08, 2026	Apr CAHN
	AB		100MG	A216363	001	Apr 08, 2026	Mar NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB	IPCA LABS LTD	60MG	A203103	001	May 01, 2026	Apr NEWA
>A>	AB		80MG	A203103	002	May 01, 2026	Apr NEWA
>A>	AB		120MG	A203103	003	May 01, 2026	Apr NEWA
>A>	AB		160MG	A203103	004	May 01, 2026	Apr NEWA

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

>A>	@	ALLIED	1MG/ML	A076400	001	Feb 26, 2003	Apr CAHN
>D>	@	FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003	Apr CAHN

SOLUTION; ORAL

HEMANGEOL

+! ETON

PROPRANOLOL HYDROCHLORIDE

! HIKMA

			4.28MG/ML	N205410	001	Mar 14, 2014	Mar CAHN
			20MG/5ML	A070690	002	May 15, 1987	Feb CMS1

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	AB	MANKIND PHARMA	10MG	A216663	001	Jan 27, 2026	Jan NEWA
	AB		20MG	A216663	002	Jan 27, 2026	Jan NEWA
	AB		40MG	A216663	003	Jan 27, 2026	Jan NEWA
	AB		60MG	A216663	004	Jan 27, 2026	Jan NEWA
	AB		80MG	A216663	005	Jan 27, 2026	Jan NEWA

PRUCALOPRIDE SUCCINATE

TABLET; ORAL

PRUCALOPRIDE SUCCINATE

	AB	AJANTA PHARMA LTD	EQ 1MG BASE	A219220	001	Jan 16, 2026	Jan NEWA
	AB		EQ 2MG BASE	A219220	002	Jan 16, 2026	Jan NEWA
	AB	TEVA PHARMS INC	EQ 1MG BASE	A219071	001	Feb 05, 2026	Jan NEWA
	AB		EQ 2MG BASE	A219071	002	Feb 05, 2026	Jan NEWA

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE; ORAL

PYRIDOSTIGMINE BROMIDE

@	IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Jan	DISC
---	----------------	-------	---------	-----	--------------	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

>D>	AB	SUN PHARM	EQ 25MG BASE	A201190	001	Mar 27, 2012	Apr DISC
>A>	@		EQ 25MG BASE	A201190	001	Mar 27, 2012	Apr DISC
>D>	AB		EQ 400MG BASE	A201190	006	Mar 27, 2012	Apr DISC
>A>	@		EQ 400MG BASE	A201190	006	Mar 27, 2012	Apr DISC

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

>D>	AB	MEDICAP LABS	EQ 50MG BASE	A202939	001	May 09, 2017	Apr CAHN
>D>	AB		EQ 150MG BASE	A202939	002	May 09, 2017	Apr CAHN
>D>	AB		EQ 200MG BASE	A202939	003	May 09, 2017	Apr CAHN
>D>	AB		EQ 300MG BASE	A202939	004	May 09, 2017	Apr CAHN
>D>	AB		EQ 400MG BASE	A202939	005	May 09, 2017	Apr CAHN
>A>	AB	PLATINUM	EQ 50MG BASE	A202939	001	May 09, 2017	Apr CAHN
>A>	AB		EQ 150MG BASE	A202939	002	May 09, 2017	Apr CAHN
>A>	AB		EQ 200MG BASE	A202939	003	May 09, 2017	Apr CAHN
>A>	AB		EQ 300MG BASE	A202939	004	May 09, 2017	Apr CAHN

	TABLET, EXTENDED RELEASE;ORAL							
	QUETIAPINE FUMARATE							
>A>	AB	EQ 400MG BASE	A202939	005	May 09, 2017	Apr	CAHN	
	<u>RABEPRAZOLE SODIUM</u>							
	TABLET, DELAYED RELEASE;ORAL							
	RABEPRAZOLE SODIUM							
	AB	AUROBINDO PHARMA USA 20MG	A205761	001	Feb 17, 2017	Jan	CAHN	
	<u>RAMELTEON</u>							
	TABLET;ORAL							
	RAMELTEON							
	AB	AUROBINDO PHARMA LTD 8MG	A215972	001	Jul 10, 2023	Feb	CTEC	
	AB	XIROMED 8MG	A216209	001	Nov 25, 2022	Mar	CTEC	
	<u>RAMIPRIL</u>							
	CAPSULE;ORAL							
	RAMIPRIL							
	AB	SENORES PHARMS 1.25MG	A078191	001	Jun 18, 2008	Jan	CAHN	
	AB	2.5MG	A078191	002	Jun 18, 2008	Jan	CAHN	
	AB	5MG	A078191	003	Jun 18, 2008	Jan	CAHN	
	AB	10MG	A078191	004	Jun 18, 2008	Jan	CAHN	
>D>	SOLUTION;ORAL							
>D>	VOSTALLY							
>D>	+	ROSEMONT PHARMS 1MG/ML	N219757	001	Jul 23, 2025	Apr	DISC	
>A>	@ +	1MG/ML	N219757	001	Jul 23, 2025	Apr	DISC	
	+	1MG/ML	N219757	001	Jul 23, 2025	Feb	CAHN	
	<u>RANITIDINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	RANITIDINE HYDROCHLORIDE							
	@	RISING EQ 150MG BASE	A075564	001	Oct 27, 2000	Mar	CAHN	
	@	EQ 300MG BASE	A075564	002	Oct 27, 2000	Mar	CAHN	
	<u>RANOLAZINE</u>							
>A>	GRANULE, EXTENDED RELEASE;ORAL							
>A>	ASPRUZYO SPRINKLE							
>A>	@ +	SPIL 500MG	N216018	001	Feb 28, 2022	Apr	CDFR	
>A>	@ +	1GM	N216018	002	Feb 28, 2022	Apr	CDFR	
>D>	GRANULES, EXTENDED RELEASE;ORAL							
>D>	ASPRUZYO SPRINKLE							
>D>	@ +	SPIL 500MG	N216018	001	Feb 28, 2022	Apr	CDFR	
>D>	@ +	1GM	N216018	002	Feb 28, 2022	Apr	CDFR	
	TABLET, EXTENDED RELEASE;ORAL							
	RANOLAZINE							
	AB	PIRAMAL 500MG	A213085	001	Jul 25, 2023	Feb	CMFD	
	AB	1GM	A213085	002	Jul 25, 2023	Feb	CMFD	
	<u>REGADENOSON</u>							
	SOLUTION;INTRAVENOUS							
	REGADENOSON							
	@	GE HEALTHCARE 0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Feb	DISC	
	<u>RELACORILANT</u>							
	CAPSULE;ORAL							
	LIFYORLI (COPACKAGED)							
	+	CORCEPT THERAP 100MG;25MG	N220641	001	Mar 25, 2026	Mar	NEWA	
	<u>REPAGLINIDE</u>							
	TABLET;ORAL							
	REPAGLINIDE							
	@	PADAGIS US 0.5MG	A201189	001	Jul 17, 2013	Mar	DISC	
	@	1MG	A201189	002	Jan 22, 2014	Mar	DISC	
	@	2MG	A201189	003	Jan 22, 2014	Mar	DISC	
	<u>RIBAVIRIN</u>							
	FOR SOLUTION;INHALATION							
	RIBAVIRIN							
	@	NAVINTA LLC 6GM/VIAL	A207366	001	Oct 06, 2016	Mar	DISC	

RIFABUTIN

CAPSULE;ORAL

RIFABUTIN

AB	I3 PHARMS	150MG	A212430	001	Mar 19, 2026	Mar NEWA
----	-----------	-------	---------	-----	--------------	----------

RIFAXIMIN

TABLET;ORAL

RIFAXIMIN

AB	ACTAVIS LABS FL INC	550MG	A208959	001	Mar 19, 2026	Mar NFTG
----	---------------------	-------	---------	-----	--------------	----------

XIFAXAN

AB	+! SALIX PHARMS	550MG	N021361	002	Mar 24, 2010	Mar CFTG
----	-----------------	-------	---------	-----	--------------	----------

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT

AB	+! JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Jan CFTG
----	------------------	--------------	---------	-----	--------------	----------

RILPIVIRINE HYDROCHLORIDE

AB	SOMERSET THERAPS LLC	EQ 25MG BASE	A218798	001	Jan 29, 2026	Jan NFTG
----	----------------------	--------------	---------	-----	--------------	----------

RILUZOLE

TABLET;ORAL

RILUTEK

@ + AZURITY

		50MG	N020599	001	Dec 12, 1995	Mar CAHN
--	--	------	---------	-----	--------------	----------

RISPERIDONE

POWDER;INTRAMUSCULAR

RISPERDAL CONSTA

AB	+! JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan CHRS
----	-------------------	-------------	---------	-----	--------------	----------

AB	+	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan CDFR
----	---	-------------	---------	-----	--------------	----------

AB	+!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan CDFR
----	----	-----------	---------	-----	--------------	----------

AB	+!	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan CHRS
----	----	-------------	---------	-----	--------------	----------

AB	+	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan CDFR
----	---	-------------	---------	-----	--------------	----------

AB	+!	50MG/VIAL	N021346	003	Oct 29, 2003	Jan CHRS
----	----	-----------	---------	-----	--------------	----------

AB	+	50MG/VIAL	N021346	003	Oct 29, 2003	Jan CDFR
----	---	-----------	---------	-----	--------------	----------

RISPERIDONE

AB	AMNEAL	12.5MG/VIAL	A218586	001	Sep 02, 2025	Jan CDFR
----	--------	-------------	---------	-----	--------------	----------

AB		25MG/VIAL	A218586	002	Sep 02, 2025	Jan CDFR
----	--	-----------	---------	-----	--------------	----------

AB		37.5MG/VIAL	A218586	003	Sep 02, 2025	Jan CDFR
----	--	-------------	---------	-----	--------------	----------

AB		50MG/VIAL	A218586	004	Sep 02, 2025	Jan CDFR
----	--	-----------	---------	-----	--------------	----------

AB	NANOMI	25MG/VIAL	A211220	001	Sep 02, 2025	Jan CDFR
----	--------	-----------	---------	-----	--------------	----------

AB		37.5MG/VIAL	A211220	002	Sep 02, 2025	Jan CDFR
----	--	-------------	---------	-----	--------------	----------

AB		50MG/VIAL	A211220	003	Sep 02, 2025	Jan CDFR
----	--	-----------	---------	-----	--------------	----------

AB	TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan CDFR
----	---------------------	-------------	---------	-----	--------------	----------

AB		25MG/VIAL	A214068	002	Dec 05, 2023	Jan CDFR
----	--	-----------	---------	-----	--------------	----------

AB		37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan CDFR
----	--	-------------	---------	-----	--------------	----------

AB		50MG/VIAL	A214068	004	Dec 05, 2023	Jan CDFR
----	--	-----------	---------	-----	--------------	----------

TABLET;ORAL

RISPERIDONE

@ NATCO PHARMA USA

@ 0.5MG

@ 1MG

@ 2MG

@ 3MG

@ 4MG

		0.25MG	A076288	001	Sep 15, 2008	Mar CAHN
--	--	--------	---------	-----	--------------	----------

		0.5MG	A076288	002	Sep 15, 2008	Mar CAHN
--	--	-------	---------	-----	--------------	----------

		1MG	A076288	003	Sep 15, 2008	Mar CAHN
--	--	-----	---------	-----	--------------	----------

		2MG	A076288	004	Sep 15, 2008	Mar CAHN
--	--	-----	---------	-----	--------------	----------

		3MG	A076288	005	Sep 15, 2008	Mar CAHN
--	--	-----	---------	-----	--------------	----------

		4MG	A076288	006	Sep 15, 2008	Mar CAHN
--	--	-----	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@ NATCO PHARMA USA

@ 0.5MG

@ 1MG

@ 2MG

@ 3MG

@ 4MG

		0.25MG	A091537	006	Feb 12, 2013	Mar CAHN
--	--	--------	---------	-----	--------------	----------

		0.5MG	A091537	001	Mar 30, 2011	Mar CAHN
--	--	-------	---------	-----	--------------	----------

		1MG	A091537	002	Mar 30, 2011	Mar CAHN
--	--	-----	---------	-----	--------------	----------

		2MG	A091537	003	Mar 30, 2011	Mar CAHN
--	--	-----	---------	-----	--------------	----------

		3MG	A091537	004	Mar 30, 2011	Mar CAHN
--	--	-----	---------	-----	--------------	----------

		4MG	A091537	005	Mar 30, 2011	Mar CAHN
--	--	-----	---------	-----	--------------	----------

RITONAVIR

TABLET;ORAL

NORVIR

AB	+ ABBVIE	100MG	N022417	001	Feb 10, 2010	Jan CHRS
----	----------	-------	---------	-----	--------------	----------

RITONAVIR

	@ AMNEAL	100MG	A208890	001	Sep 17, 2018	Mar DISC
--	----------	-------	---------	-----	--------------	----------

AB	! AUROBINDO PHARMA LTD	100MG	A206614	001	Sep 17, 2018	Jan CHRS
----	------------------------	-------	---------	-----	--------------	----------

RIVAROXABAN

FOR SUSPENSION; ORAL

RIVAROXABAN

AB	APOTEX	1MG/ML	A218427	001	Mar 02, 2026	Feb	NEWA
	TABLET; ORAL						
	RIVAROXABAN						
>D>	AB	APOTEX	10MG	A208579	001	Nov 14, 2025	Apr DISC
>A>	@		10MG	A208579	001	Nov 14, 2025	Apr DISC
>D>	AB		15MG	A208579	002	Nov 14, 2025	Apr DISC
>A>	@		15MG	A208579	002	Nov 14, 2025	Apr DISC
>D>	AB		20MG	A208579	003	Nov 14, 2025	Apr DISC
>A>	@		20MG	A208579	003	Nov 14, 2025	Apr DISC
BX	BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	Feb	CTEC
BX		10MG	A218107	002	May 14, 2025	Feb	CTEC
BX		15MG	A218107	003	May 14, 2025	Feb	CTEC
BX		20MG	A218107	004	May 14, 2025	Feb	CTEC
AB	INVAGEN PHARMS	2.5MG	A218768	001	Feb 20, 2026	Feb	NEWA

RIZATRIPTAN BENZOATE

FILM; ORAL

RIZAFILM

+! GENSCO

TABLET; ORAL

RIZATRIPTAN BENZOATE

@ PHARMOBEDIANT

@

		EQ 5MG BASE	N205394	002	Feb 26, 2026	Feb	NEWA
	@	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	DISC
	@	EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	ASPIRO	50MG/5ML (10MG/ML)	A220124	001	Mar 04, 2026	Feb	NEWA
AP		100MG/10ML (10MG/ML)	A220124	002	Mar 04, 2026	Feb	NEWA

ROFLUMILAST

TABLET; ORAL

ROFLUMILAST

@ PHARMOBEDIANT

AB	SENORES PHARMS	500MCG	A208257	001	Jul 13, 2018	Feb	DISC
AB		250MCG	A208236	002	Oct 19, 2023	Feb	CMFD
AB		500MCG	A208236	001	Oct 03, 2018	Feb	CMFD

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

@ ANVI

@

@

@

		EQ 5MG BASE	A079161	001	Jul 19, 2016	Mar	CAHN
		EQ 10MG BASE	A079161	002	Jul 19, 2016	Mar	CAHN
		EQ 20MG BASE	A079161	003	Jul 19, 2016	Mar	CAHN
		EQ 40MG BASE	A079161	004	Jul 19, 2016	Mar	CAHN

SACUBITRIL; VALSARTAN

TABLET; ORAL

SACUBITRIL AND VALSARTAN

AB	SOMERSET THERAPS LLC	24MG;26MG	A219983	001	Jan 20, 2026	Jan	NEWA
AB		49MG;51MG	A219983	002	Jan 20, 2026	Jan	NEWA
AB		97MG;103MG	A219983	003	Jan 20, 2026	Jan	NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

+! BIOMARIN PHARM

SAPROPTERIN DIHYDROCHLORIDE

AB		500MG/PACKET	N205065	002	Oct 27, 2015	Jan	CHRS
AB	MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jan	NEWA
AB		500MG/PACKET	A219511	002	Jan 08, 2026	Jan	NEWA

SELENIOS ACID

SOLUTION; INTRAVENOUS

SELENIOS ACID

@ CIPLA

@

		EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jan	DISC
		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jan	DISC
AP	KINDOS	EQ 600MCG SELENIUM/10ML (EQ	A219472	001	Feb 03, 2026	Jan	NEWA

SOLUTION;INTRAVENOUS  
SELENIOS ACID

		60MCG SELENIUM/ML)						
>D>	AP	RK PHARMA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Apr	CAHN
>D>	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Apr	CAHN
>A>	AP	STIRA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Apr	CAHN
>A>	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Apr	CAHN

SELEXIPAG

TABLET;ORAL  
SELEXIPAG

>A>	AB	RK PHARMA	0.2MG	A214055	001	Apr 16, 2026	Apr	NEWA
>A>	AB		0.4MG	A214055	002	Apr 16, 2026	Apr	NEWA
>A>	AB		0.6MG	A214055	003	Apr 16, 2026	Apr	NEWA
>A>	AB		0.8MG	A214055	004	Apr 16, 2026	Apr	NEWA
>A>	AB		1MG	A214055	005	Apr 16, 2026	Apr	NEWA
>A>	AB		1.2MG	A214055	006	Apr 16, 2026	Apr	NEWA
>A>	AB		1.4MG	A214055	007	Apr 16, 2026	Apr	NEWA
>A>	AB		1.6MG	A214055	008	Apr 16, 2026	Apr	NEWA
		UPTRAVI						
>D>		+ ACTELION	1MG	N207947	005	Dec 21, 2015	Apr	CTEC
>A>	AB	+	1MG	N207947	005	Dec 21, 2015	Apr	CTEC
>D>		+	1.2MG	N207947	006	Dec 21, 2015	Apr	CTEC
>A>	AB	+	1.2MG	N207947	006	Dec 21, 2015	Apr	CTEC

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS  
WEGOVY HD

+	NOVO	7.2MG/0.75ML (7.2MG/0.75ML)	N215256	006	Mar 19, 2026	Mar	NEWA
---	------	-----------------------------	---------	-----	--------------	-----	------

TABLET;ORAL  
OZEMPIC

+	NOVO	1.5MG	N213051	004	Dec 09, 2024	Mar	CTNA
+		4MG	N213051	005	Dec 09, 2024	Mar	CTNA
+		9MG	N213051	006	Dec 09, 2024	Mar	CTNA

WEGOVY

+	NOVO	1.5MG	N218316	001	Dec 22, 2025	Mar	CHRS
+		4MG	N218316	002	Dec 22, 2025	Mar	CHRS
+		9MG	N218316	003	Dec 22, 2025	Mar	CHRS

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL  
SERTRALINE HYDROCHLORIDE

AB		AMNEAL	EQ 150MG BASE	A219655	001	Jan 28, 2026	Mar	CAHN
AB			EQ 200MG BASE	A219655	002	Jan 28, 2026	Mar	CAHN
AB		APPCO	EQ 150MG BASE	A218712	001	Jan 20, 2026	Jan	NEWA
AB			EQ 200MG BASE	A218712	002	Jan 20, 2026	Jan	NEWA
AB		NOVITIUM PHARMA	EQ 150MG BASE	A219714	001	Jan 20, 2026	Jan	NEWA
AB			EQ 200MG BASE	A219714	002	Jan 20, 2026	Jan	NEWA
AB		SKG PHARMA	EQ 150MG BASE	A219655	001	Jan 28, 2026	Jan	NEWA
AB			EQ 200MG BASE	A219655	002	Jan 28, 2026	Jan	NEWA
AB		UMEDICA	EQ 150MG BASE	A218342	001	Jan 20, 2026	Jan	NEWA
AB			EQ 200MG BASE	A218342	002	Jan 20, 2026	Jan	NEWA
AB		ZYDUS LIFESCIENCES	EQ 150MG BASE	A220275	001	Jan 29, 2026	Jan	NEWA
AB			EQ 200MG BASE	A220275	002	Jan 29, 2026	Jan	NEWA

TABLET;ORAL  
SERTRALINE HYDROCHLORIDE

@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan	CAHN
@		EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan	CAHN
@		EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan	CAHN

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL  
REVATIO

@	VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Mar	DISC
---	---------	-----------------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

AB	!	AUROBINDO PHARMA LTD	EQ 10MG BASE/ML	A214773	001	Dec 23, 2022	Mar	CHRS
----	---	----------------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL  
SILDENAFIL CITRATE

>D>	AB	TEVA PHARMS	EQ 20MG BASE	A078380	001	Jan 07, 2013	Apr	DISC
-----	----	-------------	--------------	---------	-----	--------------	-----	------

	TABLET;ORAL						
	SILDENAFIL CITRATE						
>A>	@		EQ 20MG BASE	A078380	001	Jan 07, 2013	Apr DISC
	<u>SIPONIMOD</u>						
	TABLET;ORAL						
	MAYZENT						
	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Mar CTEC
AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Feb CTEC
	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Mar CTEC
AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Feb CTEC
	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	Mar CTEC
AB	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	Feb CTEC
	SIPONIMOD						
	@	AUROBINDO PHARMA LTD	EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Mar DISC
AB			EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Feb NEWA
	@		EQ 1MG BASE	A218459	002	Mar 06, 2026	Mar DISC
AB			EQ 1MG BASE	A218459	002	Mar 06, 2026	Feb NEWA
	@		EQ 2MG BASE	A218459	003	Mar 06, 2026	Mar DISC
AB			EQ 2MG BASE	A218459	003	Mar 06, 2026	Feb NEWA
	<u>SIROLIMUS</u>						
	POWDER; INTRAVENOUS						
	FYARRO						
>A>	+	AADI	100MG/VIAL	N213312	001	Nov 22, 2021	Apr CAHN
>D>	+	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Apr CAHN
	<u>SITAGLIPTIN PHOSPHATE</u>						
	TABLET;ORAL						
	SITAGLIPTIN PHOSPHATE						
AB		APOTEX	EQ 25MG BASE	A202425	001	Jan 20, 2026	Jan NEWA
AB			EQ 50MG BASE	A202425	002	Jan 20, 2026	Jan NEWA
AB			EQ 100MG BASE	A202425	003	Jan 20, 2026	Jan NEWA
AB		SANDOZ	EQ 25MG BASE	A202387	001	Jan 14, 2026	Jan NEWA
AB			EQ 50MG BASE	A202387	002	Jan 14, 2026	Jan NEWA
AB			EQ 100MG BASE	A202387	003	Jan 14, 2026	Jan NEWA
	<u>SODIUM ACETATE</u>						
	SOLUTION; INTRAVENOUS						
	SODIUM ACETATE						
AP		AMNEAL	40MEQ/20ML (2MEQ/ML)	A218469	003	Mar 02, 2026	Feb NEWA
>A>	AP	EXTROVIS	100MEQ/50ML (2MEQ/ML)	A220274	001	Apr 17, 2026	Apr NEWA
>A>	AP		200MEQ/100ML (2MEQ/ML)	A220274	002	Apr 17, 2026	Apr NEWA
	<u>SODIUM BICARBONATE</u>						
	SOLUTION; INTRAVENOUS						
	SODIUM BICARBONATE						
AP		AMNEAL	50MEQ/50ML (1MEQ/ML)	A217523	001	Jan 13, 2026	Jan NEWA
>A>	AP	ASPIRO	5MEQ/10ML (0.5MEQ/ML)	A220788	001	Apr 15, 2026	Apr NEWA
>A>	AP		10MEQ/10ML (1MEQ/ML)	A220788	002	Apr 15, 2026	Apr NEWA
>A>	AP		50MEQ/50ML (1MEQ/ML)	A220788	003	Apr 15, 2026	Apr NEWA
	<u>SODIUM FLUORIDE F-18</u>						
	INJECTABLE; INTRAVENOUS						
	SODIUM FLUORIDE F-18						
>D>	AP	NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr DISC
>A>	@		10-200mCi/ML	A203912	001	Apr 22, 2015	Apr DISC
	<u>SODIUM PHENYL BUTYRATE</u>						
	POWDER; ORAL						
	BUPHENYL						
	@	HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan DISC
		SODIUM PHENYL BUTYRATE					
AB	!	PH HEALTH	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jan CHRS
	TABLET; ORAL						
	BUPHENYL						
	@	HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan DISC
		SODIUM PHENYL BUTYRATE					
AB		NAVINTA LLC	500MG	A220418	001	Feb 17, 2026	Feb NEWA
AB	!	PH HEALTH	500MG	A204395	001	Apr 15, 2016	Jan CHRS

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATESOLUTION; INTRAVENOUS  
SODIUM PHOSPHATES

AP	CAPLIN	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A220683	001	Feb 23, 2026	Feb	NEWA
AP		4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	A220683	002	Feb 23, 2026	Feb	NEWA
AP		13.4GM/50ML; 13.8GM/50ML (268MG/ML; 276MG/ML)	A220683	003	Feb 23, 2026	Feb	NEWA

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTION  
SUCCINYLCHOLINE CHLORIDE

>A>	AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Apr	CAHN
>D>	AP	UMEDICA	20MG/ML	A211625	001	May 19, 2020	Apr	CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS  
SUCCINYLCHOLINE CHLORIDE

AP	!	FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Mar	CHRS
	@ +	HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Mar	DISC

SUFENTANIL CITRATEINJECTABLE; INJECTION  
SUFENTANIL CITRATE

@	HIKMA	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Mar	DISC
---	-------	-------------------	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUMOINTMENT; OPHTHALMIC  
SULFACETAMIDE SODIUM

@	PADAGIS US	10%	A080029	001		Mar	DISC
---	------------	-----	---------	-----	--	-----	------

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

AP		ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb	CMFD
----	--	---------------------	--	---------	-----	--------------	-----	------

TAFAMIDIS MEGLUMINECAPSULE; ORAL  
VYNDAQEL

@ +	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	Jan	DISC
-----	---------------	------	---------	-----	--------------	-----	------

TAPENTADOL HYDROCHLORIDESOLUTION; ORAL  
TAPENTADOL HYDROCHLORIDE

	NOVITIUM PHARMA	EQ 20MG BASE/ML	A219119	001	Jan 26, 2026	Jan	NFTG
--	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL  
NUCYNTA

AB	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Jan	CFTG
AB	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Jan	CFTG
AB	+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008	Jan	CFTG

TAPENTADOL HYDROCHLORIDE

AB		HIKMA	EQ 50MG BASE	A205057	001	Feb 10, 2026	Jan	NEWA
AB			EQ 75MG BASE	A205057	002	Feb 10, 2026	Jan	NEWA
AB			EQ 100MG BASE	A205057	003	Feb 10, 2026	Jan	NEWA
AB		HUMANWELL	EQ 50MG BASE	A214378	001	Jan 27, 2026	Jan	NFTG
AB			EQ 75MG BASE	A214378	002	Jan 27, 2026	Jan	NFTG
AB			EQ 100MG BASE	A214378	003	Jan 27, 2026	Jan	NFTG

TAVABOROLESOLUTION; TOPICAL  
TAVABOROLE

@	CIPLA	5%	A212224	001	Feb 09, 2021	Jan	DISC
@	LUPIN	5%	A212168	001	Feb 08, 2021	Feb	DISC
@	PADAGIS US	5%	A211848	001	Oct 13, 2020	Mar	DISC

TAZAROTENECREAM; TOPICAL  
TAZAROTENE

AB		SOLARIS PHARMA CORP	0.05%	A214560	001	Nov 24, 2025	Jan	CAHN
----	--	---------------------	-------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M BICISATE KITINJECTABLE; INJECTION  
NEUROLITE

	+	!	SHINE	N/A	N020256	001	Nov 23, 1994	Feb	CAHN
--	---	---	-------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION  
CARDIOLITE

AP		+	!	SHINE	N/A	N019785	001	Dec 21, 1990	Feb	CAHN
				MIRALUMA						
		@		SHINE	N/A	N019785	003	May 23, 1997	Feb	CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS  
TECHNELITE

		+	!	SHINE	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	Feb	CAHN
		@			0.0083-2.7 CI/GENERATOR	N017771	001		Feb	CAHN

TEMAZEPAMCAPSULE; ORAL  
TEMAZEPAM

AB				AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Jan	CMFD
AB					15MG	A203482	002	May 23, 2016	Jan	CMFD
AB					22.5MG	A203482	003	May 23, 2016	Jan	CMFD
AB					30MG	A203482	004	May 23, 2016	Jan	CMFD

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB				SENORES PHARMS	EQ 1MG BASE	A074823	001	Mar 30, 1998	Feb	CAHN
AB					EQ 2MG BASE	A074823	002	Mar 30, 1998	Feb	CAHN
AB					EQ 5MG BASE	A074823	003	Mar 30, 1998	Feb	CAHN
AB					EQ 10MG BASE	A074823	004	Mar 30, 1998	Feb	CAHN

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB				CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Feb	CMFD
AB					14MG	A218663	002	Apr 07, 2025	Feb	CMFD

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

		@		CAPLIN ONE LABS	100MG/ML	A040615	001	Aug 10, 2006	Mar	DISC
AO					100MG/ML	A040615	001	Aug 10, 2006	Jan	CAHN
		@			200MG/ML	A040615	002	Aug 10, 2006	Mar	DISC
AO					200MG/ML	A040615	002	Aug 10, 2006	Jan	CAHN

THALIDOMIDE

CAPSULE; ORAL

THALIDOMIDE

>A>				NATCO	50MG	A213267	002	Apr 24, 2026	Apr	NFTG
>A>	AB				100MG	A213267	003	Apr 24, 2026	Apr	NFTG
>A>	AB				200MG	A213267	004	Apr 24, 2026	Apr	NFTG
				THALOMID						
>D>		+		BRISTOL-MYERS	50MG	N020785	001	Jul 16, 1998	Apr	CFTG
>A>	AB				50MG	N020785	001	Jul 16, 1998	Apr	CFTG
>D>		+			100MG	N020785	002	Jan 17, 2003	Apr	CFTG
>A>	AB				100MG	N020785	002	Jan 17, 2003	Apr	CFTG
>D>		+	!		200MG	N020785	003	Jan 17, 2003	Apr	CFTG
>A>	AB				200MG	N020785	003	Jan 17, 2003	Apr	CFTG

THEOPHYLLINESOLUTION, ELIXIR; ORAL  
ELIXOPHYLLIN

		@	+	SOLIS PHARMS	80MG/15ML	A085186	001		Jan	DISC
				THEOPHYLLINE						
		!		PHARM ASSOC	80MG/15ML	A206344	001	Dec 16, 2016	Jan	CHRS
					80MG/15ML	A206344	001	Dec 16, 2016	Jan	CTEC

THIOTEPAINJECTABLE; INJECTION  
THIOTEPA

>D>	AP	HENGRUI PHARMA	15MG/VIAL	A209150	001	May 04, 2018	Apr	DISC
>A>	@		15MG/VIAL	A209150	001	May 04, 2018	Apr	DISC
		POWDER; INTRAVENOUS						
		TEPADINA AND SODIUM CHLORIDE						
		+! ADIENNE SA	400MG	N208264	004	Jan 15, 2026	Jan	NEWA

TICAGRELORTABLET; ORAL  
TICAGRELOR

	@	AMNEAL	60MG	A208531	002	Oct 28, 2025	Mar	DISC
AB		MANKIND PHARMA	60MG	A217679	001	Feb 06, 2026	Jan	NEWA
AB			90MG	A217679	002	Feb 06, 2026	Jan	NEWA
>A>	AB	MICRO LABS	60MG	A208539	001	Apr 27, 2026	Apr	NEWA
>A>	AB		90MG	A208539	002	Apr 27, 2026	Apr	NEWA
AB		ZHEJIANG JINGXIN	60MG	A219006	001	Mar 24, 2026	Mar	NEWA
AB			90MG	A219006	002	Mar 24, 2026	Mar	NEWA

TIGECYCLINEPOWDER; INTRAVENOUS  
TIGECYCLINE

@ +	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Mar	DISC
-----	--------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL MALEATETABLET; ORAL  
TIMOLOL MALEATE

@	MYLAN	5MG	A072668	002	Jun 08, 1990	Mar	DISC
@		20MG	A072668	001	Jun 08, 1990	Mar	DISC
	RISING	5MG	A207556	001	May 02, 2019	Mar	CTEC
!		20MG	A207556	003	May 02, 2019	Mar	CHRS
		20MG	A207556	003	May 02, 2019	Mar	CTEC

TINIDAZOLETABLET; ORAL  
TINIDAZOLE

AB		UNIQUE	250MG	A202489	001	Oct 09, 2013	Mar	CAHN
AB			500MG	A202489	002	Oct 09, 2013	Mar	CAHN

TIOPRONINTABLET, DELAYED RELEASE; ORAL  
TIOPRONIN

@	AMNEAL	100MG	A216278	002	Aug 29, 2025	Mar	DISC
@		300MG	A216278	001	Aug 15, 2023	Mar	DISC

TIRZEPATIDESOLUTION; SUBCUTANEOUS  
MOUNJARO

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	013	Jan 07, 2026	Jan	NEWA
+!		20MG/2.4ML (8.33MG/ML)	N215866	014	Jan 07, 2026	Jan	NEWA
+!		30MG/2.4ML (12.5MG/ML)	N215866	015	Jan 07, 2026	Jan	NEWA
+!		40MG/2.4ML (16.7MG/ML)	N215866	016	Jan 07, 2026	Jan	NEWA
+!		50MG/2.4ML (20.8MG/ML)	N215866	017	Jan 07, 2026	Jan	NEWA
+!		60MG/2.4ML (25MG/ML)	N215866	018	Jan 07, 2026	Jan	NEWA

MOUNJARO KWIKPEN

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	019	Jan 20, 2026	Jan	NEWA
+!		20MG/2.4ML (8.33MG/ML)	N215866	020	Jan 20, 2026	Jan	NEWA
+!		30MG/2.4ML (12.5MG/ML)	N215866	021	Jan 20, 2026	Jan	NEWA
+!		40MG/2.4ML (16.7MG/ML)	N215866	022	Jan 20, 2026	Jan	NEWA
+!		50MG/2.4ML (20.8MG/ML)	N215866	023	Jan 20, 2026	Jan	NEWA
+!		60MG/2.4ML (25MG/ML)	N215866	024	Jan 20, 2026	Jan	NEWA

ZEPBOUND

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	013	Jan 07, 2026	Jan	NEWA
+!		20MG/2.4ML (8.33MG/ML)	N217806	014	Jan 07, 2026	Jan	NEWA
+!		30MG/2.4ML (12.5MG/ML)	N217806	015	Jan 07, 2026	Jan	NEWA
+!		40MG/2.4ML (16.7MG/ML)	N217806	016	Jan 07, 2026	Jan	NEWA
+!		50MG/2.4ML (20.8MG/ML)	N217806	017	Jan 07, 2026	Jan	NEWA
+!		60MG/2.4ML (25MG/ML)	N217806	018	Jan 07, 2026	Jan	NEWA

ZEPBOUND KWIKPEN

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	019	Jan 20, 2026	Jan	NEWA
----	------------------	------------------------	---------	-----	--------------	-----	------

## SOLUTION;SUBCUTANEOUS

## ZEPBOUND KWIKPEN

+	20MG/2.4ML (8.33MG/ML)	N217806	020	Jan 20, 2026	Jan NEWA
+	30MG/2.4ML (12.5MG/ML)	N217806	021	Jan 20, 2026	Jan NEWA
+	40MG/2.4ML (16.7MG/ML)	N217806	022	Jan 20, 2026	Jan NEWA
+	50MG/2.4ML (20.8MG/ML)	N217806	023	Jan 20, 2026	Jan NEWA
+	60MG/2.4ML (25MG/ML)	N217806	024	Jan 20, 2026	Jan NEWA

TIZANIDINE HYDROCHLORIDE

## CAPSULE;ORAL

## TIZANIDINE HYDROCHLORIDE

AB	INGENUS PHARMS LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb CAHN	
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb CAHN	
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb CAHN	
AB	SENORES PHARMS	EQ 4MG BASE	A213365	001	May 13, 2024	Jan CAHN	
AB		EQ 6MG BASE	A213365	002	May 13, 2024	Jan CAHN	
ZANAFLEX							
AB	+	LEGACY PHARMA USA	EQ 4MG BASE	N021447	002	Aug 29, 2002	Mar CHRS
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Mar CHRS

TOBRAMYCIN SULFATE

## INJECTABLE;INJECTION

## TOBRAMYCIN SULFATE

>D>	@	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Apr CMFD
>A>	AP		EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Apr CMFD

TOFACITINIB CITRATE

## TABLET;ORAL

## TOFACITINIB CITRATE

>D>	@	AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021	Apr CMFD
>A>	AB		EQ 10MG BASE	A212943	001	Jun 01, 2021	Apr CMFD
>D>	@	MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Apr CMFD
>A>	AB		EQ 5MG BASE	A209738	001	Mar 13, 2023	Apr CMFD
>D>	@	ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Apr CMFD
>A>	AB		EQ 5MG BASE	A209829	001	Mar 13, 2023	Apr CMFD
XELJANZ							
>D>	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Apr CTEC
>A>	AB	+	EQ 5MG BASE	N203214	001	Nov 06, 2012	Apr CTEC
>D>	+		EQ 10MG BASE	N203214	002	May 30, 2018	Apr CTEC
>A>	AB	+	EQ 10MG BASE	N203214	002	May 30, 2018	Apr CTEC

## TABLET, EXTENDED RELEASE;ORAL

## TOFACITINIB CITRATE

>D>	@	AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Apr CMFD
>A>	AB		EQ 11MG BASE	A219542	001	Aug 19, 2025	Apr CMFD
>D>	@	AUROBINDO PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Jan DISC
>A>	AB		EQ 11MG BASE	A218462	001	Jun 03, 2024	Apr CMFD
>D>	@	DEXCEL	EQ 11MG BASE	A218462	001	Jun 03, 2024	Apr CMFD
>A>	AB		EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr CMFD
>D>	@	ZYDUS PHARMS	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr CMFD
>A>	AB		EQ 11MG BASE	A214264	001	Aug 19, 2021	Apr CMFD
>D>	@		EQ 11MG BASE	A214264	001	Aug 19, 2021	Apr CMFD
>A>	AB	!	EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr CMFD
>A>	AB		EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr CHRS
XELJANZ XR							
>D>	+	PFIZER	EQ 22MG BASE	N208246	002	Dec 12, 2019	Apr CTEC
>A>	AB	+	EQ 22MG BASE	N208246	002	Dec 12, 2019	Apr CTEC

TOLCAPONE

## TABLET;ORAL

## TASMAR

+	100MG	N020697	001	Jan 29, 1998	Mar CTEC	
TOLCAPONE						
@	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Mar DISC
AB		100MG	A208937	001	Aug 07, 2018	Feb CAHN

TOLTERODINE TARTRATE

## TABLET;ORAL

## TOLTERODINE TARTRATE

AB	UNIQUE	1MG	A204721	001	Jan 24, 2020	Mar CAHN
AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN

TOLVAPTAN

TABLET;ORAL  
TOLVAPTAN

>A>	AB2	ALKEM LABS LTD	15MG	A220147	001	Apr 21, 2026	Apr	NEWA
>A>	AB2		30MG	A220147	002	Apr 21, 2026	Apr	NEWA
>A>	AB		45MG	A220147	003	Apr 21, 2026	Apr	NEWA
>A>	AB2		60MG	A220147	004	Apr 21, 2026	Apr	NEWA
>A>	AB		90MG	A220147	005	Apr 21, 2026	Apr	NEWA

TOPIRAMATE

CAPSULE;ORAL  
TOPIRAMATE

AB		SENORES PHARMS	15MG	A218642	001	Oct 10, 2024	Jan	CAHN
AB			25MG	A218642	002	Oct 10, 2024	Jan	CAHN
AB		STRIDES PHARMA	50MG	A078418	003	Feb 02, 2026	Jan	NEWA

CAPSULE, EXTENDED RELEASE;ORAL  
TOPIRAMATE

AB1		ASCENT PHARMS INC	25MG	A217443	001	Jan 12, 2026	Jan	NEWA
AB1			50MG	A217443	002	Jan 12, 2026	Jan	NEWA
AB1			100MG	A217443	003	Jan 12, 2026	Jan	NEWA
AB1			200MG	A217443	004	Jan 12, 2026	Jan	NEWA

TABLET;ORAL

TOPIRAMATE

@		SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	Jan	CAHN
@			50MG	A090353	002	Sep 01, 2010	Jan	CAHN
@			100MG	A090353	003	Sep 01, 2010	Jan	CAHN
@			200MG	A090353	004	Sep 01, 2010	Jan	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION  
TOPOTECAN HYDROCHLORIDE

AP		INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Feb	CAHN
----	--	--------------------	------------------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS  
TOPOTECAN HYDROCHLORIDE

@		NATCO PHARMA USA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	CAHN
---	--	------------------	----------------------------------	---------	-----	--------------	-----	------

TORSEMIDE

TABLET;ORAL  
TORSEMIDE

>A>	AB	MICRO LABS	5MG	A217239	001	May 01, 2026	Apr	NEWA
>A>	AB		10MG	A217239	002	May 01, 2026	Apr	NEWA
>A>	AB		20MG	A217239	003	May 01, 2026	Apr	NEWA

TRAMADOL HYDROCHLORIDE

SOLUTION;ORAL  
QDOLO

@ +		ROSEMONT	5MG/ML	N214044	001	Sep 01, 2020	Mar	CAHN
-----	--	----------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		RUBICON	25MG	A208708	003	Nov 27, 2023	Mar	CTEC
AB		STRIDES PHARMA	25MG	A202075	002	Mar 23, 2026	Mar	NEWA

TRANDOLAPRIL

TABLET;ORAL  
TRANDOLAPRIL

@		SENORES PHARMS	1MG	A078493	001	Aug 25, 2008	Jan	CAHN
@			2MG	A078493	002	Aug 25, 2008	Jan	CAHN
@			4MG	A078493	003	Aug 25, 2008	Jan	CAHN

TRANEXAMIC ACID

TABLET;ORAL  
TRANEXAMIC ACID

AB		I 3 PHARMS	650MG	A219702	001	Jan 26, 2026	Jan	NEWA
----	--	------------	-------	---------	-----	--------------	-----	------

TRETINOIN

CREAM;TOPICAL  
TRETINOIN

AB1		ENCUBE	0.05%	A217832	001	Mar 25, 2026	Mar	NEWA
AB			0.1%	A217833	001	Feb 10, 2026	Jan	NEWA

		GEL; TOPICAL							
		RETIN-A-MICRO							
>D>		+! BAUSCH	0.06%	N020475	004	Oct 23, 2017	Apr	CFTG	
>A>	AB	+!	0.06%	N020475	004	Oct 23, 2017	Apr	CFTG	
		TRETINOIN MICROSPHERE							
>A>	AB	ENCUBE	0.06%	A215609	002	Apr 15, 2026	Apr	NFTG	
<u>TRIAMCINOLONE ACETONIDE</u>									
		INJECTABLE; INJECTION							
		KENALOG-10							
AB		+! APOTHECON	10MG/ML	N012041	001		Jan	CHRS	
		TRIAMCINOLONE ACETONIDE							
		@ CAPLIN	10MG/ML	A090166	001	May 27, 2009	Jan	CAHN	
<u>TRIAZOLAM</u>									
		TABLET; ORAL							
		TRIAZOLAM							
		@ BRECKENRIDGE	0.125MG	A216890	001	Nov 08, 2022	Feb	DISC	
		@	0.25MG	A216890	002	Nov 08, 2022	Feb	DISC	
AB		INGENUS PHARMS LLC	0.125MG	A214219	001	Oct 20, 2020	Feb	CAHN	
AB			0.25MG	A214219	002	Oct 20, 2020	Feb	CAHN	
<u>TRIENTINE HYDROCHLORIDE</u>									
		CAPSULE; ORAL							
		TRIENTINE HYDROCHLORIDE							
		! RISING	500MG	A212238	002	Sep 22, 2023	Jan	CHRS	
<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>									
		TABLET; ORAL							
		TRIFLUOPERAZINE HYDROCHLORIDE							
>D>		@ ATHEM	EQ 1MG BASE	A040153	001	Oct 25, 1996	Apr	CAHN	
>D>		@	EQ 2MG BASE	A040153	002	Oct 25, 1996	Apr	CAHN	
>D>		@	EQ 5MG BASE	A040153	003	Oct 25, 1996	Apr	CAHN	
>D>		@	EQ 10MG BASE	A040153	004	Oct 25, 1996	Apr	CAHN	
>A>		@ POM PHARMA	EQ 1MG BASE	A040153	001	Oct 25, 1996	Apr	CAHN	
>A>		@	EQ 2MG BASE	A040153	002	Oct 25, 1996	Apr	CAHN	
>A>		@	EQ 5MG BASE	A040153	003	Oct 25, 1996	Apr	CAHN	
>A>		@	EQ 10MG BASE	A040153	004	Oct 25, 1996	Apr	CAHN	
<u>TROSPIUM CHLORIDE</u>									
		TABLET; ORAL							
		TROSPIUM CHLORIDE							
AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Jan	CAHN	
<u>URSODIOL</u>									
		CAPSULE; ORAL							
		URSODIOL							
		STRIDES PHARMA	150MG	A210344	002	Jan 16, 2026	Jan	NFTG	
<u>VALACYCLOVIR HYDROCHLORIDE</u>									
		TABLET; ORAL							
		VALACYCLOVIR HYDROCHLORIDE							
AB		! HETERO LABS LTD V	EQ 1GM BASE	A203047	002	Apr 08, 2015	Feb	CHRS	
		VALTREX							
AB		+ GLAXOSMITHKLINE	EQ 1GM BASE	N020487	002	Jun 23, 1995	Feb	CHRS	
<u>VALGANCICLOVIR HYDROCHLORIDE</u>									
		FOR SOLUTION; ORAL							
		VALGANCICLOVIR HYDROCHLORIDE							
AB		MICRO LABS	50MG/ML	A218838	001	Mar 19, 2026	Mar	NEWA	
<u>VALSARTAN</u>									
		TABLET; ORAL							
		VALSARTAN							
>A>	AB	LAURUS	40MG	A218897	001	Apr 21, 2026	Apr	NEWA	
>A>	AB		80MG	A218897	002	Apr 21, 2026	Apr	NEWA	
>A>	AB		160MG	A218897	003	Apr 21, 2026	Apr	NEWA	
>A>	AB		320MG	A218897	004	Apr 21, 2026	Apr	NEWA	
		@ RENATA	40MG	A218169	001	Aug 05, 2024	Feb	CAHN	
		@	80MG	A218169	002	Aug 05, 2024	Feb	CAHN	
		@	160MG	A218169	003	Aug 05, 2024	Feb	CAHN	
		@	320MG	A218169	004	Aug 05, 2024	Feb	CAHN	

VANCOMYCIN HYDROCHLORIDE

## CAPSULE;ORAL

## VANCOMYCIN HYDROCHLORIDE

AB	PAI HOLDINGS	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	CMFD
AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	CMFD

## FOR SOLUTION;ORAL

## FIRVANQ KIT

>D>	AB	+! AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Apr	CTEC
>A>	AA	+!	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Apr	CTEC
>D>	AB	+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Apr	CTEC
>A>	AA	+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Apr	CTEC

## VANCOMYCIN HYDROCHLORIDE

>D>	AB	ALKEM LABS LTD	EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Apr	CTEC
>A>	AA		EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Apr	CTEC
>D>	AB		EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Apr	CTEC
>A>	AA		EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Apr	CTEC

## INJECTABLE;INJECTION

## VANCOMYCIN HYDROCHLORIDE

AP	EUROFARMA	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	CAHN

## POWDER;INTRAVENOUS

## VANCOMYCIN HYDROCHLORIDE

!	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan	CHRS
		EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan	CTNA

VARENICLINE TARTRATE

## TABLET;ORAL

## VARENICLINE TARTRATE

AB	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jan	CMFD
AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Jan	CMFD
AB	UMEDICA	EQ 0.5MG BASE	A218985	001	Jan 09, 2026	Jan	NEWA
AB		EQ 1MG BASE	A218985	002	Jan 09, 2026	Jan	NEWA

VASOPRESSIN

## SOLUTION;INTRAVENOUS

## VASOPRESSIN

>A>	AP	@ EAGLE PHARMS	20UNITS/ML (20UNITS/ML)	A211538	001	Dec 15, 2021	Mar	DISC
>A>	AP	SANDOZ	20UNITS/ML (20UNITS/ML)	A212068	001	May 06, 2026	Apr	NEWA
>A>	AP		200UNITS/10ML (20UNITS/ML)	A212069	001	May 06, 2026	Apr	NFTG

## VASOSTRICT

>D>	AP	+! PH HEALTH	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Apr	CFTG
>A>	AP	+!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Apr	CFTG

VENLAFAXINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

## VENLAFAXINE HYDROCHLORIDE

>D>	AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Apr	CAHN
>D>	AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Apr	CAHN
>D>	AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Apr	CAHN
>A>	AB	PLATINUM	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Apr	CAHN
>A>	AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Apr	CAHN
>A>	AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Apr	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## VENLAFAXINE HYDROCHLORIDE

@	ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Mar	DISC
@	PHARMADAX	EQ 75MG BASE	A214423	001	Jan 04, 2022	Mar	CAHN
@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Mar	CAHN

VERAPAMIL HYDROCHLORIDE

## SOLUTION;INTRAVENOUS

## VERAPAMIL HYDROCHLORIDE

@	AMNEAL	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Mar	DISC
@		10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Mar	DISC

VIGABATRIN

## FOR SOLUTION;ORAL

## VIGABATRIN

@	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Jan	DISC
---	-----------------	--------------	---------	-----	--------------	-----	------

VORICONAZOLEPOWDER; INTRAVENOUS  
VORICONAZOLE

>A>	AP	ZHEJIANG NOVUS	200MG/VIAL	A220078	001	May 05, 2026	Apr	NEWA
-----	----	----------------	------------	---------	-----	--------------	-----	------

XENON XE-133GAS; INHALATION  
XENON XE 133

SHINE

10mCi/VIAL  
20mCi/VIALN017284 001  
N017284 002Feb CAHN  
Feb CAHNZICONOTIDE ACETATEINJECTABLE; INTRATHECAL  
PRIALT

>A>		+!	ESTEVE	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Apr	CAHN
>A>		@		200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Apr	CAHN
>A>		+!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Apr	CAHN
>A>		+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Apr	CAHN
>D>		+!	TERSERA	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Apr	CAHN
>D>		@		200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Apr	CAHN
>D>		+!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Apr	CAHN
>D>		+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Apr	CAHN

ZINC CHLORIDEINJECTABLE; INJECTION  
ZINC CHLORIDE

>D>	AP	RK PHARMA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr	CAHN
>A>	AP	STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr	CAHN

ZINC SULFATESOLUTION; INTRAVENOUS  
ZINC SULFATE

>D>	AP	RK PHARMA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Apr	CAHN
>D>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Apr	CAHN
>D>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	Apr	CAHN
>A>	AP	STIRA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Apr	CAHN
>A>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Apr	CAHN
>A>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	Apr	CAHN

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

AP		GLAND	EQ 4MG BASE/100ML	A219984	001	Feb 05, 2026	Jan	NEWA
		@	HOSPIRA INC	A202837	001	Apr 05, 2013	Jan	DISC

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ SENORES PHARMS

5MG

A077985 001 Apr 23, 2007 Jan CAHN

@

10MG

A077985 002 Apr 23, 2007 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB		BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020	Jan	CMFD
AB			12.5MG	A213592	002	Jun 04, 2020	Jan	CMFD

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL  
AVAGARD

>D>	+	3M	61%;1%	N021074	001	Jun 07, 2001	Apr	CAHN
>A>	+	SOLVENTUM	61%;1%	N021074	001	Jun 07, 2001	Apr	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL  
AZELASTINE HYDROCHLORIDE  
@ AMNEAL

0.2055MG/SPRAY A216576 001 Jun 05, 2024 Feb DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY  
@ AMNEAL PHARMS NY 5MG  
@ 10MG  
CETIRIZINE HYDROCHLORIDE HIVES RELIEF  
@ AMNEAL PHARMS NY 5MG  
@ 10MG

A078780 001 Jan 21, 2010 Mar DISC  
A078780 004 Jan 21, 2010 Mar DISC  
A078780 003 Jan 21, 2010 Mar DISC  
A078780 002 Jan 21, 2010 Mar DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL  
DYNA-HEX 2  
+! XTTRIUM  
DYNA-HEX 4  
XTTRIUM

2% N019422 001 Dec 17, 1985 Feb CTNA  
4% N019125 001 Dec 24, 1984 Feb CTNA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL  
SOLUPREP S

>D>	+	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018	Apr	CAHN
>A>	+	SOLVENTUM	2%;70%	N208288	001	Aug 08, 2018	Apr	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL  
DEXTROMETHORPHAN POLISTIREX

>A>		AUROBINDO PHARMA LTD	EQ 30MG HYDROBROMIDE/5ML	A218417	001	Apr 15, 2026	Apr	NEWA
-----	--	----------------------	--------------------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL  
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE  
@ AMNEAL PHARMS CO 25MG;220MG

A209726 001 Oct 23, 2018 Mar DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY  
@ TEVA 30MG  
TIME CAP LABS 30MG  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES  
@ TEVA 30MG  
TIME CAP LABS 30MG  
FEXOFENADINE HYDROCHLORIDE ALLERGY  
@ RISING 60MG  
@ 180MG  
@ TEVA 60MG  
@ 180MG  
TIME CAP LABS 60MG  
180MG  
FEXOFENADINE HYDROCHLORIDE HIVES  
@ RISING 60MG  
@ 180MG  
@ TEVA 60MG  
TIME CAP LABS 60MG  
180MG

A076447 004 Apr 13, 2011 Mar DISC  
A079112 002 Feb 08, 2012 Mar CAHN  
A076447 005 Apr 13, 2011 Mar DISC  
A079112 001 Feb 08, 2012 Mar CAHN  
A077081 006 Jul 21, 2011 Mar DISC  
A077081 008 Jul 21, 2011 Mar DISC  
A076447 006 Apr 13, 2011 Mar DISC  
A076447 008 Apr 13, 2011 Mar DISC  
A079112 004 Feb 08, 2012 Mar CAHN  
A079112 006 Feb 08, 2012 Mar CAHN  
A077081 007 Jul 21, 2011 Mar DISC  
A077081 009 Jul 21, 2011 Mar DISC  
A076447 007 Apr 13, 2011 Mar DISC  
A079112 003 Feb 08, 2012 Mar CAHN  
A079112 005 Feb 08, 2012 Mar CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 180MG;240MG A215232 001 Apr 17, 2025 Feb CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

>D> GLENMARK PHARMS LTD 0.05MG/SPRAY A218742 001 Mar 16, 2026 Apr CAHN  
 0.05MG/SPRAY A218742 001 Mar 16, 2026 Mar NEWA  
 >A> GLENMARK SPECLT 0.05MG/SPRAY A218742 001 Mar 16, 2026 Apr CAHN

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

RUBICON RESEARCH 100MG/5ML A220239 001 Mar 05, 2026 Feb NEWA

TABLET;ORAL

IBUPROFEN

>D> AMNEAL PHARMS 200MG A079233 001 Mar 18, 2014 Apr DISC  
 >A> @ 200MG A079233 001 Mar 18, 2014 Apr DISC  
 @ AMNEAL PHARMS NY 200MG A071333 001 Feb 17, 1987 Mar DISC

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

DURAPREP

>D> +! 3M EQ 0.7% IODINE;74% (6ML) N021586 001 Sep 29, 2006 Apr CAHN  
 >D> +! EQ 0.7% IODINE;74% (26ML) N021586 002 Sep 29, 2006 Apr CAHN  
 >A> +! SOLVENTUM EQ 0.7% IODINE;74% (6ML) N021586 001 Sep 29, 2006 Apr CAHN  
 >A> +! EQ 0.7% IODINE;74% (26ML) N021586 002 Sep 29, 2006 Apr CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

>D> APOTEX INC EQ 0.025% BASE A077354 001 May 09, 2006 Apr DISC  
 >A> @ EQ 0.025% BASE A077354 001 May 09, 2006 Apr DISC

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

INSTAPILL 5MG A212795 001 Sep 18, 2020 Feb CAHN  
 10MG A213294 001 Oct 30, 2020 Feb CAHN

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+! HISAMITSU PHARM CO 3%;10% N022029 002 Nov 05, 2012 Mar CHRS

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ FDC LTD EQ 0.2% BASE A217051 001 Jul 14, 2025 Feb DISC

PERMETHRIN

LOTION;TOPICAL

PERMETHRIN

@ PERRIGO NEW YORK 1% A076090 001 Dec 20, 2001 Feb DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

>A> ALLIED 17GM/SCOOPFUL A090812 001 Oct 07, 2009 Apr CAHN  
 >D> LGM PHARMA 17GM/SCOOPFUL A090812 001 Oct 07, 2009 Apr CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ RISING EQ 75MG BASE A075497 001 Jan 14, 2000 Mar CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2026**

NO APRIL 2026 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2026 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	11166951	Aug 11, 2035	U-4426		>A> D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	11166951	Aug 11, 2035	U-4426		>A> D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
<u>ACECLIDINE HYDROCHLORIDE - VIZZ</u>						
N 218585 001	12533347	Oct 08, 2039	U-3741			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	12539290	Aug 16, 2039	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFICAMTEN - MYOORZO</u>						
N 219083 001	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 002	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 003	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 004	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 002	>A> 10177951	Mar 13, 2029	DP			
	>A> 8410077	Mar 13, 2029	DP			
	>A> 9200088	Mar 13, 2029	DP			
	>A> 9493582	Feb 27, 2033	DP			
	>A> 9750822	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 003	>A> 10177951	Mar 13, 2029	DP			
	>A> 8410077	Mar 13, 2029	DP			
	>A> 9200088	Mar 13, 2029	DP			
	>A> 9493582	Feb 27, 2033	DP			
	>A> 9750822	Mar 13, 2029	DP			
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001	7977488	Apr 10, 2030	DS			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11723898	Jan 14, 2041	U-4449			
	>A> 12303497	Jan 30, 2040	U-4448			
	>A> 12303497	Jan 30, 2040	U-4494			
	RE50642	Sep 23, 2033	U-4450			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11723898	Jan 14, 2041	U-4449			
	>A> 12303497	Jan 30, 2040	U-4448			
	>A> 12303497	Jan 30, 2040	U-4494			
	RE50642	Sep 23, 2033	U-4450			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	>A> 12576034	Nov 30, 2033	DP U-1858			
	>A> 12576034	Nov 30, 2033	DP U-4290			
	>A> 12576034	Nov 30, 2033	DP U-4291			
	>A> 12576034*PED	May 30, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	>A> 12576034	Nov 30, 2033	DP U-1858			
	>A> 12576034	Nov 30, 2033	DP U-4290			
	>A> 12576034	Nov 30, 2033	DP U-4291			
	>A> 12576034*PED	May 30, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	>A> 12576034	Nov 30, 2033	DP U-1858			
	>A> 12576034	Nov 30, 2033	DP U-4290			
	>A> 12576034	Nov 30, 2033	DP U-4291			
	>A> 12576034*PED	May 30, 2034				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001	12390442	Feb 16, 2044	U-4433			
<u>ARTICAINE HYDROCHLORIDE - CYKLX</u>						
N 218643 001	11096922	Mar 27, 2039	DP U-4423			
	11826347	Mar 27, 2039	DP U-4423			
	12403126	Mar 27, 2039	DP U-4422			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	12521369	Feb 23, 2041	U-3980			
	12582631	Mar 25, 2043	U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2027	DS			
	9617546	Feb 14, 2027	DS U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	8906938	Jan 06, 2034	DS DP			
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	12509450	Dec 29, 2042	DP		>A> ODE-525	May 08, 2032
<u>AXITINIB - INLYTA</u>						
N 202324 001	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
<u>AXITINIB - INLYTA</u>						
N 202324 002	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	8987441	Oct 24, 2032	DS DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12551491	Jul 23, 2045	U-713			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
>A>	12590068	Nov 01, 2039	DS DP			
>A>	12590068*PED	May 01, 2040				
>A>	12590069	Nov 01, 2039	DS DP			
>A>	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
>A>	12590068	Nov 01, 2039	DS DP			
>A>	12590068*PED	May 01, 2040				
>A>	12590069	Nov 01, 2039	DS DP			
>A>	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 001	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
>A>	12590068	Nov 01, 2039	DS DP			
>A>	12590068*PED	May 01, 2040				
>A>	12590069	Nov 01, 2039	DS DP			
>A>	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 002	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
>A>	12590068	Nov 01, 2039	DS DP			
>A>	12590068*PED	May 01, 2040				
>A>	12590069	Nov 01, 2039	DS DP			
>A>	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
>A>	12590068	Nov 01, 2039	DS DP			
>A>	12590068*PED	May 01, 2040				
>A>	12590069	Nov 01, 2039	DS DP			
>A>	12590069*PED	May 01, 2040				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 004	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	>A> 12590068	Nov 01, 2039	DS DP			
	>A> 12590068*PED	May 01, 2040				
	>A> 12590069	Nov 01, 2039	DS DP			
	>A> 12590069*PED	May 01, 2040				
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	>A> 12594243	Oct 05, 2041	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	>A> 12594244	Nov 08, 2036	DP U-257			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	>A> 12594244	Nov 08, 2036	DP U-257			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2027	DS DP			
<u>BRIMONIDINE TARTRATE; CARBACHOL - YUVEZZI</u>						
N 220142 001	12268662	Nov 10, 2042	DP U-3741		NP	Jan 28, 2029
	12268662	Nov 10, 2042	DP U-4419			
	12268662	Nov 10, 2042	DP U-4420			
	8455494	May 24, 2030	U-3741			
	8455494	May 24, 2030	U-4419			
	8455494	May 24, 2030	U-4420			
<u>BUMETANIDE - ENBUMYST</u>						
N 219500 001	12558330	May 14, 2045	DP U-4279			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10583110*PED	Apr 27, 2031				
	10716777	Oct 27, 2030	U-2856			
	10716777*PED	Apr 27, 2031				
	12453712	Oct 27, 2030	U-4334			
	12453712*PED	Apr 27, 2031				
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	>A> 12582622	Feb 22, 2041	U-4044			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030			PED	Jun 18, 2029
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 005	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 005	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029		U-2543		
	RE47350	Jul 16, 2029		U-2544		
	RE47350	Jul 16, 2029		U-2545		
	RE47350	Jul 16, 2029		U-3503		
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110	Jul 16, 2029		U-3503		
	RE49110*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 006	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029		U-2543		
	RE47350	Jul 16, 2029		U-2544		
	RE47350	Jul 16, 2029		U-2545		
	RE47350	Jul 16, 2029		U-3503		
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110	Jul 16, 2029		U-3503		
	RE49110*PED	Jan 16, 2030				
<u>CHEMIDIOL - CTECLI</u>						
N 219488 001					>A> ODE-523	Feb 21, 2032
<u>CITALOPRAM HYDROBROMIDE - CITALOPRAM HYDROBROMIDE</u>						
A 219985 001					CGT	Sep 16, 2026
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	>A> 12576072	Jun 23, 2034	DP U-3261			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	12533408	Sep 10, 2041		U-4395		
	12539329	Sep 10, 2041		U-4399		
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	11179465	Aug 31, 2030	DP U-1858			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	12576032	Jul 28, 2041		U-2357		
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12514819	Nov 22, 2036		U-2814		
<u>COPPER - MIUDELLA</u>						
N 218201 001	>A> 9180040	Mar 22, 2034	DP			
<u>COPPER HISTIDINATE - ZYCUBO</u>						
N 211241 001					NCE >A> ODE-520	Jan 12, 2031 Jan 12, 2033

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	>A> 12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	>A> 12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	>A> 12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	>A> 12582634	Jan 12, 2043	DS			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150		PED	Sep 30, 2028
	10028912*PED	Apr 15, 2033				
	10166184	Oct 15, 2032	DP U-3149			
	10166184*PED	Apr 15, 2033				
	10835492	Oct 15, 2032	U-3150			
	10835492*PED	Apr 15, 2033				
	7850990	Jan 23, 2027	DP U-3147			
	7850990*PED	Jul 23, 2027				
	8022279	Sep 14, 2027	DP U-3147			
	8022279*PED	Mar 14, 2028				
	8092828	Apr 01, 2029	U-3147			
	8092828*PED	Oct 01, 2029				
	9271931	Jan 23, 2027	DP			
	9271931*PED	Jul 23, 2027				
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211156 001				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211156 002				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211312 001				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211312 002				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211467 001				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211467 002				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211470 001				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211470 002				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211482 001				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211482 002				>A> PC		Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211523 001				>A> PC		Oct 03, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211523	002				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211541	001				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211541	002				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211545	001				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211545	002				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211560	001				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211560	002				>A> PC	Oct 03, 2026
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099	001	12329742		Jun 17, 2042	DP	
<u>DASATINIB - PHYRAGO</u>						
N 216099	001	12544376		Jan 22, 2041	U-3767	
		12544376		Jan 22, 2041	U-3768	
		12544376		Jan 22, 2041	U-3769	
		12544376		Jan 22, 2041	U-3770	
		12544376		Jan 22, 2041	U-3771	
		12544376		Jan 22, 2041	U-3772	
<u>DASATINIB - PHYRAGO</u>						
N 216099	002	12544376		Jan 22, 2041	U-3767	
		12544376		Jan 22, 2041	U-3768	
		12544376		Jan 22, 2041	U-3769	
		12544376		Jan 22, 2041	U-3770	
		12544376		Jan 22, 2041	U-3771	
		12544376		Jan 22, 2041	U-3772	
<u>DASATINIB - PHYRAGO</u>						
N 216099	003	12544376		Jan 22, 2041	U-3767	
		12544376		Jan 22, 2041	U-3768	
		12544376		Jan 22, 2041	U-3769	
		12544376		Jan 22, 2041	U-3770	
		12544376		Jan 22, 2041	U-3771	
		12544376		Jan 22, 2041	U-3772	
<u>DASATINIB - PHYRAGO</u>						
N 216099	004	12544376		Jan 22, 2041	U-3767	
		12544376		Jan 22, 2041	U-3768	
		12544376		Jan 22, 2041	U-3769	
		12544376		Jan 22, 2041	U-3770	
		12544376		Jan 22, 2041	U-3771	
		12544376		Jan 22, 2041	U-3772	
<u>DASATINIB - PHYRAGO</u>						
N 216099	005	12544376		Jan 22, 2041	U-3767	
		12544376		Jan 22, 2041	U-3768	
		12544376		Jan 22, 2041	U-3769	
		12544376		Jan 22, 2041	U-3770	
		12544376		Jan 22, 2041	U-3771	
		12544376		Jan 22, 2041	U-3772	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	12529052	Jun 22, 2032	DP			
	12534722	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DEHYDRATED ALCOHOL - DEHYDRATED ALCOHOL</u>						
N 214988 001					>A> ODE-521	Oct 23, 2032
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	12558349	Mar 14, 2034	U-3967			
<u>DESMOPRESSIN ACETATE - DESMODA</u>						
N 219873 001	12214010	Apr 03, 2044	DP			
	12343372	Apr 03, 2044	DP U-4432			
<u>DEUCRAVACITINIB - SOTYKTU</u>						
N 214958 001	12521390	Feb 11, 2043	DP U-3434		>A> I-986	Mar 06, 2029
	12521390	Feb 11, 2043	DP U-4451			
	RE47929	Nov 07, 2033	DS DP U-3434			
	RE47929	Nov 07, 2033	DS DP U-4452			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	>A> 12589075	Jun 10, 2041	U-1995			
	>A> 12589075	Jun 10, 2041	U-3055			
	>A> 12599598	Jun 10, 2041	U-1995			
	>A> 12599598	Jun 10, 2041	U-3055			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	>A> 10081621	Mar 25, 2031	DP U-4087		>A> ODE-526	Dec 20, 2031
	>A> 10081621	Mar 25, 2031	DP U-4468			
	>A> 10239867	Apr 09, 2027	DS DP U-4090			
	>A> 10239867	Apr 09, 2027	DS DP U-4464			
	>A> 11564916	Aug 13, 2029	U-4095			
	>A> 11564916	Aug 13, 2029	U-4466			
	>A> 11578062	Mar 25, 2031	DP U-4096			
	>A> 11578062	Mar 25, 2031	DP U-4465			
	>A> 11639347	Apr 09, 2027	DS DP U-4090			
	>A> 11639347	Apr 09, 2027	DS DP U-4464			
	>A> 11866450	Feb 14, 2039	U-4082			
	>A> 11866450	Feb 14, 2039	U-4463			
	>A> 11873300	Aug 13, 2040	DS DP U-4083			
	>A> 11873300	Aug 13, 2040	DS DP U-4462			
	>A> 8324242	Aug 05, 2027	U-4090			
	>A> 8324242	Aug 05, 2027	U-4464			
	>A> 8415387	Nov 12, 2027	U-4082			
	>A> 8415387	Nov 12, 2027	U-4463			
	>A> 8598181	May 01, 2027	U-4090			
	>A> 8598181	May 01, 2027	U-4463			
	>A> 9181192	May 17, 2032	DS DP U-4094			
	>A> 9181192	May 17, 2032	DS DP U-4472			
	>A> 9512079	May 17, 2032	DS DP U-4098			
	>A> 9512079	May 17, 2032	DS DP U-4471			
	>A> 9670163	Dec 28, 2026	DP U-4080			
	>A> 9670163	Dec 28, 2026	DP U-4470			
	>A> 9931334	Dec 28, 2026	DP U-4080			
	>A> 9931334	Dec 28, 2026	DP U-4469			
	>A> 9974781	Apr 09, 2027	DP U-4082			
	>A> 9974781	Apr 09, 2027	DP U-4463			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	>A> 10081621	Mar 25, 2031	DP U-4087		>A> ODE-526	Dec 20, 2031
	>A> 10081621	Mar 25, 2031	DP U-4468			
	>A> 10206877	Apr 14, 2035	DP U-4092			
	>A> 10206877	Apr 14, 2035	DP U-4467			
	>A> 10239867	Apr 09, 2027	DS DP U-4090			
	>A> 10239867	Apr 09, 2027	DS DP U-4464			
	>A> 11564916	Aug 13, 2029	U-4095			
	>A> 11564916	Aug 13, 2029	U-4466			
	>A> 11578062	Mar 25, 2031	DP U-4096			
	>A> 11578062	Mar 25, 2031	DP U-4465			
	>A> 11639347	Apr 09, 2027	DS DP U-4090			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	>A> 11639347	Apr 09, 2027	DS DP U-4464			
	>A> 11866450	Feb 14, 2039	U-4082			
	>A> 11866450	Feb 14, 2039	U-4463			
	>A> 11873300	Aug 13, 2040	DS DP U-4083			
	>A> 11873300	Aug 13, 2040	DS DP U-4462			
	>A> 11951212	Apr 14, 2035	DP U-4089			
	>A> 11951212	Apr 14, 2035	DP U-4461			
	>A> 12186306	Jan 10, 2043	U-4088			
	>A> 12186306	Jan 10, 2043	U-4460			
	>A> 8324242	Aug 05, 2027	U-4090			
	>A> 8324242	Aug 05, 2027	U-4464			
	>A> 8415387	Nov 12, 2027	U-4082			
	>A> 8415387	Nov 12, 2027	U-4463			
	>A> 8598181	May 01, 2027	U-4090			
	>A> 8598181	May 01, 2027	U-4463			
	>A> 9181192	May 17, 2032	DS DP U-4094			
	>A> 9181192	May 17, 2032	DS DP U-4472			
	>A> 9512079	May 17, 2032	DS DP U-4098			
	>A> 9512079	May 17, 2032	DS DP U-4471			
	>A> 9670163	Dec 28, 2026	DP U-4080			
	>A> 9670163	Dec 28, 2026	DP U-4470			
	>A> 9931334	Dec 28, 2026	DP U-4080			
	>A> 9931334	Dec 28, 2026	DP U-4469			
	>A> 9974781	Apr 09, 2027	DP U-4082			
	>A> 9974781	Apr 09, 2027	DP U-4463			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM - MUCINEX 12HR COLD &amp; FEVER MULTI-SYMPTOM</u>						
N 217338 001	11278506	Oct 11, 2036	DP			
	12257218	Oct 11, 2036	DP			
	12370189	Oct 11, 2036	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12521400	Mar 27, 2029	DP			
	>A> 12599611	Jun 10, 2042	U-4455			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12521400	Mar 27, 2029	DP			
	>A> 12599611	Jun 10, 2042	U-4455			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12521400	Mar 27, 2029	DP			
	>A> 12599611	Jun 10, 2042	U-4455			
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976 001				>A> NPP		Mar 27, 2029
<u>DIFAMILAST - ADOUEY</u>						
N 219474 001	10588893	Dec 31, 2036	DS DP		NCE	Feb 12, 2031
	RE46792	Mar 01, 2028	DS DP U-4445			
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	12533351	Feb 26, 2039	DP			
<u>DIHYDROERGOTAMINE MESYLATE - ATZUMI</u>						
N 217901 001	>A> 12594273	Sep 24, 2033	DP			
<u>DORAVIRINE; ISLATRAVIR - IDVNSO</u>						
N 216964 001				>A> NCE		Apr 20, 2031
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	8193182	Sep 24, 2032	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	8193182	Sep 24, 2032	DS			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12527769	Nov 12, 2041	U-4111			
	12569469	Nov 12, 2041	U-4111			
	>A> 12599586	Nov 01, 2039	DP			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001	12582625	Feb 12, 2036	U-4444			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	>A> 12589086	Mar 30, 2037	U-4473			
<u>ELAMIPRETIDE HYDROCHLORIDE - FORZINITY</u>						
N 215244 001	7576061	Jan 20, 2027	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	>A> 10081621	Mar 25, 2031	DP U-3032			
	>A> 10081621	Mar 25, 2031	DP U-3157			
	>A> 10081621	Mar 25, 2031	DP U-4075			
	>A> 10081621	Mar 25, 2031	DP U-4480			
	>A> 10239867	Apr 09, 2027	DS DP U-3033			
	>A> 10239867	Apr 09, 2027	DS DP U-3158			
	>A> 10239867	Apr 09, 2027	DS DP U-4056			
	>A> 10239867	Apr 09, 2027	DS DP U-4475			
	>A> 10758534	Oct 06, 2035	DS DP U-3028			
	>A> 10758534	Oct 06, 2035	DS DP U-3144			
	>A> 10758534	Oct 06, 2035	DS DP U-4073			
	>A> 10758534	Oct 06, 2035	DS DP U-4475			
	>A> 10793547	Dec 08, 2037	DS DP U-3028			
	>A> 10793547	Dec 08, 2037	DS DP U-3144			
	>A> 10793547	Dec 08, 2037	DS DP U-4073			
	>A> 10793547	Dec 08, 2037	DS DP U-4475			
	>A> 11179367	Dec 08, 2037	DP U-3253			
	>A> 11179367	Dec 08, 2037	DP U-4071			
	>A> 11179367	Dec 08, 2037	DP U-4487			
	>A> 11426407	Oct 06, 2035	DS DP U-3425			
	>A> 11426407	Oct 06, 2035	DS DP U-4070			
	>A> 11426407	Oct 06, 2035	DS DP U-4475			
	>A> 11517564	Dec 08, 2037	DP U-3498			
	>A> 11517564	Dec 08, 2037	DP U-4067			
	>A> 11517564	Dec 08, 2037	DP U-4475			
	>A> 11564916	Aug 13, 2029	U-3525			
	>A> 11564916	Aug 13, 2029	U-4063			
	>A> 11564916	Aug 13, 2029	U-4491			
	>A> 11578062	Mar 25, 2031	DP U-3544			
	>A> 11578062	Mar 25, 2031	DP U-4054			
	>A> 11578062	Mar 25, 2031	DP U-4490			
	>A> 11639347	Apr 09, 2027	DS DP U-3587			
	>A> 11639347	Apr 09, 2027	DS DP U-4056			
	>A> 11639347	Apr 09, 2027	DS DP U-4475			
	>A> 12350262	Jul 17, 2038	U-4221			
	>A> 12350262	Jul 17, 2038	U-4475			
	>A> 12458635	Aug 13, 2029	DP U-4330			
	>A> 12458635	Aug 13, 2029	DP U-4486			
	>A> 8324242	Aug 05, 2027	U-3028			
	>A> 8324242	Aug 05, 2027	U-3144			
	>A> 8324242	Aug 05, 2027	U-4073			
	>A> 8324242	Aug 05, 2027	U-4475			
	>A> 8415387	Nov 12, 2027	U-3028			
	>A> 8415387	Nov 12, 2027	U-3144			
	>A> 8415387	Nov 12, 2027	U-4073			
	>A> 8415387	Nov 12, 2027	U-4475			
	>A> 8598181	May 01, 2027	U-3028			
	>A> 8598181	May 01, 2027	U-3144			
	>A> 8598181	May 01, 2027	U-4056			
	>A> 8598181	May 01, 2027	U-4475			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	>A> 9670163	Dec 28, 2026	DP U-3031			
	>A> 9670163	Dec 28, 2026	DP U-3155			
	>A> 9670163	Dec 28, 2026	DP U-4078			
	>A> 9670163	Dec 28, 2026	DP U-4477			
	>A> 9931334	Dec 28, 2026	DP U-3031			
	>A> 9931334	Dec 28, 2026	DP U-3155			
	>A> 9931334	Dec 28, 2026	DP U-4078			
	>A> 9931334	Dec 28, 2026	DP U-4479			
	>A> 9974781	Apr 09, 2027	DP U-3028			
	>A> 9974781	Apr 09, 2027	DP U-3144			
	>A> 9974781	Apr 09, 2027	DP U-4073			
	>A> 9974781	Apr 09, 2027	DP U-4475			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	>A> 10081621	Mar 25, 2031	DP U-3157			
	>A> 10081621	Mar 25, 2031	DP U-4075			
	>A> 10081621	Mar 25, 2031	DP U-4480			
	>A> 10239867	Apr 09, 2027	DS DP U-3158			
	>A> 10239867	Apr 09, 2027	DS DP U-4056			
	>A> 10239867	Apr 09, 2027	DS DP U-4475			
	>A> 10758534	Oct 06, 2035	DS DP U-3144			
	>A> 10758534	Oct 06, 2035	DS DP U-4073			
	>A> 10758534	Oct 06, 2035	DS DP U-4475			
	>A> 10793547	Dec 08, 2037	DS DP U-3144			
	>A> 10793547	Dec 08, 2037	DS DP U-4073			
	>A> 10793547	Dec 08, 2037	DS DP U-4475			
	>A> 11179367	Dec 08, 2037	DP U-3253			
	>A> 11179367	Dec 08, 2037	DP U-4071			
	>A> 11179367	Dec 08, 2037	DP U-4487			
	>A> 11426407	Oct 06, 2035	DS DP U-3425			
	>A> 11426407	Oct 06, 2035	DS DP U-4070			
	>A> 11426407	Oct 06, 2035	DS DP U-4475			
	>A> 11517564	Dec 08, 2037	DP U-3498			
	>A> 11517564	Dec 08, 2037	DP U-4069			
	>A> 11517564	Dec 08, 2037	DP U-4475			
	>A> 11564916	Aug 13, 2029	U-3525			
	>A> 11564916	Aug 13, 2029	U-4063			
	>A> 11564916	Aug 13, 2029	U-4491			
	>A> 11578062	Mar 25, 2031	DP U-3544			
	>A> 11578062	Mar 25, 2031	DP U-4054			
	>A> 11578062	Mar 25, 2031	DP U-4490			
	>A> 11639347	Apr 09, 2027	DS DP U-3587			
	>A> 11639347	Apr 09, 2027	DS DP U-4056			
	>A> 11639347	Apr 09, 2027	DS DP U-4475			
	>A> 12350262	Jul 17, 2038	U-4222			
	>A> 12350262	Jul 17, 2038	U-4475			
	>A> 12458635	Aug 13, 2029	DP U-4330			
	>A> 12458635	Aug 13, 2029	DP U-4486			
	>A> 8324242	Aug 05, 2027	U-3144			
	>A> 8324242	Aug 05, 2027	U-4073			
	>A> 8324242	Aug 05, 2027	U-4475			
	>A> 8415387	Nov 12, 2027	U-3144			
	>A> 8415387	Nov 12, 2027	U-4073			
	>A> 8415387	Nov 12, 2027	U-4475			
	>A> 8598181	May 01, 2027	U-3144			
	>A> 8598181	May 01, 2027	U-4056			
	>A> 8598181	May 01, 2027	U-4475			
	>A> 9670163	Dec 28, 2026	DP U-3155			
	>A> 9670163	Dec 28, 2026	DP U-4078			
	>A> 9670163	Dec 28, 2026	DP U-4477			
	>A> 9931334	Dec 28, 2026	DP U-3155			
	>A> 9931334	Dec 28, 2026	DP U-4078			
	>A> 9931334	Dec 28, 2026	DP U-4479			
	>A> 9974781	Apr 09, 2027	DP U-3144			
	>A> 9974781	Apr 09, 2027	DP U-4073			
	>A> 9974781	Apr 09, 2027	DP U-4475			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	>A> 10081621	Mar 25, 2031	DP U-3600			
	>A> 10081621	Mar 25, 2031	DP U-4065			
	>A> 10081621	Mar 25, 2031	DP U-4481			
	>A> 10239867	Apr 09, 2027	DS DP U-3590			
	>A> 10239867	Apr 09, 2027	DS DP U-4053			
	>A> 10239867	Apr 09, 2027	DS DP U-4476			
	>A> 10272046	Feb 27, 2033	DP U-3599			
	>A> 10272046	Feb 27, 2033	DP U-4062			
	>A> 10272046	Feb 27, 2033	DP U-4482			
	>A> 10758534	Oct 06, 2035	DS DP U-3589			
	>A> 10758534	Oct 06, 2035	DS DP U-4066			
	>A> 10758534	Oct 06, 2035	DS DP U-4476			
	>A> 10793547	Dec 08, 2037	DS DP U-3588			
	>A> 10793547	Dec 08, 2037	DS DP U-4066			
	>A> 10793547	Dec 08, 2037	DS DP U-4476			
	>A> 11147770	Feb 27, 2033	DP U-3598			
	>A> 11147770	Feb 27, 2033	DP U-4060			
	>A> 11147770	Feb 27, 2033	DP U-4483			
	>A> 11179367	Dec 08, 2037	DP U-3597			
	>A> 11179367	Dec 08, 2037	DP U-4059			
	>A> 11179367	Dec 08, 2037	DP U-4484			
	>A> 11426407	Oct 06, 2035	DS DP U-3595			
	>A> 11426407	Oct 06, 2035	DS DP U-4058			
	>A> 11426407	Oct 06, 2035	DS DP U-4476			
	>A> 11517564	Dec 08, 2037	DP U-3586			
	>A> 11517564	Dec 08, 2037	DP U-4057			
	>A> 11517564	Dec 08, 2037	DP U-4476			
	>A> 11564916	Aug 13, 2029	U-3585			
	>A> 11564916	Aug 13, 2029	U-4055			
	>A> 11564916	Aug 13, 2029	U-4485			
	>A> 11578062	Mar 25, 2031	DP U-3584			
	>A> 11578062	Mar 25, 2031	DP U-4054			
	>A> 11578062	Mar 25, 2031	DP U-4488			
	>A> 11639347	Apr 09, 2027	DS DP U-3583			
	>A> 11639347	Apr 09, 2027	DS DP U-4053			
	>A> 11639347	Apr 09, 2027	DS DP U-4476			
	>A> 11752106	Feb 27, 2033	DP U-3696			
	>A> 11752106	Feb 27, 2033	DP U-4052			
	>A> 11752106	Feb 27, 2033	DP U-4489			
	>A> 12214083	Feb 27, 2033	DP U-4141			
	>A> 12214083	Feb 27, 2033	DP U-4492			
	>A> 12458635	Aug 13, 2029	DP U-4333			
	>A> 12458635	Aug 13, 2029	DP U-4493			
	>A> 8324242	Aug 05, 2027	U-3589			
	>A> 8324242	Aug 05, 2027	U-4066			
	>A> 8324242	Aug 05, 2027	U-4476			
	>A> 8415387	Nov 12, 2027	U-3589			
	>A> 8415387	Nov 12, 2027	U-4066			
	>A> 8415387	Nov 12, 2027	U-4476			
	>A> 8598181	May 01, 2027	U-3589			
	>A> 8598181	May 01, 2027	U-4066			
	>A> 8598181	May 01, 2027	U-4476			
	>A> 9670163	Dec 28, 2026	DP U-3591			
	>A> 9670163	Dec 28, 2026	DP U-4068			
	>A> 9670163	Dec 28, 2026	DP U-4478			
	>A> 9931334	Dec 28, 2026	DP U-3591			
	>A> 9931334	Dec 28, 2026	DP U-4068			
	>A> 9931334	Dec 28, 2026	DP U-4478			
	>A> 9974781	Apr 09, 2027	DP U-3589			
	>A> 9974781	Apr 09, 2027	DP U-4066			
	>A> 9974781	Apr 09, 2027	DP U-4476			

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)

N 217660 002	>A> 10081621	Mar 25, 2031	DP U-3600			
	>A> 10081621	Mar 25, 2031	DP U-4065			
	>A> 10081621	Mar 25, 2031	DP U-4481			
	>A> 10239867	Apr 09, 2027	DS DP U-3590			
	>A> 10239867	Apr 09, 2027	DS DP U-4053			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	>A> 10239867	Apr 09, 2027	DS DP U-4476			
	>A> 10272046	Feb 27, 2033	DP U-3599			
	>A> 10272046	Feb 27, 2033	DP U-4062			
	>A> 10272046	Feb 27, 2033	DP U-4482			
	>A> 10758534	Oct 06, 2035	DS DP U-3589			
	>A> 10758534	Oct 06, 2035	DS DP U-4066			
	>A> 10758534	Oct 06, 2035	DS DP U-4476			
	>A> 10793547	Dec 08, 2037	DS DP U-3588			
	>A> 10793547	Dec 08, 2037	DS DP U-4066			
	>A> 10793547	Dec 08, 2037	DS DP U-4476			
	>A> 11147770	Feb 27, 2033	DP U-3598			
	>A> 11147770	Feb 27, 2033	DP U-4060			
	>A> 11147770	Feb 27, 2033	DP U-4483			
	>A> 11179367	Dec 08, 2037	DP U-3597			
	>A> 11179367	Dec 08, 2037	DP U-4059			
	>A> 11179367	Dec 08, 2037	DP U-4484			
	>A> 11426407	Oct 06, 2035	DS DP U-3595			
	>A> 11426407	Oct 06, 2035	DS DP U-4058			
	>A> 11426407	Oct 06, 2035	DS DP U-4476			
	>A> 11517564	Dec 08, 2037	DP U-3586			
	>A> 11517564	Dec 08, 2037	DP U-4057			
	>A> 11517564	Dec 08, 2037	DP U-4476			
	>A> 11564916	Aug 13, 2029	U-3585			
	>A> 11564916	Aug 13, 2029	U-4055			
	>A> 11564916	Aug 13, 2029	U-4485			
	>A> 11578062	Mar 25, 2031	DP U-3584			
	>A> 11578062	Mar 25, 2031	DP U-4054			
	>A> 11578062	Mar 25, 2031	DP U-4488			
	>A> 11639347	Apr 09, 2027	DS DP U-3583			
	>A> 11639347	Apr 09, 2027	DS DP U-4053			
	>A> 11639347	Apr 09, 2027	DS DP U-4476			
	>A> 11752106	Feb 27, 2033	DP U-3696			
	>A> 11752106	Feb 27, 2033	DP U-4052			
	>A> 11752106	Feb 27, 2033	DP U-4489			
	>A> 12214083	Feb 27, 2033	DP U-4141			
	>A> 12214083	Feb 27, 2033	DP U-4492			
	>A> 12350262	Jul 17, 2038	U-4220			
	>A> 12350262	Jul 17, 2038	U-4476			
	>A> 12458635	Aug 13, 2029	DP U-4333			
	>A> 12458635	Aug 13, 2029	DP U-4493			
	>A> 8324242	Aug 05, 2027	U-3589			
	>A> 8324242	Aug 05, 2027	U-4066			
	>A> 8324242	Aug 05, 2027	U-4476			
	>A> 8415387	Nov 12, 2027	U-3589			
	>A> 8415387	Nov 12, 2027	U-4066			
	>A> 8415387	Nov 12, 2027	U-4476			
	>A> 8598181	May 01, 2027	U-3589			
	>A> 8598181	May 01, 2027	U-4066			
	>A> 8598181	May 01, 2027	U-4476			
	>A> 9670163	Dec 28, 2026	DP U-3591			
	>A> 9670163	Dec 28, 2026	DP U-4068			
	>A> 9670163	Dec 28, 2026	DP U-4478			
	>A> 9931334	Dec 28, 2026	DP U-3591			
	>A> 9931334	Dec 28, 2026	DP U-4068			
	>A> 9931334	Dec 28, 2026	DP U-4478			
	>A> 9974781	Apr 09, 2027	DP U-3589			
	>A> 9974781	Apr 09, 2027	DP U-4066			
	>A> 9974781	Apr 09, 2027	DP U-4476			
<u>ELINZANETANT - LYNKUET</u>						
N 219469 001	12533358	May 14, 2045	U-4402			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335			
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10005761	Aug 27, 2030	U-4440			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	10258622	Nov 21, 2032	U-4439			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	8541575	Feb 26, 2030	DS DP U-4440			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9314464	Jul 04, 2031	U-4440			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9474754	Aug 05, 2033	U-4440			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
	9850230	Aug 27, 2030	U-4440			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 215425 001	12539283	Jan 17, 2045	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	>A> 8906887	Aug 27, 2032	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	>A> 8906887	Aug 27, 2032	DP			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	>A> 8080580	Dec 19, 2031	DS DP U-2214			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	>A> 8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001	>A> 8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	>A> 8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	>A> 8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	>A> 8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	>A> 8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	>A> 8080580	Dec 19, 2031	DS DP U-2214			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	12551447	Nov 05, 2042	DP			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002					D-199	Jan 16, 2029
<u>ETRIPAMIL - CARDAMYST</u>						
N 218571 001	10010522	Jun 19, 2028	U-38			
	10010523	Jun 19, 2028	DS			
	10117848	Apr 13, 2036	DP U-4370			
	12257224	Jul 15, 2042	U-4370			
	9227918	Jun 19, 2028	DP			
	9463179	Jun 19, 2028	U-4370			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2027	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 001	8436180	Aug 26, 2033	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	8436180	Aug 26, 2033	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 003	8436180	Aug 26, 2033	DS DP			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001					I-983	Dec 13, 2028
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168 001	12527884	May 13, 2042	DP U-4406			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLUTICASONE PROPIONATE</u>						
A 219602 001					CGT	Sep 20, 2026
<u>FOSFOMYCIN DISODIUM - CONTEPO</u>						
N 212271 001					NP GAIN	Oct 22, 2028 Oct 22, 2033
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007					NPP	Feb 20, 2029
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	8318714	Nov 28, 2031	DP			
<u>GEMCITABINE HYDROCHLORIDE - INLEXZO</u>						
N 219683 001	12576253	Dec 17, 2030	DP			
<u>GEPOTIDACIN MESYLATE - BLUJEPÄ</u>						
N 218230 001	12528809	Dec 13, 2042	DS DP U-4361			
	12528809	Dec 13, 2042	DS DP U-4408			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	7329689	Jan 15, 2027	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	8148401	Apr 14, 2029	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	8148401	Apr 14, 2029	DS DP			
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001					>A> NPP	Mar 17, 2028
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	12551448	Mar 03, 2036	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOTROKINRA HYDROCHLORIDE - ICOTYDE</u>						
N 220149 001	11845808	Jan 14, 2041	DS U-4447		>A> NCE	Mar 17, 2031
	11939361	Nov 19, 2041	DP U-4447			
	12552836	Jul 12, 2039	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2026	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2026	DS DP			
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-4249		I-985	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4413		NPP	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4414			
	10131907	Aug 24, 2028	DS DP U-4249			
	10131907	Aug 24, 2028	DS DP U-4413			
	10131907	Aug 24, 2028	DS DP U-4414			
	10851377	Aug 25, 2036	U-4249			
	10851377	Aug 25, 2036	U-4413			
	10851377	Aug 25, 2036	U-4414			
	8106022	Dec 12, 2029	DS DP U-4249			
	8106022	Dec 12, 2029	DS DP U-4413			
	8106022	Dec 12, 2029	DS DP U-4414			
	8222222	Dec 29, 2027	U-4249			
	8222222	Dec 29, 2027	U-4413			
	8222222	Dec 29, 2027	U-4414			
	8809292	May 10, 2027	DS DP U-4249			
	8809292	May 10, 2027	DS DP U-4413			
	8809292	May 10, 2027	DS DP U-4414			
	8828956	Dec 04, 2028	DS DP U-4249			
	8828956	Dec 04, 2028	DS DP U-4413			
	8828956	Dec 04, 2028	DS DP U-4414			
	9370582	Dec 04, 2028	DS DP U-4249			
	9370582	Dec 04, 2028	DS DP U-4413			
	9370582	Dec 04, 2028	DS DP U-4414			
<u>IOHEXOL - IOHEXOL</u>						
A 217737 001					CGT	Jul 26, 2026
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001					>A> ODE-524	Mar 20, 2032
<u>LANDIOLOL HYDROCHLORIDE - RAPIBLYK</u>						
N 217202 001					NPP	Feb 13, 2029
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	>A> 12594267	Jul 15, 2039	DP			
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220018 001	>A> 12594267	Jul 15, 2039	DP			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	12544380	Aug 07, 2034	U-3264			
	12544380	Aug 07, 2034	U-3998			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 001	12564592	Dec 23, 2044	DP			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 002	12564592	Dec 23, 2044	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUCOVORIN CALCIUM - VYKOURA</u> N 220406 003	12564592	Dec 23, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 002	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 003	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 004	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 005	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 006	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 007	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 008	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 009	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 010	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 011	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 012	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 013	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 014	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 015	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 016	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 001	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 002	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 003	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 004	12564565	Sep 26, 2044	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 005	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 006	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 007	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 008	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 009	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 010	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 011	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 012	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 013	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 014	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 015	12564565	Sep 26, 2044	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u> N 021717 001	12558328	Jan 14, 2031	U-4421			
<u>LINACLOTIDE - LINZESS</u> N 202811 001					NPP PED	Nov 04, 2028 May 04, 2029
<u>LINERIXIBAT - LYNAYOY</u> N 220295 001	9040518	Sep 06, 2031	DS DP		>A> NCE >A> ODE-517	Mar 17, 2031 Mar 17, 2033
<u>LISDEXAMFETAMINE DIMESYLATE - ARYNTE</u> N 219847 001	12582620	Apr 16, 2040	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 001	12472172	Jul 29, 2041	U-4438			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 002	12472172	Jul 29, 2041	U-4438			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 003	12472172	Jul 29, 2041	U-4438			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 004	12472172	Jul 29, 2041	U-4438			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 007	12472172	Jul 29, 2041	U-4438			
	7932268	Aug 19, 2027	U-1316			
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 001					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 002					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 003					CGT	May 19, 2026
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	>A> 12605365	Oct 07, 2041	DP U-4159			
	>A> 12605365	Oct 07, 2041	DP U-4160			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	>A> 12589069	Jan 26, 2036	DP U-2764			
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - LOTE PREDNOL ETABONATE AND TOBRAMYCIN</u>						
A 217597 001					CGT	Jul 14, 2026
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO</u>						
N 215833 001	>A> 10398791	Mar 23, 2036	DS DP			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	>A> 12594298	Jun 14, 2044	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	>A> 12599602	Feb 12, 2040	U-3290			
	>A> 12599602	Feb 12, 2040	U-3974			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12527771	Oct 11, 2043	DS DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	12544383	Mar 10, 2045	U-1719			
	12551488	May 28, 2040	U-1719			
	12551489	May 28, 2040	U-1719			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	12533342	May 20, 2039	U-3421			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	>A> 12485111	May 14, 2043	DP U-4453			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					>A> M-14	Oct 11, 2027
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					>A> M-14	Oct 11, 2027
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					>A> M-14	Oct 11, 2027
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	>A> 12594268	May 23, 2041	U-2371			
	>A> 12599594	Jul 19, 2036	U-2371			
	>A> 12599595	Apr 28, 2028	U-2371			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 001	10563259	Jul 24, 2030	U-4436		>A> NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 002	10563259	Jul 24, 2030	U-4436		>A> NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 003	10563259	Jul 24, 2030	U-4436		>A> NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 004	10563259	Jul 24, 2030	U-4436		>A> NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	8999638	Oct 28, 2030	U-4436			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 004	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 005	10563259	Jul 24, 2030	U-4436		>A> NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 006	10563259	Jul 24, 2030	U-4436		>A> NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 007	10563259	Jul 24, 2030	U-4436		>A> NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 007	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MINOCYCLINE HYDROCHLORIDE - EMROSI</u>						
N 219015 001 >A>	12594252	Jan 07, 2039	U-4043			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001 >A>	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002 >A>	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003 >A>	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - AOVSME</u>						
N 216196 004	10632114	May 03, 2032	U-4391		NCE	Feb 17, 2027
	11254652	Nov 21, 2038	DS DP		NP	Dec 23, 2028
	11878049	Jul 31, 2041	U-4390		>A> ODE-522	Dec 23, 2032
	9193701	Oct 26, 2032	U-4393			
	9682080	May 03, 2032	U-4392			
	>A> RE49582	Apr 11, 2035	DS DP			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	12576089	Aug 21, 2039	U-4441			
	>A> 8486941	Jan 03, 2035	DS DP U-1201			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	12576089	Aug 21, 2039	U-4441			
	>A> 8486941	Jan 03, 2035	DS DP U-1201			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	12576089	Aug 21, 2039	U-4441			
	>A> 8486941	Jan 03, 2035	DS DP U-1201			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					>A> ODE-528	Feb 07, 2032
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001	12514854	Feb 05, 2041	U-4397			
<u>NAVEPEGITIDE - YUUIWEL</u>						
N 219164 001	10835578	Jan 05, 2037	DS DP U-4425		>A> NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
<u>NAVEPEGITIDE - YUUIWEL</u>						
N 219164 002	10835578	Jan 05, 2037	DS DP U-4425		>A> NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAVEPEGRTIDE - YUWIWEL</u>						
N 219164 002	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
<u>NAVEPEGRTIDE - YUWIWEL</u>						
N 219164 003	10835578	Jan 05, 2037	DS DP U-4425		>A> NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 001	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373			
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 002	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373			
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	>A> 12599587	Jul 08, 2042	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	>A> 12599587	Jul 08, 2042	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	>A> 12599587	Jul 08, 2042	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 004	10888534	Apr 26, 2039	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 002	>A> 7838657	Jul 11, 2027	DS DP			
	>A> 8361977	Dec 23, 2030	DS DP			
	>A> 8980853	Nov 24, 2030	U-1941			
	>A> 9717750	Jun 17, 2030	U-1942			
	>A> 9717750	Jun 17, 2030	U-1943			
	>A> 9717750	Jun 17, 2030	U-2093			
	>A> 9717750	Jun 17, 2030	U-2094			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 003	>A> 7838657	Jul 11, 2027	DS DP			
	>A> 8361977	Dec 23, 2030	DS DP			
	>A> 8980853	Nov 24, 2030	U-1941			
	>A> 9717750	Jun 17, 2030	U-1942			
	>A> 9717750	Jun 17, 2030	U-1943			
	>A> 9717750	Jun 17, 2030	U-2093			
	>A> 9717750	Jun 17, 2030	U-2094			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 001					CGT	Aug 02, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 002					CGT	Jul 27, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 003					CGT	Jul 27, 2026
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	12509684	May 01, 2034	U-4050			
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 001	>A> RE50455	Sep 26, 2037	DS DP U-4474		>A> NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 002	>A> RE50455	Sep 26, 2037	DS DP U-4474		>A> NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 003	>A> RE50455	Sep 26, 2037	DS DP U-4474		>A> NCE	Apr 01, 2031

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 004	>A> RE50455	Sep 26, 2037	DS DP U-4474		>A> NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 005	>A> RE50455	Sep 26, 2037	DS DP U-4474		>A> NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 006	>A> RE50455	Sep 26, 2037	DS DP U-4474		>A> NCE	Apr 01, 2031
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	12514899	Aug 29, 2029	U-4398			
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	12514899	Aug 29, 2029	U-4398			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7771707	Oct 09, 2028	DP			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	12528836	Oct 07, 2036	U-4394			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	12552792	Oct 03, 2040	DS DP			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	>A> 12201615	Oct 25, 2039	U-3804			
	>A> 12576066	Oct 25, 2039	U-3804			
	>A> 12576067	Oct 25, 2039	U-3804			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
N 216830 001	12564561	Aug 08, 2044	DP			
<u>PIFLUFOLASTAT F-18 - PYLARIFY TRUVU</u>						
N 220089 001	10947197	Jun 09, 2037	DS DP U-3317		>A> NCE	May 26, 2026
	11851407	Jun 09, 2037	DS DP U-3317			
	12070513	Jul 31, 2029	DS DP U-3317			
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3317			
	9861713	Jul 31, 2029	DS DP U-3317			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10517860	Mar 23, 2037		U-1974		
	10517860*PED	Sep 23, 2037				
	10953000	Mar 23, 2037		U-1974		
	10953000*PED	Sep 23, 2037				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10449185	Aug 27, 2038	DP			
	10449185*PED	Feb 27, 2039				
	10646480	Aug 27, 2038	DP			
	10646480*PED	Feb 27, 2039				
	10849891	Aug 27, 2038	DP U-1974			
	10849891*PED	Feb 27, 2039				
	11452721	Aug 27, 2038	DP			
	11452721*PED	Feb 27, 2039				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					I-981	Dec 02, 2028
				>A>	ODE-518	Dec 03, 2032
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					I-981	Dec 02, 2028
				>A>	ODE-518	Dec 03, 2032
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					>A>	ODE-519
						Feb 13, 2033
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					>A>	ODE-519
						Feb 13, 2033
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 001					PC	Aug 30, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 002					PC	Aug 30, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 003					PC	Aug 30, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 004					PC	Aug 30, 2026
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP	Jan 27, 2029
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698		NPP	Jan 27, 2029
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9023790	Jul 04, 2031	DP U-4415			
	9023790	Jul 04, 2031	DP U-4416			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-4415			
	9358297	Jun 24, 2031	DP U-4416			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					I-984	Jan 27, 2029
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 001	12539314	Mar 07, 2039	DP			
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 002	12539314	Mar 07, 2039	DP			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	12448366	Jul 07, 2042	DS			
	12539303	Apr 03, 2039	U-2828			
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972 001	12544337	Dec 23, 2039	DP U-4026			
<u>RELACORILANT - LIFYORLI (COPACKAGED)</u>						
N 220641 001	>A> 10456392	May 24, 2033	U-4457		>A> NCE	Mar 25, 2031
	>A> 11285145	May 26, 2041	U-4457			
	>A> 11285145	May 26, 2041	U-4458			
	>A> 11285145	May 26, 2041	U-4459			
	>A> 11464764	Apr 14, 2040	DP			
	>A> 11576907	May 24, 2033	DS DP U-4457			
	>A> 11576907	May 24, 2033	DS DP U-4458			
	>A> 11576907	May 24, 2033	DS DP U-4459			
	>A> 11925626	Dec 18, 2039	DP			
	>A> 12152028	Dec 22, 2041	DP U-4457			
	>A> 12152028	Dec 22, 2041	DP U-4458			
	>A> 12152028	Dec 22, 2041	DP U-4459			
	>A> 12514849	Dec 18, 2039	DP			
	>A> 12589094	May 26, 2041	U-4457			
	>A> 12589094	May 26, 2041	U-4458			
	>A> 12589094	May 26, 2041	U-4459			
	>A> 8859774	May 24, 2033	DS DP			
	>A> 9273047	May 24, 2033	U-4457			
	>A> 9273047	May 24, 2033	U-4458			
	>A> 9273047	May 24, 2033	U-4459			
<u>REMIBRUTINIB - RHAPSIDO</u>						
N 218436 001	>A> 12419889	Jan 19, 2043	U-4281			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	>A> 8722619	May 09, 2036	DS DP U-3566			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	12544379	Aug 07, 2034	U-3975			
	12544380	Aug 07, 2034	U-4404			
	12544380	Aug 07, 2034	U-4405			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001					I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002					I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003					I-982	Dec 17, 2028
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12544381	May 20, 2031	DP			
	12564593	May 20, 2031	DP			
	>A> 12589096	Sep 04, 2040	U-3505			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	9457154	Sep 29, 2027	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	12514822	May 02, 2034	U-2628			
	>A> 12594326	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	12514822	May 02, 2034	U-2628			
	>A> 12594326	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	12514822	May 02, 2034	U-2628			
	>A> 12594326	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 004	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 005	12514822	May 02, 2034	U-2628			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 006	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
<u>SEMAGLUTIDE - WEGOVY HD</u>						
N 215256 006	10888605	Aug 24, 2038	DP U-4418			
	11318191	Feb 17, 2041	DP U-4418			
	11752198	Aug 24, 2038	DP U-4418			
	12029779	Oct 10, 2038	U-4418			
	12214017	Aug 24, 2038	DP U-4418			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-4418			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 001	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 002	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 003	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	9278123	Dec 16, 2031	DP U-4389			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					>A> I-987	Mar 19, 2029
<u>SEVABERTINIB - HYRNUO</u>						
N 219972 001	10428063	Oct 10, 2035	DS DP			
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 001	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 002	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 003	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 004	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	12533340	Apr 23, 2036	U-4407			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	>A> 12569183	Apr 05, 2039	U-4456			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10195160 12569453	May 23, 2036 Dec 18, 2039	DP U-4048			
<u>TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT</u>						
N 022335 001	7722856	Feb 24, 2031	U-4442			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12539299	Nov 26, 2042	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	>A> 12605391	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	>A> 12605391	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	>A> 12605391	Apr 12, 2039	U-1103			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 004	9931458	May 31, 2037	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 013	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 014	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
	<u>TIRZEPATIDE - MOUNJARO</u>					
N 215866 015	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
	<u>TIRZEPATIDE - MOUNJARO</u>					
N 215866 016	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
	<u>TIRZEPATIDE - MOUNJARO</u>					
N 215866 017	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
	<u>TIRZEPATIDE - MOUNJARO</u>					
N 215866 018	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
	<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>					
N 215866 019	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 020	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 021	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 022	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 023	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 024	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 013	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 013	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 014	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 015	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 016	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 017	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 018	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 019	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 019	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 020	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 021	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 022	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 023	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 024	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
<u>TRADIPITANT - NEREUS</u>						
N 220152 001	10772880	Mar 04, 2036	U-4396			
	10821099	Mar 04, 2036	U-4396			
	11324735	Mar 04, 2036	U-4396			
	12318375	Aug 09, 2036	U-4396			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	7199162	Oct 12, 2026	U-4142			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	7199162	Oct 12, 2026	U-4142			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001	12551461	Nov 14, 2034	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12527798	Dec 05, 2037	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE-425	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 002	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 003	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 001	12558317	Oct 29, 2039	DP			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 002	12558317	Oct 29, 2039	DP			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 003	12558317	Oct 29, 2039	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	>A> 8648087	Apr 17, 2034	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TUCATINIB - TUKYSA</u>						
N 213411 002 >A>	8648087	Apr 17, 2034	DS DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001 >A>	12570664	Oct 17, 2036	U-4454			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	12569474	Jun 04, 2034	U-3876			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	12569474	Jun 04, 2034	U-3876			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	12569474	Jun 04, 2034	U-3876			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001 >A>	12576080	Oct 19, 2035	U-1900			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003					D-198	Jan 21, 2029
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12576054	Jun 08, 2043	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2027	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001	7977488	Apr 10, 2030	DS			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002	7977488	Apr 10, 2030	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12514906	Aug 01, 2036	DP U-3927			
	>A> 8198242	Jun 11, 2035	DS DP U-3927			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12514906	Aug 01, 2036	DP U-3927			
	>A> 8198242	Jun 11, 2035	DS DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12514906	Aug 01, 2036	DP U-3927			
	>A> 8198242	Jun 11, 2035	DS DP U-3927			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					>A> ODE-527	Mar 20, 2032
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	>A> 8481546	Jun 26, 2034	DS DP U-3555			
<u>ZIFTOMENIB - KOMZIFTI</u>						
N 220305 001	12521396	Jul 16, 2044	DP			
<u>ZOLIFLODACIN - NUZOLVENCE</u>						
N 219491 001	8658641	Jun 20, 2030	DS			
	8889671	Jan 21, 2034	DS	U-4369		
	9040528	Oct 13, 2029		U-4369		
	9187495	Jan 21, 2034	DS	U-4369		
	9540394	Jan 21, 2034		U-4369		
	9839641	Jan 21, 2034		U-4369		

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 46<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)